

CURRICULUM VITAE

8 April 2020

NAME: Donna Shapiro Neuberg
ACADEMIC TITLE: Senior Lecturer on Biostatistics

WORK ADDRESS: Department of Data Sciences
Dana-Farber Cancer Institute
450 Brookline Avenue, LC1052
Boston, MA 02215

EMAIL: neuberg@ds.dfci.harvard.edu

HOME ADDRESS: 451 S Barrington Avenue Apt 204
Los Angeles, CA 90049:

EDUCATION:

1967	Russian	B.A.	Northwestern University
1969	Slavic Languages and Literatures	M.A.	University of Chicago
1979	Statistics	M.S.	SUNY at Stony Brook
1988	Biostatistics	Sc.D.	Harvard School of Public Health

ACADEMIC APPOINTMENTS

1989–1991 Postdoctoral Research Fellow, Department of Biostatistics, Harvard School of Public Health and Dana-Farber Cancer Institute
1991–1992 Lecturer, Department of Biostatistics, Harvard School of Public Health and Dana-Farber Cancer Institute
1992–1998 Assistant Professor, Department of Biostatistics, Harvard School of Public Health and the Department of Biostatistical Science, Dana-Farber Cancer Institute
1998–2005 Lecturer, Department of Biostatistics, Harvard School of Public Health and Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute
2005–present Senior Lecturer, Department of Biostatistics, Harvard School of Public Health and the Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston, MA

OTHER ACADEMIC APPOINTMENTS

1991 Visiting Lecturer, Programme in Biostatistics, Limburgs Universitair Centrum, Diepenbeek, Belgium

MAJOR PROFESSIONAL RESPONSIBILITIES

1987–2000 Eastern Cooperative Oncology Group Committee Responsibilities
1987–1996 Breast Committee

1987–1992 New Agents and Pilot Studies Committee, full committee and pharmacology subcommittee
1987–1996 Statistics Center Randomization Committee
1989–1996 Chair
1989–1996 Radiation Oncology
1991–2000 Biologic Response Modifiers Committee
1991–1995 Constitution Committee
1992–1996 Pharmacology Committee
1992–1997 Response Subcommittee
1992–1996 Brain Tumor Working Group
1993–2000 Coordinating Statistician
1993–2000 Aging Subcommittee
1996–2000 Leukemia Committee

1989-present Dana-Farber Cancer Institute's Program Responsibilities
1991-present Lymphoma
1991–1998 Nursing
1995–2019 Pediatric Oncology (acute lymphoblastic leukemia, brain tumors)
1996–present Leukemia
1996–present Nonmalignant Hematology

Dr. Neuberg is currently Senior Biostatistician for the Dana-Farber/Harvard Cancer Center Programs in Leukemia, Lymphoma, and Nonmalignant Hematology, supporting a group of six masters-level statisticians in this effort. Total effort supported by Dr. Neuberg, including herself: 4.5 FTEs.

COMMITTEE SERVICE:

HCSPH DEPARTMENTAL AND SCHOOL SERVICE:

1990–1991 Member, Committee on Core Curriculum
1990–2000 Member, Student Advising Committee, Department of Biostatistics
1997–2000 Chair 1997–2000, Student Advising Committee, Department of Biostatistics
2002–2003 Member, Student Advising Committee, Department of Biostatistics
1992–1993 Medical Education Committee, Department of Biostatistics
1993–1996 Member, Admissions Committee, Department of Biostatistics
2003–2004 Member, Admissions Committee, Department of Biostatistics
2005–2006 Member, Admissions Committee, Department of Biostatistics
2010–2014 Member, Admissions Committee, Department of Biostatistics
2015–2019 Member, Masters Degree Admissions Committee, Department of Biostatistics
1999–2005 Member, Curriculum Committee, Department of Biostatistics
2009–2010 Member, Curriculum Committee, Department of Biostatistics
2001–2005 Member, Degree Program Committee, Department of Biostatistics
2002–2005 Chair, Degree Program Committee, Department of Biostatistics
2001–2005 Member, Committee on Molecular and Genetic Epidemiology, HSPH
2002–2003 Member, Schering-Plough Workshop Planning Committee, Department of Biostatistics
2007–2008 Member, One Year Masters Planning Committee, Department of Biostatistics

DANA-FARBER CANCER INSTITUTE SERVICE:

1991–1994 Quality-of-Life Scientific Review Committee

1995–2007 Pediatric Scientific Review Committee
2001–2002 Committee on Cores

NATIONAL CANCER INSTITUTE SERVICE:

1997–2001 Member, Cancer Clinical Investigation Review Committee (NCI Subcommittee H)
2000–2005 Member, Clinical Oncology Investigational Review Group (CONC Study Section)
2000–2002 Member, Brain Tumor Progress Review Group (National Cancer Institute and National Institute of Neurologic Disorders and Stroke)
2010 Member, Chronic Lymphocytic Leukemia Working Group
2011 Member, Acute Lymphoblastic Leukemia Working Group
2011-2014 Member, Leukemia Steering Committee
2011-2020 Member, Pediatric Leukemia and Lymphoma Steering Committee
2015-2018 Member, Lymphoma Steering Committee

PROFESSIONAL SOCIETY SERVICE:

1993–1994 Planning Committee for International Symposium on the Impact of Biotechnology on Predictive Oncology and Therapy, December 1994, for the International Society for the Prevention of Cancer
2005 Member, American Association for Cancer Research Annual Meeting Education Committee
2005–2007 Member, American Society of Clinical Oncology Cancer Education Committee
2011-2014 Member, American Society of Clinical Oncology Cancer Education Committee
2011-2013 Member, American Society of Clinical Oncology Cancer Research Committee
2013-present Member, Joint Oversight Committee, Translational Research Training in Hematology workshop, American Society of Hematology and European Hematology Association
2014-2015 Co-Chairperson, 2015 American Association for Cancer Research Annual Meeting Program Committee
2018-present Member, Data Hub Oversight Group on behalf of the American Society of Hematology Research Collaborative

OTHER SERVICE:

2012-present Voting Member, Children’s Oncology Group Data and Safety Monitoring Committee
2005–2010 Member, External Advisory Board, Herbert Irving Comprehensive Cancer Center, Columbia University
2006–2014 External Advisor, Lymphoma SPORE in Development, Northwestern University, Chicago, IL. Leo Gordon, P.I.
2017-present Member, IlyAD Data and Safety Monitoring Committee, U of Rochester
2018-present External Advisor, SPORE in Leukemia, Washington University in Saint Louis, Dan Link, MD, PI
2019-present External Advisor, SPORE in Lymphoma, Washington University in Saint Louis, Brad Kahl, MD and Todd Fehniger, MD, PhD, co-PIs

PROFESSIONAL SOCIETY MEMBERSHIP:

American Statistical Association

American Society of Hematology
American Association for Cancer Research
American Society for Clinical Oncology
European Hematology Association

GRANT REVIEW ACTIVITIES:

1997–2001 Member, National Cancer Institute Cancer Clinical Investigation Review Committee (NCI Subcommittee H)
2000–2005 Member, National Cancer Institute Clinical Oncology Investigational Review Group (CONC Study Section)
2005–2012 Ad hoc reviewer for National Heart Lung and Blood Institute
2013 Ad hoc reviewer for National Institute of Arthritis and Musculoskeletal and Skin Diseases
2013–present Study Section Member, Translational Research Training in Hematology applications, American Society of Hematology
2017 Study Section Member, ASH Scholar Awards, American Society of Hematology
2017 Study Section Member, Clinical Research Training Institute applications, American Society of Hematology

EDITORIAL ROLES

Ad hoc reviewer:

1998–present Reviewer, *Journal of Clinical Oncology*
2000–present Reviewer, *Circulation*
2000–2003 Reviewer, *Medical and Pediatric Oncology*
2004–present Reviewer, *Pediatric Blood and Cancer*

2003–present Reviewer, *Blood*
2003–2005 Reviewer, *Cancer Epidemiology, Biomarkers and Prevention*
2005–present Reviewer, *Cancer Research*
2005–present Reviewer, *Clinical Cancer Research*
2010–2012 Reviewer, *The Oncologist*
2010–2012 Reviewer, *Journal of Biomedicine and Biotechnology*
2011–present Reviewer, *Nature*
2013–present Reviewer, *Haematologica*
2013–present Reviewer, *American Journal of Hematology*
2016–present Reviewer, *Cell Systems*
2016–present Reviewer, *Cell Metabolism*

Other editorial roles:

2006–2008 Member, Editorial Board, *Journal of Clinical Oncology*
2000–2009 Member, Editorial Board, *Neuro-Oncology*
2004–present Member, Editorial Board, *Pediatric Blood and Cancer*
2004–2010 Member, Editorial Board, *Leukemia*
2007–2012 Associate Section Editor for Biostatistics, *Clinical Cancer Research*
2015–present Associate Editor, *Pediatric Blood and Cancer*
2014–2017 Member, Editorial Board, *Blood*
2019–present Member, Statistical Review Committee, Cell Press

HONORS AND DISTINCTIONS

1967	Phi Beta Kappa, Northwestern University
1968–71	NDEA Title VI Fellowship in Russian, University of Chicago
1979	President's Award for Excellence in Teaching by a Graduate Student, SUNY at Stony Brook
1982–86	National Cancer Institute--National Institutes of Health Trainee in Biometry and Epidemiology, Department of Biostatistics, Harvard School of Public Health
2000–2001	Junior Faculty Sabbatical Award, Harvard School of Public Health
2010-2011	Dana Foundation grant to develop teaching module on “Practical Statistics for Chemical Biology” with James Bradner, M.D.
2015-2016	Dana Foundation grant to lead an immunology journal club to education biostatisticians about immuno-oncology

FUNDED GRANTS AND UNFUNDED PROJECTS (past 5 years):

COMPLETED GRANTS

2/10/2016 – 1/31/2019	Risk-Adapted Thromboprophylaxis of Hospitalized Cancer Patients NIH/NHLBI R34HL127156 (Zwicker) Subcontract from Beth Israel Deaconess Medical Center Site PI and Senior Biostatistician \$7,500 Senior Statistician Dr. Neuberger will provide a robust design of this study within the Dana-Farber/Harvard Cancer Center.
1/1/2017 – 12/31/2019	Leukemia Disease Program: Biostatistical Support Massachusetts General Hospital subcontract Biostatistician Dr. Neuberger will be working collaboratively with faculty members in the Leukemia Disease Program of the MGH Cancer Center, providing biostatistical expertise and support for new clinical trials in Leukemia. This will include study design and integrity, review and analysis of data accrued as a result of these studies. Dr. Neuberger will work closely with all faculty in order to ensure that all trials meet all benchmarks for design, significance and analysis.
10/1/2015 – 9/30/2018	Deciphering and Targeting Clonal Evolution in Hematologic Malignancies: Core B – DFCI Leukemia and Lymphoma Society grant (Ghobrial) Senior Statistician The overall goal of these projects is to combine genomics studies of tumor samples at the serial stages of disease progression in a prospective clinical trial and use mouse models to better understand how blood cancers evolve over time and how disease progression occurs during transformation from precursor states to full blown MM or AML.
5/21/2014 – 4/30/2018	Evolution of Vemurafenib Resistance in Circulating Melanoma Cells

NIH/NCI R01CA185151 (Novina)
Biostatistician

The goals of this proposal are to (1) generate transcriptional profiles from melanoma CTCs, (2) determine pathways of vemurafenib resistance, and (3) restore vemurafenib sensitivity in human melanoma cells by modulating CTC resistance pathways.

6/1/2014 - 5/31/2018

(PQ1) Impact of Cytotoxic and Targeted Therapy on Clonal Evolution of CLL

NIH/NCI R01CA184922 (Wu)
Senior Biostatistician

The major goals of this project are: 1) determine the role of clonal evolution in relapse to fludarabine-based treatment, 2) define the impact of targeted BTK inhibition on clonal evolution in CLL, and 3) establish the impact of mutation fitness and therapy on CLL clonal evolution in an animal model.

9/29/2013 – 7/31/2017

Dysregulated MicroRNA Function in Diamond Blackfan Anemia

NIH/NIDDK R01DK102165 (Novina)
Biostatistician

These studies will provide a rigorous biological basis for ribosomal gene mutations leading to anemia and cancer formation observed in Diamond Blackfan Anemia patients.

9/29/2016 – 9/14/2018

Discovering New Drug Targets in Radiation-Induced Myeloproliferative Neoplasms

DOD W81XWH-16-1-0591 (Balk) Subcontract from Beth Israel Deaconess Medical Center

Site PI and Senior Biostatistician \$6,214

The major goals on this project are to examine differences in prevalence of somatic *JAK2*, *MPL*, and *CALR* mutations in patients with MPN's exposed to ionizing radiation vs unexposed patients; perform whole-exome sequencing and high-density SNP array analysis and compare the somatic mutations and copy number variants acquired in patients with PMF who were previously exposed to ionizing radiation, compared to patients with PMF who were unexposed.

9/1/2011 - 7/31/2017 (NCE)

Analysis of Cap-Dependent Translational Repression by microRNAs in Oncogenesis

NIH/NCI R01CA140986 (Novina)
Biostatistician

T

The major goals of this project are: 1) determine the effect of eIF4E perturbation on cancer-relevant changes in melanomas, and 2) identify and functionally validate miRNA-targeted mRNAs affected by perturbing eIF4E in melanomas.

7/15/2012—6/30/2017

A Controlled Clinical Trial of Regadenoson in Sickle Cell Anemia

NIH/NHLBI P50HL1107905 (Nathan)
Biostatistician

This proposal supports a randomized, double-blind, placebo-controlled phase IIb trial of regadenoson for the treatment of acute vaso-occlusive episodes in children (>14 years) and adults with sickle cell disease.

2/11/2016 – 12/31/2019 **Targeting PML for Leukemia Therapy**
NIH/NCI subcontract, 5R01CA142874-04 (Pandolfi) Subcontract from Beth Israel Deaconess Medical Center
Site PI and Biostatistician \$6,205
Dr. Neuberg will be responsible for the design of the clinical study of the PPAR alpha inhibitor and for the analysis of all clinical and laboratory data collected on this study.

ACTIVE GRANTS

9/1/2015 – 7/31/2020 **Hematopoietic Stem Cell Transplantation for Young Adults with Sickle Cell Disease – DCC**
NIH/NHLBI 5U01HL128568-05 (Eapen) Subcontract from Medical College of Wisconsin
Site PI and Senior Biostatistician \$19,034
The goal of this project is to conduct a clinical trial which will test whether HCT from an HLA-matched donor is safe and effective in young adults with severe sickle cell disease, compared to a cohort lacking a donor.

6/1/2011 - 4/30/2021 **Personal Tumor Neoantigens for Immunity Against Chronic Lymphoma**
NIH/NCI R01CA155010 (Wu)
Biostatistician
The goals are to provide biostatistical support for the expansion of classes of targetable personal cancer neoantigens, the improvement of rules for predicting cancer neoantigens from sequencing data, and determine the co-evolution of immune response and CLL with neoantigen-specific immunity.

7/1/2016 – 6/30/2021 **Targetable Immune Evasion Pathways in Hodgkin Lymphoma**
NIH/NCI R01CA161026 (Shipp)
Biostatistician
The major goals of this project are to determine how *PD-L1/PD-L2* alterations in Hodgkin lymphoma impact response to PD-1 blockade.

9/1/2016 – 8/31/2021 **Comprehensive dissection of the CLL genome and phenome to improve patient outcomes – Core C: Biostatistics**
NIH/NCI 5P01CA206978-04 (Wu)
Core Director
Core C: Biostatistics will work with the members of Projects 2 and 3, and with the prima grafting component of Core B, to provide appropriate statistical designs for mouse and basic science studies, and will perform all analyses on behalf of these entities.

7/1/2016 – 6/30/2023 **Mechanisms and Vulnerabilities of Aberrant Transcriptional Enhancers in Cancer**

NIH/NCI 5R35CA210064-04 (Look)
Senior Biostatistician

The long-term goal of this Outstanding Investigator Award application is to experimentally dissect the specific DNA sequences, transcription factors, transcriptional adaptors and mediators, and epigenetic readers, writers and erasers that are required to form and sustain aberrant transcriptional enhancers capable of driving high levels of key oncogene expression in human cancer cells.

7/1/2016 - 6/30/2021

STOP-CA: Statins to Prevent Cardiotoxicity from Anthracyclines

NIH/NHLBI 5R01HL130539-04 (Scherrer-Crosbie/Neilan) Subcontract from Massachusetts General Hospital

Site PI and Senior Statistician \$23,505

Dr. Neuberg will be responsible for the statistical design of the study, the statistical analysis of the completed data, and the interpretation of the data. She will also supervise the junior statistician on the project.

9/30/2017 – 6/30/2022

Cancer Immune Monitoring and Analysis Center

NIH/NCI 5U24CA224331-03 (Wu)

Senior Biostatistician

The major goals of this project are to: 1) standardize a suite of high-quality immune monitoring techniques and protocols implemented across the proposed CIMACs; 2) collaborate amongst the CIMACs/CIDC to develop a coordinated data-collection structure; 3) perform a defined set of immune assays and analyses according to trial-specific priorities.

9/1/2016 - 8/31/2021

Personalized Vaccine for Patients with AML

NIH/NCI 5R01CA212649-04 (Avigan) Subcontract from Beth Israel Deaconess Medical Center

Site PI and Senior Biostatistician \$18,382

The major goals on this project are to conduct a clinical trial evaluating an autologous DC/AML fusion cell vaccine alone and in combination with an anti-PDL1 antibody, evaluating immune response and 2-year relapse-free survival. Correlative immune endpoints will also be studied. The project will also define biomarkers of response and characterize the immune landscape of the bone marrow microenvironment.

9/19/2017 – 7/31/2022

SPORE in Myeloid Malignancies - Core 1: Biostatistics

NIH/NCI 5P50CA206963-03 (Ebert)

Core Director

The overall goal of this SPORE in Myeloid Malignancies is to take advantage of our increased understanding of the genetic and molecular basis of AML and MDS to develop novel, effective therapeutic strategies for patients with these treatment-resistant neoplasms

7/5/2017 – 6/30/2020

Thromboprophylaxis with Rosuvastatin Following Surgery for Ovarian Cancer

NIH/NHLBI 5R34HL135226-03 (Zwicker) \$5,000 Subcontract from Beth Israel Deaconess Medical Center

Site PI and Senior Statistician

Dr. Neuberg will oversee the efforts of the junior statistician on this project and will advise on the details of analysis and design of the clinical and laboratory studies proposed in this R34.

5/11/2017 – 4/30/2022

(PQ8) Genetically Faithful Murine Models for Studying Disease Progression in Chronic Lymphocytic Leukemia

NIH/NCI 5R01CA216273-03 (Wu)

Senior Statistician

The major goals of this project include: 1) defining the mechanisms by which CLL is initiated, 2) determining CLL-intrinsic features that accelerate disease onset, and 3) identifying mutational events that lead to Richter's transformation (RT).

9/25/2019 – 8/31/2024

Biomaterials to Create T Cell Immunity

NIH/NCI 1U54CA244726-01 (Mooney) Subcontract from Harvard University

Biostatistician

T lymphocyte (**T-cell**) responses are key **to** cancer immunotherapy, and this proposal is focused on enhancing the anti-cancer activity of these cells using **biomaterials**. **T-cell** function can be compromised in a number of manners, and we will develop **biomaterials** that act at various stages of **T-cell** differentiation and activation **to** enhance anti-cancer **immunity** in a number of settings. By addressing a set of fundamental questions in immunoengineering, the results of these studies will advance the entire field, and at the same time yield major translational advances in cancer immunotherapy.

2/1/2019 – 2/1/2022

Clonal Hematopoiesis in Young Breast Cancer Survivors: Prevalence, Clonal Evolution, and Association with Clinical Outcomes and Late Effects

DT2019-009 V Foundation (Partridge)

Biostatistician

People who have been treated for cancer are not only at risk of cancer returning, but also at risk of long-term side effects of their treatments some of which may threaten their life, including heart disease and other cancers. Some people will develop changes in their blood cells called "Clonal Hematopoiesis" (CH) and people with these changes have recently been found to be at higher risk of developing serious problems such as cancer and heart attacks and dying. CH is found more in older than younger people and more commonly in people who have been treated for cancer. We don't know how common CH is in cancer survivors, who is at risk, when it develops and when and if we should be looking for it. But we are finding it more commonly with genetic tests that are being done as a part of their care. Our team hopes to provide answers to these questions by looking for CH in a group of women who were treated for breast cancer at a young age and agreed to give us blood samples and let us follow them over time. We will do special testing to find CH in their stored blood and see how it is different in different women, and changes over time. We will also ask them how they might feel about learning about CH results if they had

CH, how learning about these risks that might affect them, and what they might need to support them best to help them to manage these risks.

11/1/2018 – 10/31/2021

Biomarkers for a Phase I/II trial with anti-miR-155 in Diffuse Large B-cell Lymphoma

V Foundation T2018-007 (Slack) Subcontract from Beth Israel Deaconess Medical Center

Site PI and Biostatistician \$7,217

The major goals of this project include: 1) defining the mechanisms by which CLL is initiated, 2) determining CLL-intrinsic features that accelerate disease onset, and 3) identifying mutational events that lead to Richter's transformation).

9/1/2019 – 8/31/2024

Development of Novel Therapeutic Strategies in Human Myeloid Leukemias (Biostatistics Core 2)

NIH/NCI P01 (Ebert)

Core Director \$70,000

The major goals of this project are to provide biostatistical collaboration on the clinical, laboratory, murine and piscine studies of the grant.

8/1/2018 – 7/31/2023

Biomarkers and Mechanisms in Cancer-Associated Thrombosis

NIH/NHLBI 1U01HL143365-02 (Zwicker)

Site PI and Senior Statistician \$20,000

(Neuberg participation to begin year 3)

Blood clots are a common complication of cancer and are associated with significant suffering and increased likelihood of death. Our studies will use cutting-edge proteomic technology to identify markers of cancer-associated thrombosis allowing caregivers to identify cancer patients at greatest risk of thrombosis. These studies will also evaluate novel culture techniques and thrombotic pathways to identify factors that predispose pancreatic cancer patients to blood clots.

4/1/2020 – 3/31/2025

Understanding and Overcoming T cell Immunosuppression in GBM

NIH P01 (Chiocca)

Core Co-Director

Donna Neuberg, Sc.D. will take overall responsibility for the biostatistical support to the projects in this grant. This includes oversight of work done by Ms. Giobbie-Hurder in support of the clinical study and its correlatives in Project 1. Dr. Neuberg and Mr. Fell will take responsibility for support for the murine studies of Projects 2, 3, and 4.

9/1/2020 – 8/31/2023

Combining Locally Administered Ipilimumab with a Personalized Neoantigen Cancer Vaccine to Improve T Cell Priming and Anti-Tumor Immunity in High-Risk Renal Cell Carcinoma

DOD Research Grant (Choueiri)

Biostatistician

The specific aims of this project are: 1) Identify and characterize antigen presenting cells (APCs) that stimulate neoantigen-specific T cells following personal neoantigen vaccine with local IPI; 2) Determine the magnitude and characterize the phenotype, state, and functional

avidity of neoantigen-specific T cells following personal neoantigen vaccine with local IPI.

PENDING GRANTS

12/1/2019 – 11/30/2024

Conformational Regulation and Therapeutic Targeting of Oncogenic KRAS NIH/NCI 1R01CA233978-01A1 (Engen/Walensky)

Biostatistician

The major goals of this project are to advance the structure-function understanding of KRAS and inform a wholly new strategy for therapeutic targeting of KRAS in human cancer.

4/1/2019 – 3/31/2024

Loss of an Atypical Ribosomal Protein Kinase Riok2 Phenocopies MDS: Pathogenic Role of IL-22

NCI/NHLBI 1R01HL147110-01 (Glimcher)

Biostatistician

This proposal aims at uncovering and characterizing the mechanisms through which Riok2 contributes to MDS via its effect on two different cell types. Furthermore, this study will also undertake a translational approach in testing the efficacy of disabling IL-22 secreted by immune cells in alleviating MDS symptoms and reducing risk of progression to AML.

UNFUNDED PROJECTS

9/1/2018 – 8/31/2023

Cellular pathways and vulnerabilities impacted by SF3B1 mutation in CLL

The major goals of this project are to 1) define the key cellular pathways impacted by SF3B1 mutation, 2) validate candidate mediators of altered CLL pathways associated with mutated SF3B1, and 3) identify therapeutic opportunities generated by mutated SF3B1.

10/1/2018 – 9/30/2023

Deciphering and Targeting Clonal Evolution in Hematologic Malignancies: Core B

The overall goal of these projects is to combine deep sequencing of tumor samples at the serial stages of disease progression, the use of murine models of hematological malignancies, as well as state the art analysis of spatial and sequential clonal evolution in vivo to better understand how hematological malignancies evolve over time and how disease progression occurs during hematopoietic transformation.

12/1/2018 – 11/30/2022

The Unfolded Protein Response and Thrombosis in Pancreatic Cancer

The overall goals of this project include: 1) evaluating the mechanistic link between the UPR and hypercoagulability in pancreatic cancer, and 2) identifying UPR biomarkers and prothrombotic factors that predict thrombosis in patients with pancreatic cancer.

1/1/2019 – 12/31/2023

Phase 1 Clinical trial for Recurrent Glioblastoma with a Novel Oncolytic Virus and Cyclophosphamide Immunomodulation

This project plans to employ a form of immunotherapy that involves direct injection of a novel tumor-selective virus in the deadly brain cancer, glioblastoma. We plan to test in an early phase clinical trial in humans if there is a dose of this agent that is tolerated in humans with glioblastoma with or without additional modulation of the immune response with the drug, cyclophosphamide. As part of this clinical trial, we also will collect tumors, blood and MRIs to perform multiple scientific analyses.

7/1/2019 – 6/30/2024

CLL – A Molecular and Immunologic Model for Studying the Continuum of Cancer

Dr. Donna Neuberg is the senior statistician for the program in Lymphoma. She has worked in basic science, correlative, genomic, murine, and clinical studies in chronic lymphocytic leukemia (CLL) for nearly 30 years. Ms. Lillian Werner has worked in CLL for 10 years, and Mr. Robert Redd for 5 years. Together they will support the efforts of the P01 “CLL– A Molecular and Immunologic Model for Studying the Continuum of Cancer”. This involves the design, implementation, and analysis of basic science studies in all four Projects on this P01; of murine studies in Project 4; studies of the genetic basis of the kinetics of CLL; and of the immune cells that co-exist with CLL in Projects 2, 3, and 4. The clinical context from which the patients materials arise ranges from watch-and-wait after initial diagnosis through the continuum of CLL to the aggressive conversion to Richter's transformation.

6/1/2018 – 5/31/2023

Chronic Lymphocytic Leukemia Research Consortium – Core 1: Biostatistics

Donna Neuberg, Sc.D., has served as Core Leader for Biostatistics from the inception of the CRC. Dr. Neuberg oversees the biostatistical collaborations in the CRC, and has now again centralized statistical support at DFCI in Boston. She has participated in, and will continue to participate in, the Clinical Advisory Committee, the Internal Advisory Board, and, as a non-voting member, the Data Safety and Monitoring Board of the CRC. She will continue to provide logistical and statistical review of proposals to Dr. Rassenti of Core 2 to use samples deposited in the Tissue Core. She has worked with members of the Medical Informatics Group within the CRC and the Clinical Core (Core 3) to establish data collection, oversight, and output guidelines. She will continue her work with Dr. Wu, who now heads Project 2, and with Dr. Kipps of Project 3. She will over oversee the efforts of Ms. Werner and Mr. Redd in support of Project 4.

4/1/2018 – 3/31/2023

Molecular analysis and therapeutic targeting of intraclonal populations of CLL

Dr. Neuberg will oversee the statistical analysis of intraclonal fractions that will be performed through this grant and is responsible for the designs and analyses of the statistical studies.

10/1/2017 – 9/30/2020

GADD45A Promoter Methylation: Prognostic Utility in Elderly AML and Functional Characterization

Donna Neuberg, ScD will oversee the statistical analyses to be performed on this grant, and will advise on methods of experimental design and statistical analysis.

- 8/1/2017 – 7/31/2022 **BMI1 as Novel Oncomarker and Therapeutic Target in Small Cell Lung Cancer**
Donna Neuberg, ScD will oversee the design of the animal and single cell RNA-seq experiments, to assure robust and correct statistical design. She will also oversee the statistical technique selected for the analyses.
- 7/1/2017 – 6/30/2022 **Anti-BMI1 therapy in Non Small Cell Lung Cancer**
Donna Neuberg, ScD will oversee the design of the animal and single cell RNA-seq experiments, to assure robust and correct statistical design. She will also oversee the statistical technique selected for the analyses.
- 4/1/2017 – 3/31/2022 **DF/HCC SPORE in Melanoma and Skin Cancer: Core 2 - Biostatistics and Bioinformatics**
Core 2 - Biostatistics and Bioinformatics will provide all manner of statistical and computational support to the four projects in this SPORE, to the Developmental Research Projects, and to the individuals selected for the Career Enhancement Program. For the biostatistics component, this will include, but is not limited to, assistance with study design, data collection plans, statistical analysis, interim and final reporting, abstract and paper preparation, and assembly of data for public posting. For the bioinformatics component, this will include, but is not limited to, generating raw data, processing the results through established pipelines, analyzing the data, and public posting.
- 7/1/2016 – 6/30/2022 **The Boston Regional Sickle Cell Disease Implementation Consortium**
Dr. Donna Neuberg will provide statistical support for the design, implementation, and statistical analysis of the data collected in this effort to assess the standards of care and the reasons for declining longitudinal care in patients with sickle cell disease. She will also design and assist with the implementation of interventions to improve the quality of care identified through this effort, and will assess their success statistically.

TEACHING AND TRAINING

TEACHING IN HARVARD CHAN SCHOOL COURSES

Regular Courses, Department of Biostatistics, Primary Instructor

1987, 1988	BIO 251ab/BIO 220ab	Methods of Data Analysis
1989, 1990	HPB 203bc	Statistics for Health Policy and Management
1994, 1995	BIO 211cd	Regression and Analysis of Variance for Experimental Research
1995	BIO 268ab	Statistical Methods in Human Genetics
1996	BIO 217t	Linear Regression and Longitudinal Analyses
1997, 1998	BIO 214c	Principles of Clinical Trials
1998, 1999	BIO 222ab	Basics of Statistical Inference
2003	BIO 286	Introduction to Genomics
2003, 2004	BIO 232	Methods I
2004	BIO 289	Reading the Medical Literature
2005	BIO 205	Statistical Methods for Health and Social Policy

2009 BIO232 Methods I (course content revised from 2003–4)
2011-2014 BIO312 Consulting

Reading Courses, Department of Biostatistics, Primary Instructor

1996 Introduction to Computational Biology
1997 Introduction to Clinical and Biological Issues in Cancer
1999 Reading the Medical Literature Statistically

TEACHING IN OTHER COURSES

1991 Survival Analysis, taught to graduate students in biostatistics at Limburgs Universitair Centrum (LUC), Diepenbeek, Belgium.

1995–1997 Introduction to Biostatistics, a four hour short course for physicians, nurses, and data managers. Offered at semi-annual meetings of the Eastern Cooperative Oncology Group and at regular intervals at the Dana-Farber Cancer Institute.

2004–2006 Faculty Member, Methods in Clinical Cancer Research, Workshop Sponsored by American Society for Clinical Oncology and American Association for Cancer Research, Vail, Colorado.

2005 Faculty Member, The Astra/Zeneca Molecular and Translational Oncology Workshop, sponsored by the Cancer Education Consortium, March 16-20, Amelia Island, Florida

2008-2013 Instructor, Clinical Investigator Training Program, Beth-Israel Deaconess Medical Center. 20 hours of lecture on statistics for fellows and junior faculty entering second year of two-year program offering MMSc degree.

2009-2013 Module on Statistics for Hematology-Oncology Fellows, Beth Israel-Deaconess Medical Center.

2009 Faculty Member, Cancer Biostatistics Workshop sponsored by American Association for Cancer Research, Sonoma, California

2009-2016 Faculty Member, Clinical Investigator Training Seminars, Dana-Farber Cancer Institute training seminars for Fellows, Boston, MA

2009–2013 Faculty Member, Module on Statistics for Dana-Farber Cancer Institute Fellows, Clinical Research Institute, Dana-Farber Cancer Institute

2010-2011 Core Faculty Member, Translational Research Training in Hematology, sponsored by European Hematology Association and the American Society of Hematology, Marbella, Spain.

2010-2014 Faculty Member, Clinical Research Training Program, Sponsored by the American Society of Hematology, LaJolla, California

2011- 2013 Faculty Member, CB2200 Introduction to Chemical Biology, Harvard Medical School

- 2011-2014 Faculty Member, AACR Translational Cancer Research for Basic Scientists Workshop, Boston, Massachusetts
- 2012-2019 Core Faculty Member, Translational Research Training in Hematology, sponsored by European Hematology Association and the American Society of Hematology, Milano, Italy
- 2012 Faculty Member, American Association of Blood Banks Annual Meeting, “The Statistics Toolbox”, Boston, Massachusetts
- 2014-2015 Faculty Member, Lymphoma Research Foundation Lymphoma Clinical Research Mentoring Program (LCRMP), Scottsdale, Arizona
- 2016-2018 Biostatistics Faculty, Poussaint Pre-Matriculation Summer Program, Harvard Medical School, Boston, Massachusetts

ADVISORY AND SUPERVISORY RESPONSIBILITIES

TRAINING AND MENTORING

Dissertation Committee Member in Biostatistics, HCSPH

Patricia Stephenson (2002)
 Mahlet Tadesse (2002)
 Patrick Loerch (2007)

Dissertation Committee Member, representing the student's outside field in Biostatistics

Tina Bahadori	Environmental Health (1998)
Mark Woodin	Environmental Health (1998)
Rey de Castro	Environmental Health (2000)
David Miller	Environmental Health (2001)
Lisa Wang	Environmental Health and Epidemiology (2002)
Fiona Percy	Population and International Health (1999)
William MacLeod	Population and International Health (1999)
Carole Mitnick	Population and International Health (2001)
Christopher Huang	Division of Biological Sciences (2002)
Marsha Wilcox	Epidemiology (1999)

MENTEES

Statistical Mentees, Department of Data Sciences, Dana-Farber Cancer Institute

Shuli Li, PhD (2013-2018), currently a Research Scientist within the Department
 Emanuele Mazzola, PhD (2012-2016), currently a Research Scientist within the Department

Statistical Mentees through Pipelines in Biostatistics, HCSPH, ongoing mentorship

Sergio Barrera, PhD candidate in Health Economics, U Minnesota, Minneapolis, MN (class of 2015)

Rebekah Loving, PhD candidate in Computational Biology, California Institute of Technology, Pasadena, CA (class of 2016)

Thabat Dahdoul, PhD candidate in Biostatistics, UC Irvine, Irvine, CA (class of 2016)

Clinical Mentees through Clinical Research Training Institute (American Society of Hematology)

Huong Thien Marie Nguyen, MD (Stanford University, now at Assistant Professor, U Michigan, 2011)

Danielle Townsley, MD (NHLBI, 2013, now also at Medimmune)

Carla Casulo, MD (now Assistant Professor at U Rochester, 2013)

Betty Ky Hamilton, MD (now Associate Director, Blood and Marrow Transplant Program, Cleveland Clinic, 2013)

James Blachly, MD (now Assistant Professor, Ohio State University, 2014)

Emily Curran, MD, PhD (now Instructor, University of Chicago, 2015)

Clinical and Laboratory Research Mentees, Dana-Farber Cancer Institute

Jonathan Friedberg, MD, Professor of Medicine, U of Rochester, Rochester, NY, 1998-2004

Lili Wang, MD, PhD, Associate Professor of Medicine, City of Hope, Duarte, CA, 2010-2018

R. Coleman Lindsley, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, 2012-present

Jacqueline S. Garcia, MD, Instructor in Medicine, Harvard Medical School, Boston, MA, 2015-present

David Braun, MD, PhD, Instructor in Medicine, Harvard Medical School, Boston, MA, 2017-present

Statistical Mentoring to Members of the lab of Catherine J. Wu, MD, DFCI

Laboratory Mentees in Hematology through Translational Research Training in Hematology (sponsored by American Society of Hematology and European Hematology Association) (reflects ongoing mentorship beyond the expectations of the program)

Christian Scharenberg, MD, PhD, Karolinska Institute, Stockholm, Sweden, 2010-present

Simon Hallan, MD, PhD, Barts Health NHS Trust, London, England, UK, 2010-2014

Renee Beekman, MD, PhD, Centre for Genomic Regulation, Barcelona, Spain, 2011-present

Francine Garrett-Bakelman, MD, PhD, University of Virginia, Charlottesville, VA, 2012-present

Fabienne Lucas, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, 2011-2019

David Sykes, MD, PhD, Massachusetts General Hospital, Boston, MA, 2013-present

Elisa Ten Hacken, PhD, Dana-Farber Cancer Institute, Boston, MA, 2016-present

Julia Maxson, PhD, Oregon Health & Science University, Portland, OR, 2018-2020

Rikhia Chakraborty, PhD, Texas Children's Hospital, Houston, TX, 2018-present

Small Group Leader, Women in Hematology Mentoring Program, Annual Meeting of the American Society of Hematology, 2017

INVITED PRESENTATIONS

August 2001 Introductory Overview, Lecture on Microarray, Joint Statistical Meeting, Atlanta, GA.

May 2002 Meet the Professor Session, American Society of Clinical Oncology, Orlando, FL.

May 2003 Special Fellows Session, "Writing a Protocol and Getting it Approved," American Society of Clinical Oncology, Chicago, IL.

- June 2004 Clinical Research Grantsmanship for Junior Faculty, “Statistical Requirements for a Competitive Grant,” New Orleans, LA
- 2005 “Statistical Considerations: Clinical Trials of Novel Agents,” CEC/Astra Zeneca Molecular and Translational Oncology Workshop.
- April 2006 Scientist–Survivor Lecture, “Biostatistics: A Framework for Critique,” American Association for Cancer Research, Washington, D.C.
- April 2006 Educational Session, “Design Challenges of Targeted Therapies: An Overview,” American Association for Cancer Research, Washington, D.C.
- June 2006 Meet the Professor Session, “Caveat Lector: Potential Pitfalls in Interpreting Trial Results,” American Society of Clinical Oncology, Atlanta, GA.
- June 2006 Fellows Education Session, Mock Study Section, American Society of Clinical Oncology, Atlanta, GA.
- June 2008 Educational Session, “Early Data: Presentation and Publication of Preliminary Data,” American Society of Clinical Oncology, Chicago, IL. Chair and Speaker.
- March 2009 “Identification and Selection of Endpoints for Cancer Studies,” City of Hope, Duarte, California.
- May 2009 “Statistical Considerations: Beyond Clinical Endpoints,” Advanced Grant Writing Workshop, American Society of Clinical Oncology, Orlando, FL.
- January 2010 “The Challenge of Animal Studies,” City of Hope, Duarte, California.
- April 2010 “Targeting Design and Implementation in Personalized Medicine,” American Association for Cancer Research Annual Meeting, Washington, D.C. Chair and Speaker
- June 2010 “Statistical Consideration: Getting that Grant” Grant Writing Workshop, American Society of Clinical Oncology, Chicago, Illinois
- April 2011 “Biostatistics,” Scientist ↔ Survivor Program, American Association for Cancer Research Annual Meeting, Orlando, Florida.
- June 2011 “Statistical Consideration: Getting that Grant”, Grant Writing Workshop, American Society of Clinical Oncology, Chicago, Illinois
- June 2012 “How to talk with a statistician”, Grant Writing Workshop, American Society of Clinical Oncology, Chicago, Illinois
- October 2012 “The Statistics Toolbox”, Meeting of the American Association of Blood Banks, Boston, MA.
- June 2013 “How to talk with a statistician”, Grant Writing Workshop, American Society of Clinical Oncology, Chicago, Illinois

- November 2013 “The Role of Variability”, Translational Cancer Research for Basic Scientists Workshop, American Association for Cancer Research, Boston, MA
- November 2013 "The Answer is the Question: A Statistician's Perspective on Issues of Omics in Oncology", Satellite Workshop on Panomics Data Analysis, 45 minute presentation, IX. Diagnostic, Predictive and Experimental Oncology Days, Olomouc, Czech Republic. Sponsored by the Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic.
- November 2013 "Statistics in biomedicine in the 21st century: The challenges of collaboration", 60 minute presentation, IX. Diagnostic, Predictive and Experimental Oncology Days, Olomouc, Czech Republic. Sponsored by the Institute of Molecular and Translational Medicine, Palacky University, Olomouc, Czech Republic.
- December 2013 “Statistics and Basic/Translational Study Design”, ASH Trainee Day, Annual meeting of the American Society of Hematology, New Orleans, LA.
- September 2014 “Statistics and Basic/Translational Study Design”, Hematology/Oncology Grand Rounds, Rhode Island Hospital, Providence, RI
- November 2014 “The Role of Variability”, Translational Cancer Research for Basic Scientists Workshop, American Association for Cancer Research, Boston, MA
- March 2015 “Current Statistical Challenges in AML”, Hematology/Oncology Grand Rounds, Ulm University Hospital, Ulm, Germany
- May 2015 “Trials and Tribulations in AML”, Hematology/Oncology Grand Rounds in honor of International Clinical Trials Day, Manitoba CancerCare, Winnipeg, Manitoba, Canada
- June 2015 “Advice on Writing Grants”, with Heike Pahl, MD, PhD. As part of the Early Career Program, European Hematology Association Congress, Vienna, Austria
- June 2015 “Advice on Writing Papers”, with Heike Pahl, MD, PhD. As part of the Early Career Program, European Hematology Association Congress, Vienna, Austria
- November 2015 “The Role of Variability”, Translational Cancer Research for Basic Scientists Workshop, American Association for Cancer Research, Boston, MA
- January 2016 “The Challenge of Clinical Research”, Hematology/Oncology Grand Rounds, Mayo Clinic, Scottsdale, AZ
- January 2016 “Advice about Statistics”, Cell Press, Cambridge, MA.
- April 2016 “A Taxonomy of Early Phase Clinical Trials”, presentation to the Leukemia Clinical Program of the DF/HCC
- November 2016 “The Role of Variability”, Translational Cancer Research for Basic Scientists Workshop, American Association for Cancer Research, Boston, MA
- June 2017 “Be(a)ware of Biostatistics”. Invited talk at the 22nd Annual Congress of the European Hematology Association, Madrid, Spain

PATENTS

- 2012 Signatures for predicting the survivability of myelodysplastic syndrome subjects (with Benjamin Ebert, Rafael Bejar, and Kristen Stevenson) PCT/US2012/042734
- 2014 Methods for determining response to a hypomethylating agent (with Benjamin Ebert, Rafael Bejar, and Kristen Stevenson) PCT/US2014/037717

BIBLIOGRAPHY

PEER-REVIEWED PUBLICATIONS:

Original Research

1. Green R, Finch SJ, Neuberg DS. Sex-typed motor behaviors of "feminine" boys, conventionally masculine boys, and conventionally feminine girls. *Sex Roles*. 1983; 9(5):571-579.
2. Freeman WR, Chen A, Henderly DE, Levine AM, Luttrull JR, Urrea PT, Arthur J, Rasheed S, Cohen JL, Neuberg D, Leung RJ. Prevalence and significance of acquired immunodeficiency syndrome-related retinal microvasculopathy. *Am J Ophthalmology*. 1989; 107(3):229-235.
3. Robins HI, Neuberg DS, Benson AB, Pandya KJ, Tormey DC. Phase II Study of Lonidamine in patients with metastatic breast cancer: An Eastern Cooperative Oncology Group Study. *Invest New Drugs*. 1990; 8(4):397-399.
4. Ransom DT, Neuberg D, Loprinzi CL, Tormey DC, Blum RH, Harris JE, Asbury RF, Falkson G. A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer. *Am J Clin Oncol*. 1991; 14(1):45-48.
5. Gelman R, Neuberg D. Making cocktails versus making soup. *J Clin Oncol*. 1991; 9(2):200-203.
6. Rabinowe SN, Soiffer R, Tarbell N, Neuberg D, Freedman AS, Seifter J, Blake K, Gribben JG, Anderson KC, Takvorian T, Ritz J, Nadler LM. Hemolytic-Uremic Syndrome following bone marrow transplantation for hematologic malignancies. *Blood*. 1991; 77(8):1837-1844.
7. Freedman AS, Ritz J, Neuberg D, Anderson KC, Rabinowe SN, Takvorian T, Mauch P, Soiffer R, Blake K, Yeap B, Coral F, Heflin L, Nadler LM. Autologous bone marrow transplantation in 69 patients with low-grade B-cell non-Hodgkin's lymphoma. *Blood*. 1991; 77(11):2524-2529.
8. Benacerraf BR, Neuberg D, Frigoletto FD. Humeral shortening in second-trimester fetuses with Down syndrome. *Obstet Gynecol*. 1991; 77(2):223-227.
9. Gribben JG, Freedman AS, Neuberg D, Roy DC, Blake KW, Woo SD, Grossbard ML, Rabinowe SN, Coral F, Freeman GJ, Ritz J, Nadler LM. Immunologic purging of marrow assessed by PCR before autologous bone marrow transplantation for B-cell lymphoma. *N Engl J Med*. 1991; 325(22):1525-1533.
10. Milton DK, Feldman HA, Neuberg DS, Bruckner RJ, Greaves IA. Environmental endotoxin measurement: The kinetic limulus assay with resistant-parallel-line estimation. *Environ Res*. 1992; 57(2):212-230.
11. Benacerraf B, Neuberg D, Bromley B, Frigoletto F. Sonographic scoring index for prenatal detection of chromosomal abnormalities. *J Ultrasound Med*. 1992; 11(9):449-458.

12. Tahan SR, Neuberg DS, Dieffenbach A, Yacoub L. Prediction of early relapse and shortened survival in patients with breast cancer by proliferating cell nuclear antigen (PCNA) score. *Cancer*. 1993; 71(11):3552-3559.
13. Freedman AS, Takvorian T, Neuberg D, Mauch P, Rabinowe SN, Anderson KC, Soiffer RJ, Spector N, Robertson MJ, Blake K, Coral F, Canellos GP, Ritz J, Nadler LM. Autologous bone marrow transplantation in poor prognosis intermediate grade and high grade B-cell non Hodgkin's lymphoma in first remission: a pilot study. *J Clin Oncol*. 1993; 11(5):931-936.
14. Gribben JG, Neuberg D, Freedman AS, Gimmi CD, Pesek KW, Barber M, Saporito L, Woo SD, Coral F, Spector N, Rabinowe SN, Grossbard ML, Ritz J, Nadler LM. Detection by Polymerase Chain Reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. *Blood*. 1993; 81(12):3449-3457.
15. Saphner T, Troxel AB, Tormey DC, Neuberg D, Robert NJ, Bennett JM, Edmonson JH, Rosenbluth RJ, Abeloff MD. Phase II study of goserelin for patients with postmenopausal breast cancer. *J Clin Oncol*. 1993; 11:1529-1535.
16. Rabinowe SN, Soiffer RJ, Gribben JG, Daly H, Freedman AS, Daley J, Pesek K, Neuberg D, Pinkus G, Leavitt PR, Spector NA, Grossbard ML, Anderson K, Robertson MJ, Mauch P, Chayt-Marcus K, Ritz J, Nadler LM. Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia. *Blood*. 1993; 82(4):1366-1377.
17. Rabinowe SN, Neuberg D, Bierman PJ, Vose JM, Nemunaitis J, Singer JW, Freedman AS, Mauch P, Demetri G, Onetto N, Gillis S, Oette D, Buckner D, Hansen JA, Ritz J, Armitage JO, Nadler LM, Appelbaum FR. Long term follow-up of a phase III study of rhGM-CSF after autologous bone marrow transplantation for lymphoid malignancies. *Blood*. 1993; 81(7):1903-1908.
18. Forastiere AA, Neuberg D, Taylor SG, DeConti R, Adams G. Phase II evaluation of taxol in advanced head and neck cancer: an Eastern Cooperative Oncology Group Trial. *JNCI Monographs*. 1993; (15):181-184.
19. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S, Abner A, Recht A, Vicini F, Harris JR. Relationship of patient age to pathologic features of the tumor and prognosis for patients with Stage I or II breast cancer. *J Clin Oncol*. 1994; 12(5):888-894.
20. Breuer CK, Tarbell NJ, Mauch PM, Weinstein HJ, Morrissey M, Neuberg D, Shamberger RC. The importance of staging laparotomy in pediatric Hodgkin's Disease. *J Ped Surg*. 1994; 29(8):1085-1089.
21. Nixon AJ, Recht A, Neuberg D, Connolly J, Schnitt S, Abner A, Harris JR. The relation between the surgery-radiotherapy interval and treatment outcome in patients treated with breast-conserving surgery and radiation therapy without systemic therapy. *Int J Radiat Oncol Biol Phys*. 1994; 30(1):17-21.
22. Roth BJ, Dreicer R, Einhorn LH, Neuberg D, Johnson DH, Smith JL, Hudes GR, Schultz SM, Loehrer PJ. Significant activity of Paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group. *J Clin Oncol*. 1994; 12(11):2264-2270
23. Stone RM, Neuberg D, Soiffer R, Takvorian T, Whelan M, Rabinowe SN, Aster JC, Leavitt P, Mauch P, Freedman AS, Nadler LM. Myelodysplastic Syndrome as a late complication following autologous bone marrow transplantation for non-Hodgkin's Lymphoma. *J Clin Oncol*. 1994; 12(12):2535-2542.
24. O'Day S, Rabinowe S, Neuberg D, Freedman A, Soiffer R, Robertson M, Spector N, Grossbard M, Anderson K, Whelan M, Pesek K, Ritz J, Nadler L. A Phase II study of continuous infusion

- recombinant human granulocyte-macrophage colony-stimulating factor (rhGM-CSF) as an adjunct to autologous bone marrow transplantation for non-Hodgkin's lymphoma in first remission. *Blood*. 1994; 83(9):1903-1908.
25. Gribben JG, Neuberg D, Barber M, Moore J, Pesek KW, Freedman AS, Nadler LM. Detection of residual lymphoma cells by polymerase chain reaction in peripheral blood is significantly less predictive for relapse than detection of bone marrow. *Blood*. 1994; 83(12):3800-3807.
 26. Pai SY, Fruman DA, Leong T, Neuberg D, Rosano TG, McGarigle C, Antin JH, Bierer BE. Inhibition of calcineurin phosphatase activity in adult bone marrow transplant patients treated with cyclosporine A. *Blood*. 1994; 84(11):3974-3979.
 27. Sledge GW Jr, Robert N, Sparano JA, Cobleigh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill-Stevens W. Paclitaxel (Taxol)/doxorubicin combinations in advanced breast cancer: the Eastern Cooperative Oncology Group experience. *Seminars in Oncology*. 1994; 21(5 Suppl 8):15-18.
 28. Whittington R, Neuberg D, Testev WJ, Haller DG, Benson AB III. Protracted intravenous Fluorouracil infusion with radiation therapy in the management of localized pancreaticobiliary carcinoma: A phase I ECOG trial. *J Clin Oncol*. 1995; 13(1):227-232.
 29. Wolff AC, Ettinger DS, Neuberg D, Comis RL, Ruckdeschel JL, Bonomi PD, Johnson DH. Phase II study of ifosfamide, carboplatin, and oral etoposide chemotherapy for extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group Pilot Study. *J Clin Oncol*. 1995; 13(7):1615-1622.
 30. Clark JL, Kucuk O, Neuberg DS, Benson AB, Taylor SG, Pandya KJ, Mansour EG, Douglass HO, Haller DG. Phase II trial of etoposide, doxorubicin, and cisplatin combination in advanced measurable gastric cancer. *Am J Clin Oncol*. 1995; 18(4):318-324.
 31. Molrine DC, George S, Tarbell N, Mauch P, Diller L, Neuberg D, Shamberger RC, Anderson EL, Phillips NR, Kinsella K, Ambrosino DM. Antibody responses to polysaccharide and polysaccharide-conjugate vaccines following treatment for hodgkin's disease. *Ann Intern Med*. 1995;123(11):828-834.
 32. Shipp MA, Neuberg D, Janicek M, Canellos G, Shulman LN. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-hodgkin's lymphoma: a dose-finding pilot study. *J Clin Oncol*. 1995; 13(12):2916-2923.
 33. Wadler S, Burk RD, Neuberg D, Rameau R, Runowicz CD, Goldberg G, McGill F, Tachezy R, Comis R, Edmonson J, Wiernik PH. Lack of efficacy of interferon- α therapy in recurrent, advanced cervical cancer. *J Interferon & Cytokine Res*. 1995; 15(12):1011-1016.
 34. Sledge GW Jr, Robert N, Sparano JA, Cogleigh M, Goldstein LJ, Neuberg D, Rowinsky E, Baughman C, McCaskill-Stevens W. Eastern Cooperative Oncology Group studies of paclitaxel and doxorubicin in advanced breast cancer. *Semin Oncol* 1995;22(3 Suppl. 6):105-8.
 35. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R, Benson A. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. *J Clin Oncol*. 1996; 14(1):149-155.
 36. Cobau CD, Declercq K, Neuberg D, Ingle J, Tormey DC. A randomized trial of megestrol acetate with or without premarin in the treatment of potentially responsive metastatic breast cancer: a study of the Eastern Cooperative Oncology Group (E2185). *Cancer*. 1996; 77(3):483-9.
 37. Freedman AS, Gribben JG, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Pandite L, Robertson MJ, Kroon M, Ritz J, Nadler LM. High dose therapy and autologous bone marrow transplantation in patients with follicular lymphoma during first remission. *Blood*. 1996; 88(7):2780-2786.

38. Provan D, Zwicky C, Bartlett-Pandite L, Maddocks A, Corradini P, Soiffer R, Neuberg D, Ritz J, Nadler LM, Gribben JG. Eradication of PCR detectable chronic lymphocytic leukemia cells is associated with improved outcome after bone marrow transplantation. *Blood*. 1996; 88(6): 2228-2235.
39. McLean TW, Ringold S, Neuberg D, Stegmaier K, Tantravahi R, Ritz J, Koeffler HP, Takeuchi S, Janssen JWG, Seria T, Bartram CR, Sallan SE, Gilliland OG, Golub TR. TEL/AML-1 dimerizes and is associated with a favorable outcome in childhood acute lymphoblastic leukemia. *Blood*. 1996; 88(11):4252-4238.
40. Einzig AI, Neuberg D, Remick SC, Karp DD, O'Dwyer PJ, Stewart JA, Benson III AB. Phase II trial of docetaxel (taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results (E1293). *Medical Oncology*. 1996; 13(2): 87-93.
41. Einzig AI, Neuberg D, Wiernik PH, Grochow LB, Ramirez G, O'Dwyer PJ, Petrelli NJ. Phase II trial of paclitaxel in patients with advanced colon cancer previously untreated with cytotoxic chemotherapy: An ECOG trial (PA286). *Am J Ther* 1996; 3(11):750-754.
42. Olson JE, Neuberg D, Pandya KJ, Richter MP, Solin LJ, Gilchrist KW, Tormey DC, Veeder M, Falkson G. The role of radiotherapy in the management of operable locally advanced breast carcinoma. *Cancer*. 1997; 79(6):1138-1149.
43. Janicek M, Kaplan W, Neuberg D, Canellos GP, Shulman LN, Shipp MA. Early restaging gallium scans predict outcome in poor-prognosis patients with aggressive non-hodgkin's lymphoma treated with high-dose CHOP chemotherapy. *J Clin Oncol*. 1997; 15(4):1631-1637.
44. Sparano JA, Neuberg D, Glick JH, Robert NJ, Goldstein LJ, Sledge GW, Wood W. Phase II trial of biweekly paclitaxel and cisplatin in advanced breast carcinoma: an Eastern Cooperative Oncology Group Study. *J Clin Oncol*. 1997; 15(5):1880-1884.
45. Leaf AN, Schwartz E, Forestiere A, Neuberg D, Wadler S, Ritch P. An Eastern Cooperative Oncology Group Phase II study of amonafide in squamous cell carcinoma head and neck. *Investigational New Drugs*. 1997, 15(2):165-172.
46. Paietta E, Racevskis J, Neuberg D, Rowe JM, Wiernik PH. Expression of CD25 (Interleukin-2 receptor % chain) in adult acute lymphoblastic leukemia predicts for the presence of BCR/ABL fusion transcripts: results of a preliminary laboratory analysis of ECOG/MRC intergroup study E2993. *Leukemia*. 1997; 11(11):1887-1890.
47. Freedman A, Neuberg D, Mauch P, Gribben J, Soiffer R, Anderson K, Robertson M, Fisher DC, Schlossman R, Kroon, Rhuda C, Khulman C, Ritz J, Nadler L. Cyclophosphamide, doxorubicin, vincristine, prednisone dose intensification with granulocyte colony-stimulating factor markedly depletes stem cell reserve for autologous bone marrow transplantation. *Blood*. 1997; 90(12):4996-5001.
48. Schiller JH, Neuberg D, Burns D, Ritch P, Levitt M, Dutcher J. An Eastern Cooperative Oncology Group Phase I Trial of all-trans retinoic acid and interferon-alpha E2Y92. *Investigational New Drugs*. 1997; 15(4):319-324.
49. Claret EJ, Alyea EP, Orsini E, Pickett CC, Collins H, Wang Y, Neuberg D, Soiffer RJ, Ritz J. Characterization of T cell repertoire in patients with graft-versus-leukemia following donor lymphocyte infusion. *Journal of Clinical Investigation*. 1997; 100(4):855-866.
50. Andersen NS, Donovan JW, Borus JS, Poor CM, Neuberg D, Aster JC, Nadler, LM, Freedman AS, Gribben JG. Resistance to immunological purging in mantle cell lymphoma assessed by PCR detection of minimal residual disease. *Blood*. 1997; 90(10):4212-4221.

51. McCaskill-Stevens W, Sparano J, Cobleigh M, Robert N, Baughman C, Neuberg D, Rowinsky E, Sledge Jr GW. Pilot trial of alternating paclitaxel and doxorubicin in advanced breast cancer. *Breast Journal*. 1997; 3(1):19-24.
52. Wadler S, Bajaj R, Neuberg D, Agarwal V, Haynes H, Benson AB. Prognostic implications of c-Ki-ras2 mutations in patients with advanced colorectal cancer treated with 5-fluorouracil and interferon: a study of the Eastern Cooperative Oncology Group (EST 2292). *Cancer J Sci Am*. 1997; 3(5):284-288.
53. Larson GP, Zhang GX, Ding SF, Foldenauer K, Udar N, Gatti RA, Neuberg D, Lunetta KL, Ruckdeschel JC, Longmate J, Flanagan S, Krontiris TG. An allelic variant at the ATM locus is implicated in breast cancer susceptibility. *Genetic Testing*. 1997; 1(3):165-170.
54. Hegedus KS, Madden JE, Neuberg D. Incongruence between nurses' and parents' perceptions of nurses' caring behaviors in a neonatal intensive care unit. *J Perinatol*. 1997; 17(5):393-6.
55. Freedman AS, Neuberg D, Gribben JG, Mauch P, Soiffer RJ, Fisher DC, Anderson KC, Andersen N, Schlossman R, Kroon M, Ritz J, Aster J, Nadler LM. High-dose chemoradiotherapy and anti-b-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle cell lymphoma: no evidence for long-term remission. *J Clin Oncol*. 1998; 16(1): 13-18.
56. Hellman R, Neuberg DS, Wagner H, Grunnet M, Robins HI, Karp D, Flynn P, Adams G. A therapeutic trial of radiation therapy with Vincristine, VP-16, and Procarbazine (VVP) in high grade intracranial gliomas: an Eastern Cooperative Oncology Group Study (E2392). *J Neurooncol*. 1998; 37(1):55-62.
57. Forastiere AA, Shank D, Neuberg D, Taylor IV SG, DeConti RC, Adams G. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck. An Eastern Cooperative Oncology Group Trial (PA390). *Cancer*. 1998; 82(11):2270-2274.
58. Yakushijin Y, Steckel J, Kharbanda S, Hasserjian R, Neuberg D, Jiang W-M, Anderson I, Shipp MA. A directly spliced exon 10-containing CD44 variant promotes the metastasis and homotypic aggregation of aggressive non-hodgkin's lymphoma. *Blood*. 1998; 91(11): 4282-4291.
59. Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J. Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplantation. *Blood*. 1998; 91(10):3671-3680.
60. Wadler S, Atkins M, Karp D, Neuberg D, Haynes H, Dutcher JP. Clinical trials of weekly intensive therapy with 5-fluorouracil on two different schedules combined with interferon α -2a and filgrastim in patients with advanced solid tumors: Eastern Cooperative Oncology Group Study P-Z991. *The Cancer Journal from Scientific American*. 1998; 4(4):261-268.
61. Diller L, Ghahremani M, Morgan J, Grundy P, Reeves C, Breslow N, Green D, Neuberg D, Pelletier J, Li FP. Constitutional WT1 mutations in Wilms' tumor patients. *J Clin Oncol*. 1998; 16(11):3634-3640.
62. Soiffer R, Lynch T, Mihm M, Jung K, Rhuda C, Schmollinger JC, Hod FS, Liebster L, Lam P, Mentzer S, Singer S, Tanabe KT, Cosimi AB, Duda R, Sober A, Bhan A, Daley J, Neuberg D, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Clift S, Cohen LK, Mulligan RC, Dranoff G. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. *Proc Natl Acad Sci*. 1998; 95(22):13141-13146.
63. Soiffer RJ, Freedman AS, Neuberg D, Fisher DC, Alyea EP, Gribben J, Schlossman RL, Bartlett-Pandite L, Kuhlman C, Murray C, Freeman A, Mauch P, Anderson KC, Nadler LM, Ritz J. CD6+

- T cell depleted allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. *Bone Marrow Transplantation*. 1998; 21(12):1177-1181.
64. Paietta E, Racevskis J, Bennett JM, Neuberg D, Cassileth PA, Rowe JM, Wiernik PH, for the Eastern Cooperative Oncology Group. Biologic heterogeneity in Philadelphia chromosome positive acute leukemia with myeloid morphology: The Eastern Cooperative Oncology Group. *Leukemia*. 1998; 12(12):1881-1885.
 65. Eng C, Thomas GA, Neuberg DS, Mulligan LM, Healey CS, Houghton C, Frilling A, Raue F, Williams ED, Ponder AJ. Mutation of the RET proto-oncogene is correlated with RET immunostaining in subpopulations of cells in sporadic medullary thyroid carcinoma. *J Clin Endocrinol Metab*. 1998; 83(12):4310-4313.
 66. Gollob JA, Schnipper CP, Orsini E, Murphy E, Daley JF, Lazo SB, Frank DA, Neuberg D, Ritz J. Characterization of a novel subset of CD8(+) T cells that expands in patients receiving interleukin-12. *J Clin Invest*. 1998; 102(3):561-575.
 67. Mach-Pascual S, Legare RD, Lu D, Kroon M, Neuberg D, Tantravahi R, Stone RM, Freedman AS, Nadler LM, Gribben JG, Gilliland DG. Predictive value of clonality assays in patients with non-Hodgkin' lymphoma undergoing autologous bone marrow transplant: a single institution study. *Blood*. 1998; 91(12):4496-4503.
 68. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, Kinchla NM, Neuberg D, Waller EK, Antin JH, Soiffer R, Vredenburgh J, Lill M, Woolfrey AE, Bearman SI, Iacobelli M, Fareed J, Guinan EC. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. *Blood*. 1998; 92(3):737-744.
 69. Loh ML, Silverman LB, Young ML, Neuberg D, Golub TR, Sallan SE, Gilliland DG. Incidence of TEL/AML1 fusion in children with relapsed acute lymphoblastic leukemia. *Blood*. 1998; 92(12):4792-4797.
 70. Gimm O, Neuberg DS, Marsh DJ, Dahia PLM, Hoang-Vu C, Friedhelm R, Hinze R, Dralle H, Eng C. Over-representation of a germline RET sequence variant in patients with sporadic medullary thyroid carcinoma and somatic RET codon 918 mutation. *Oncogene*. 1999; 18(6):1369-1373.
 71. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson AB III. Final report of intergroup trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. *Int J Radiation Oncol Biol. Phys*. 1999; 43(3):517-523.
 72. Nichols KE, Levitz S, Shannon KE, Wohrer DCR, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishiaka C, Haber DA, Diller L. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. *J Clin Oncol*. 1999; 17(4):1259-1266.
 73. Guinan EC, Boussiotis VA, Neuberg D, Brennan LL, Hirano N, Nadler LM, Gribben JG. Transplantation of anergic histoincompatible bone marrow allografts. *N Engl J Med*. 1999; 340(22):1704-1714.
 74. She J-X, Ellis TM, Wilson SB, Wasserfall CH, Marron M, Reimsneider S, Kent SC, Hafler DA, Neuberg DS, Muir A, Strominger JL, Atkinson MA. Heterophile antibodies segregate in families and are associated with protection from type 1 diabetes. *Proc Natl Acad Sci USA*. 1999; 96(14):8116-8119.
 75. Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, Takvorian T, Fisher DC, Schlossman R, Fallow H, Kuhlman C, Ritz J, Freedman AS. Autologous bone marrow

- transplantation after histologic transformation of indolent B cell malignancies. *Biology of Blood and Bone Marrow Transplantation*. 1999; 5(4):262-268.
76. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A, Mauch PM, Gribben JG, Ritz J, Nadler LM, Soiffer R, Freedman A. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. *J Clin Oncol* 1999; 17(10):3128-3135.
 77. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC, Schlossman R, Alyea EP, Takvorian T, Jallow H, Kuhlman C, Ritz J, Nadler LM, Gribben JG. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. *Blood* 1999; 94(10):3325-3333.
 78. Lunetta KL, Wilcox M, Smoller J, Neuberg D. Exploring linkage for alcoholism using affection status and quantitative event related potential phenotypes. *Genetic Epidemiology* 1999; 17(Suppl 1):S241-S246.
 79. Wilcox M, Smoller J, Lunetta KL, Neuberg D. Using recursive partitioning for exploration and follow-up of linkage and association analyses. *Genetic Epidemiology* 1999; 17(Suppl 1):S391-S396.
 80. Grossbard ML, Multani PS, Freedman AS, O'Day S, Gribben JG, Rhuda C, Neuberg D, Nadler LM. A phase II study of adjuvant therapy with anti-B4-blocked ricin after autologous bone marrow transplantation for patients with relapsed B-cell non-hodgkin's lymphoma. *Clin Cancer Res* 1999; 5(9): 2392-2398.
 81. Duerr EM, Gimm O, Neuberg DS, Kum JB, Clifford SC, Toledo SP, Maher ER, Dahia PL, Eng C. Differences in allelic distribution of two polymorphisms in the VHL-associated gene CUL2 in pheochromocytoma patients without somatic CUL2 mutations. *J Clin Endocrinol Metab*. 1999, Sep; 84(9):3207-11.
 82. Wu CJ, Chillemi A, Alyea EP, Orsini E, Neuberg D, Soiffer RJ, Ritz J. Reconstitution of T-cell receptor repertoire diversity following T-cell depleted allogeneic bone marrow transplantation is related to hematopoietic chimerism. *Blood* 2000; 95(1):352-359.
 83. Horning SJ, Williams J, Bartlett NL, Bennett JM, Hoppe RT, Neuberg D, Cassileth P. Assessment of the Stanford V Regimen and consolidative radiotherapy for bulky and advanced Hodgkin's disease: ECOG Pilot Study E1492. *J Clin Oncol* 2000; 18(5):972-980.
 84. Orsini E, Alyea EP, Schlossman R, Canning C, Soiffer RJ, Chillemi A, Neuberg D, Anderson KC, Ritz J. Changes in T cell receptor repertoire associated with graft-versus-tumor effect and graft-versus-host disease in patients with relapsed multiple myeloma after donor lymphocyte infusion. *Bone Marrow Transplantation* 2000; 25(6):623-632.
 85. Sternberg DW, Aird W, Neuberg D, Thompson L, MacNeill K, Amrein P, Shulman LN. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine. *Cancer*. 2000; 88(9):2037-2041.
 86. Porteus MH, Narkool P, Neuberg D, Guthrie K, Breslow N, Green DM, Diller L. Characteristics and outcome of children with Beckwith-Wiedemann Syndrome and Wilms' Tumor: A report from the National Wilms Tumor Study Group. *J Clin Oncol* 2000; 18(10):2026-2031.
 87. Donovan JW, Ladetto M, Zou G, Neuberg D, Poor C, Bowers D, Gribben JG. Immunoglobulin heavy-chain consensus probes for real-time PCR quantification of residual disease in acute lymphoblastic leukemia. *Blood* 2000; 95(8):2651-2658.
 88. Woodin MA, Liu Y, Neuberg D, Hauser R, Smith TJ, Christiani DC. Acute respiratory symptoms in workers exposed to vanadium-rich fuel-oil ash. *Am J Ind Med* 2000; 37(4):353-363.

89. DeFranceschi L, Bachir D, Galacteros F, Tchernia G, Cynober T, Neuberg D, Beuzard Y, Brugnara C. Oral magnesium pidolate: effects of long-term administration in patients with sickle cell disease. *Br J Haematol* 2000; 108(2):284-289.
90. Frohlich DE, Chen JL, Neuberg D, Kehoe KM, Van den Abbeele AD. When is hilar uptake of ⁶⁷Ga-citrate indicative of residual disease after CHOP chemotherapy. *J Nucl Med* 2000; 41(2):269-274.
91. Grupp SA, Stern JW, Bunin N, Nancarrow C, Ross AA, Mogul M, Adams R, Grier HE, Gorlin JB, Shamberger R, Marcus K, Neuberg D, Weinstein JH, Diller L. Tandem high-dose therapy in rapid sequence for children with high-risk neuroblastoma. *J Clin Oncol* 2000; 18(13): 2567-2575.
92. Wu CJ, Yang XF, McLaughlin S, Neuberg D, Canning C, Stein B, Alyea EP, Soiffer RJ, Dranoff G, Ritz J. Detection of a potent humoral response associated with immune-induced remission of chronic myelogenous leukemia. *J Clin Invest* 2000; 106(5):705-714.
93. Tallman MS, Neuberg DS, Bennett JM, Fancois C, Paietta E, Wiernik PH, Dewald G, Cassileth PA, Oken MM, Rowe JM. Acute megakaryocytic Leukemia: The ECOG Experience. *Blood* 2000; 96(7): 2405-2411.
94. Jacobson JO, Grossbard M, Shulman LN, Neuberg D. CHOP chemotherapy with preemptive granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma: a dose-intensity analysis. *Clinical Lymphoma* 2000; 1(3): 211-217.
95. Robinson SN, Freedman AS, Neuberg DS, Nadler LM, Mauch PM. Loss of marrow reserve from dose-intensified chemotherapy results in impaired hematopoietic reconstitution after autologous transplantation: CD34⁺, CD34⁺38⁻, and week-6 CAFC assays predict poor engraftment. *Experimental Hematology*. 2000; 28(12):1325-1333.
96. Paietta E, Neuberg D, Richards S, Bennett JM, Han, L, Racevskis J, Dewald G, Rowe JM, Wiernik, PH and the Eastern Cooperative Oncology Group. Rare adult acute lymphocytic leukemia with CD56 expression in the ECOG experience shows unexpected phenotypic and genotypic heterogeneity. *American Journal of Hematology* 2001; 66(3):189-196.
97. Hochberg EP, Chillemi AC, Wu CJ, Neuberg D, Canning C, Hartman K, Alyea EP, Soiffer RJ, Kalams SA, Ritz J. Quantitation of T-cell neogenesis in vivo after allogeneic bone marrow transplantation in adults. *Blood*. 2001; 98(4):1116-1121.
98. Friedberg JW, Neuberg D, Monson J, Fallow H, Nadler LM, Freedman AS. The impact of external beam radiation therapy prior to autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma. *Biology of Blood and Marrow Transplantation*. 2001; 7(8):446-453.
99. Gradishar WJ, Stephenson P, Glover DJ, Neuberg DS, Moore MR, Windschiti HE, Piel I, Abeloff MD. A phase II trial of cisplatin plus WR-2721 (Amifostine) for metastatic breast carcinoma. *Cancer*. 2001; 92(10):2517-2522.
100. Mutter GL, Baak JPA, Fitzgerald JT, Gray R, Neuberg D, Kust GA, Gentleman R, Gullans SR, Wei LJ, Wilcox M. Global expression changes of constitutive and hormonally regulated genes during endometrial neoplastic transformation. *Gynecol Oncol*. 2001; 83(2):177-185.
101. Page GP, Wilcox MA, Occhiuto J, Adak S, Neuberg D, Bajorunaite R, George V. Comparison of the QTD analysis for IgE in the CSGA data set. *Genet Epidemiol* 2001; 21(Suppl 1):S312-S316.
102. Husson H, Carideo EG, Cardosa A, Lugli SM, Neuberg D, Munoz O, De Leval L, Schultze J, Freedman AS. MCP-1 modulates chemotaxis by follicular lymphoma cells. *Br J Haematol*. 2001; 115(3):554-562.

103. Husson H, Careideo EG, Neuberg D, Schultze J, Munoz O, Marks PW, Donovan JW, Chillemi AC, O'Connell P, Freedman AS. Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays. *Blood*. 2002; 99(1):282-288.
104. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RCT, Gaasenbeek M, Angelo M, Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, Neuberg DS, Lander ES, Aster JC, Golub TR. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. *Nature Med*. 2002; 8(1):68-74.
105. Howard OM, Gribben JG, Neuberg DS, Grossbard M, Poor C, Janicek MJ, Shipp MA. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. *J Clin Oncol*. 2002; 20(5):1288-1294.
106. Ferrando AA, Neuberg DS, Staunton J, Loh ML, Huard C, Raimondi SC, Behm FG, Puis C-H, Downing JR, Gilliland DG, Lander ES, Golub TR, Look AT. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. *Cancer Cell*. 2002; 1(1):75-87.
107. Antin JH, Lee SJ, Neuberg D, Alyea E, Soiffer RJ, Sonis S, Ferrara JLM. A phase I/II double-blind, placebo-controlled study of recombinant human interleukin-11 for mucositis and acute GVHD prevention in allogeneic stem cell transplantation. *Bone Marrow Transpl* 2002; 29(5):373-377.
108. Hodi FS, Schmollinger JC, Soiffer RJ, Salgia R, Lynch T, Ritz J, Alyea EP, Yang J, Neuberg D, Mihm M, Dranoff G. ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction. *PNAS*. 2002; 99(10):6919-6924.
109. Diller L, Nancarrow CM, Shaffer K, Matulonis U, Mauch P, Neuberg D, Tarbell NJ, Litman H, Garber J. Breast cancer screening in women previously treated for Hodgkin's disease: a prospective cohort study. *J Clin Oncol*. 2002; 20(8):2085-91.
110. Alyea E, Neuberg D, Mauch P, Marcus K, Freedman A, Webb I, Anderson K, Schlossman R, Fisher D, Gribben J, Ritz J, Soiffer R. Effect of total body irradiation dose escalation on outcome following T-cell-depleted allogeneic bone marrow transplantation. *Biol Blood Marrow Transplant* 2002;8(3):139-144.
111. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarian H, Andreeff M, Estrov Z, Beran M, Keating M, Estey E, Albitar M. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. *Leuk Res* 2002; 26(6):551-559.
112. Kelly LM, Yu JC, Boulton CL, Apatira M, Li J, Sullivan CM, Williams I, Amaral SM, Curley DP, Duclos N, Neuberg D, Scarborough RM, Pandey A, Hollenback S, Abe K, Lokker NA, Gilliland DG, Giese NA. CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). *Cancer Cell*, 2002; 1(5):421-432.
113. Friedberg JW, Neuberg D, Gribben JG, Fisher DC, Canning C, Koval M, Poor CM, Green LM, Daley J, Soiffer R, Ritz J, Freedman AS. Combination immunotherapy with rituximab and interleukin 2 in patients with relapsed or refractory follicular non-Hodgkin's lymphoma. *Br J Haematol*. 2002;117(4):828-834.
114. Lin TS, Howard OM, Neuberg DS, Kim HH, Shipp MA. Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma. *Leukemia & Lymphoma* 2002;43(4):793-797.
115. LeBlanc R, Catley LP, Hideshima T, Lentzsch S, Mitsiades CS, Mitsiades N, Neuberg D, Goloubeva O, Pien CS, Adams J, Gupta D, Richardson PG, Munshi NC, Anderson KC. Proteasome Inhibitor PS-341 Inhibits Human Myeloma Cell Growth in Vivo and Prolongs Survival in a Murine Model. *Cancer Res* 2002; 62(17):4996-5000.

116. Webb IJ, Friedberg JW, Gribben JG, Fisher DC, Spitzer T, Neuberg D, Jallow H, Kim H, Houde H, Monroy R, Schmittling R, Freedman AS. Effective purging of autologous hematopoietic stem cells anti-B cell monoclonal antibody-coated high-dose therapy for patients with non-Hodgkin's lymphoma. *Biol Blood Marrow Transplant* 2002; 8(8):429-434.
117. Antin JH, Weisdorf D, Neuberg D, Nicklow R, Clouthier S, Lee SJ, Alyea E, McGarigle C, Blazar BR, Sonis S, Soiffer RJ, Ferrara JLM. Interleukin-1 blockade does not prevent acute graft-versus-host disease: results of a randomized, double blind, placebo-controlled trial of interleukin-1 receptor antagonist in allogeneic bone marrow transplantation. *Blood* 2002; 100(10):3479-3483.
118. Wu CJ, Neuberg D, Chillemi A, McLaughlin S, Hochberg EP, Galinsky I, DeAngelo D, Soiffer RJ, Alyea EP, Capdeville R, Stone RM, Ritz J. Quantitative monitoring of BCR/ABL transcript during STI-571 therapy. *Leuk Lymphoma* 2002 Dec; 43(12):2281-2289.
119. Mitnick C, Bayona J, Palacios E, Shin S, Furin J, Alcántara F, Sánchez E, Sarria M, Becerra M, Smith Fawzi M, Kapiga S, Neuberg D, Maguire J, Kim J.Y, Farmer P. Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima Peru. *N Engl J Med* 2003; 348(2):119-128.
120. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky E, Wood WC. Phase III Trial of Doxorubicin, Paclitaxel, and the Combination of Doxorubicin and Paclitaxel as Front-Line Chemotherapy for Metastatic Breast Cancer: An Intergroup Trial (E1193). *J Clin Oncol*. 2003;21(4):588-592.
121. Salgia R, Lynch T, Skarin A, Lucca J, Lynch C, Jung J, Hodi F.S, Jaklitsch M, Mentzer S, Swanson S, Lukanich J, Bueno R, Wain J, Mathisen D, Wright C, Fidias P, Donahue D, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Sugarbaker D, Mihm M, Dranoff G. Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma. *J Clin Oncol*. 2003; 21(4):624-630.
122. Hochberg EP, Miklos DB, Neuberg D, Eichner DA, McLaughlin SF, Mattes-Ritz A, Alyea EP, Antin JH, Soiffer RJ, Ritz J. A novel rapid single nucleotide polymorphism (SNP)-based method for assessment of hematopoietic chimerism after allogeneic stem cell transplantation. *Blood* 2003; 101(1):363-369.
123. Canellos GP, Gollub J, Neuberg D, Mauch P, Shulman LN. Primary systemic treatment of advanced Hodgkin's disease with EVA (etoposide, vinblastine, doxorubicin): 10-year follow-up. *Ann Oncol* 2003; 14(2):268-72.
124. Miller DP, De Vivo I, Neuberg D, Wain JC, Lynch TJ, Su L, Christiani DC. Association between Self reported Environmental Tobacco Smoke Exposure and lung Cancer: Modification by *GSTP1* Polymorphism. *Int J Cancer* 2003; 104(6):758-763.
125. Kim HK, Silver B, Li S, Neuberg D, Mauch P. Hodgkin's disease in elderly patients (≥ 60): Clinical outcomes and treatment strategies. *Int J Radiat Oncol Biol Phys* 2003; 56(2):556-560.
126. Cools J, Stover EH, Boulton CL, Gotlib J, Legare RD, Amaral SM, Curley DP, Duclos N, Rowan R, Kutok JL, Lee BH, Williams IR, Coutre SE, Stone RM, DeAngelo DJ, Marynen P, Manley PW, Meyer T, Fabbro D, Neuberg D, Weisberg E, Griffin JD, Gilliland DG. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR γ -induced myeloproliferative disease. *Cancer Cell* 2003; 3(5):459-469.
127. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response. *Clin Cancer Res* 2003; 9(6):2166-2172.

128. Huang CI, Neuberg D, Johnson BE, Wei JY, Christiani DC. Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma. *Cancer* 2003; 98(1):135-143.
129. Ferrando AA, Armstrong SA, Neuberg DS, Sallan SE, Silverman LB, Korsmeyer SJ, Look AT. Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. *Blood* 2003; 102(1):262-268.
130. Paietta E, Neuberg D, Bennett JM, Dewald G, Rowe JM, Cassileth PA, Cripe L, Tallman MS, Wiernik PH. Low expression of the myeloid differentiation antigen CD65s, a feature of poorly differentiated AML in older adults: study of 711 patients enrolled in ECOG trials. *Leukemia* 2003; 17(8):1544-1550.
131. Savage KJ, Monti S, Kutok JL, Cattoretti G, Neuberg D, DeLeval L, Kurtin P, Dal Cin P, Ladd C, Feuerhake F, Aguiar RC, Li S, Salles G, Berger F, Jing W, Pinkus GS, Habermann T, Dalla-Favera R, Harris NL, Aster JC, Golub TR, Shipp MA. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin's lymphoma. *Blood* 2003; 102(12):3871-3879
132. Cherry AM, Brockman SR, Paternoster SF, Hicks GA, Neuberg D, Higgins RR, Bennett JM, Greenberg PL, Miller K, Tallman MS, Rowe J, Dewald GW. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) Study. *Leuk Res* 2003; 27(12):1085-1090.
133. Hou R, Goloubeva O, Neuberg DS, Strominger JL, Wilson SB. Interleukin-12 and interleukin-2-induced invariant natural killer T-cell cytokine secretion and perforin expression independent of T-cell receptor activation. *Immunology* 2003; 110(1):30-37.
134. Friedberg JW, Neuberg D, Kim H, Miyata S, McCauley M, Fisher DC, Takvorian T, Canellos GP. Gemcitabine added to doxorubicin, bleomycin, and vinblastine for the treatment of de novo Hodgkin disease: unacceptable acute pulmonary toxicity. *Cancer* 2003; 98(5):978-982.
135. Soiffer R, Hodi FS, Haluska F, Jung K, Gillessen S, Singer S, Tanabe K, Duda R, Mentzer S, Jaklitsch M, Bueno R, Clift S, Hardy S, Neuberg D, Mulligan R, Webb I, Mihm M, Dranoff G. Vaccination with irradiated, autologous melanoma cells engineered to secrete granulocyte-macrophage colony-stimulating factor by adenoviral-mediated gene transfer augments antitumor immunity in patients with metastatic melanoma. *J Clin Oncol* 2003; 21(17):3343-3350.
136. Ng AK, Li S, Neuberg D, Silver B, Weeks JC, Mauch PM. Factors influencing treatment decision in early-stage Hodgkin disease: a physician survey. *Int J Radiat Oncol Biol Phys* 2003; 57(2 Suppl 1):S213-S214.
137. Friedberg JW, Kim H, Li S, Neuberg D, Boyd K, Daley H, Fisher DC, Gribben JG, Spitzer T, Freedman AS. Ex vivo B cell depletion using the Eligix B Cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. *Bone Marrow Transplant* 2003; 32(7):681-686.
138. Miller DP, Neuberg D, De Vivo I, Wain JC, Lynch TJ, Su L, Christiani DC. Smoking and the Risk of Lung Cancer: Susceptibility with GSTP1 Polymorphisms. *Epidemiology* 2003; 14(5):545-551.
139. Morris JP, Berghmans S, Zahrieh D, Neuberg DS, Kanki JP, Look AT. Zebrafish sperm cryopreservation with N, N-dimethylacetamide. *BioTechniques* 2003; 35(5):956-968.
140. Friedberg JW, Dong DA, Li S, Kim H, Stephans K, Noonan K, Neuberg D, Gribben JG, Fisher DC, Freedman AS, Takvorian T, Jurgens R, Battle TE, Frank DA. Oral fludarabine has significant activity in patients with previously untreated chronic lymphocytic leukemia, and leads to increased STAT1 levels in vivo. *Leuk Res* 2004; 28(2):139-147.

141. Rowe JM, Neuberg D, FriedenberG W, Bennett JM, Paietta E, Makary AZ, Liesveld JL, Abboud CN, Dewald G, Hayes FA, Tallman MS, Wiernik PH. A phase III study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. *Blood* 2004; 103(2):479-485.
142. Brown JR, Gaudet G, Friedberg JW, Neuberg D, Mauch P, Kutok JL, Takvorian T, Fisher DC, Gribben JG, Kim H, Nadler LM, Freedman AS. Autologous bone marrow transplantation for marginal zone non-Hodgkin's lymphoma. *Leuk Lymphoma* 2004; 45(2):315-320.
143. Ng AK, Li S, Neuberg D, Silver B, Weeks J, Mauch P. Factors influencing treatment recommendations in early-stage Hodgkin's disease: a survey of physicians. *Ann Oncol* 2004; 15(2):261-269.
144. Ng AK, Li S, Neuberg D, Silver B, Stevenson MA, Fisher DC, Mauch PM. Comparison of MOPP versus ABVD as salvage therapy in patients who relapse after radiation therapy alone for Hodgkin's disease. *Ann Oncol* 2004; 15(2):270-275.
145. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. *Leukemia* 2004; 18(4):809-16.
146. Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A, Antin JH, Soiffer RJ, Neuberg D, Ritz J. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. *Transfusion* 2004; 44(2):253-261.
147. Ferrando AA, Neuberg DS, Dodge RK, Paietta E, Larson RA, Wiernik PH, Rowe JM, Caligiuri MA, Bloomfield CD, Look AT. Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia. *Lancet* 2004; 363(9408):535-536.
148. Mohi MG, Boulton C, Gu TL, Sternberg DW, Neuberg D, Griffin JD, Gilliland DG, Neel BG. Combination of rapamycin and protein tyrosine kinase (PTK) inhibitors for the treatment of leukemias caused by oncogenic PTKs. *Proc Natl Acad Sci USA* 2004; 101(9):3130-3135.
149. Viswanathan AN, Grier HE, Litman HJ, Perez-Atayde A, Tarbell NJ, Neuberg D, Shamberger RC, Marcus KJ. Outcome for children with group III rhabdomyosarcoma treated with or without radiotherapy. *Int J Radiat Oncol Biol Phys* 2004; 58(4):1208-1214.
150. Li A, Rue M, Zhou J, Wang H, Goldwasser MA, Neuberg D, Dalton V, Zuckerman D, Lyons C, Silverman LB, Sallan SE, Gribben JG. Utilization of Ig Heavy-Chain Variable, Diversity and Joining Gene Segments in Children with B-lineage Acute Lymphoblastic Recombination and for Pathogenesis. *Blood* 2004; 103(12):4602-4609.
151. Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H, Dewald G, Rowe JM, Wiernik PH, Tallman MS, Look AT. Activating FLT3 Mutations in CD117/KIT Positive T-Cell Acute Lymphoblastic Leukemias. *Blood* 2004; 104(2):558-560.
152. Lee K, Parkhurst WJ, Xue J, Ozkaynak AH, Neuberg D, Spengler JD. Outdoor/Indoor/Personal ozone exposures of children in Nashville Tennessee. *J Air Waste Manag Assoc* 2004; 54(3):352-359.
153. Friedberg JW, Fischman A, Neuberg D, Kim H, Takvorian T, Ng AK, Mauch PM, Canellos GP, van den Abbeele AD. FDG-PET is superior to gallium scintigraphy in staging and more sensitive in the follow-up of patients with de novo Hodgkin lymphoma: a blinded comparison. *Leuk Lymphoma* 2004; 45(1):85-92.
154. Agarwala SS, Neuberg D, Park Y, Kirkwood JM. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673). *Cancer* 2004; 100(8):1692-1698.

155. Paietta E, Goloubeva O, Neuberg D, Bennett JM, Gallagher R, Racevski J, Dewald G, Wiernik PH, Tallman MS. A surrogate marker profile for PML/RARalpha expressing acute promyelocytic leukemia and the association of immunophenotypic markers with morphologic and molecular subtypes. *Cytometry* 2004; 59B(1):1-9.
156. Zhang GJ, Safran M, Wei W, Sorensen E, Lassota P, Zhelev N, Neuberg DS, Shapiro G, Kaelin WG. Bioluminescent imaging of Cdk2 inhibition in vivo. *Nat Med* 2004; 10(6):643-648.
157. Stone RM, De Angelo J, Galinsky I, Estey E, Klimek V, Grandin W, Lebwohl D, Yap A, Cohen P, Fox E, Neuberg D, Clark J, Gilliland DG, Griffin JD. PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial. *Ann Hematol* 2004; 83 Suppl 1:S89-S90.
158. Alyea EP, Canning C, Neuberg D, Daley H, Houde H, Giralt S, Champli R, Atkinson K, Soiffer RJ. CD8+ cell depletion of donor lymphocyte infusions using cd8 monoclonal antibody-coated high-density microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: pilot study. *Bone Marrow Transplant* 2004; 34(2):123-128.
159. Lacasce A, Howard O, Li S, Fisher D, Weng A, Neuberg D, Shipp M. Modified magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. *Leuk Lymphoma* 2004; 45(4):761-767.
160. Gricks CS, Zahrieh D, Zauls AJ, Gorgun G, Drandi D, Mauerer K, Neuberg D, Gribben JG. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. *Blood* 2004; 104(13):4002-4009.
161. Gurubhagavatula S, Liu G, Park S, Zhou W, Su L, Wain JC, Lynch TJ, Neuberg DS, Christiani DC. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. *J Clin Oncol* 2004; 22(13):2594-2601.
162. Chen J, Wall NR, Kocher K, Duclos N, Fabbro D, Neuberg D, Griffin JD, Shi Y, Gilliland DG. Stable expression of small interfering RNA sensitizes TEL-PDGFR to inhibition with imatinib or rapamycin. *J Clin Invest* 2004;113(12):1784-1791.
163. Wang LI, Neuberg D, Christiani DC. Asbestos exposure, manganese superoxide dismutase (MnSOD) genotype, and lung cancer risk. *J Occup Environ Med* 2004; 46(6):556-564.
164. Zhou W, Gurubhagavatula S, Liu G, Park S, Neuberg DS, Wain JC, Lynch TJ, Su L, Christiani DC. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. *Clin Cancer Res* 2004;10(15):4939-4943.
165. Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. *N Engl J Med* 2004; 351(9):893-901.
166. Bourquin JP, Thornley I, Neuberg D, Brennan L, Kung A, Clark J, Lehmann L, Guinan EC. Favorable outcome of allogeneic hematopoietic stem cell transplantation for relapsed or refractory acute promyelocytic leukemia in childhood. *Bone Marrow Transplant* 2004; 34(9):795-798.
167. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. A combination of distribution – and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. *J Clin Epidemiol* 2004; 57(9):898-910.
168. Mutter GL, Zahrieh D, Liu C, Neuberg D, Finklestein D, Baker HE, Warrington, JA. Comparison of frozen and RNALater solid tissue storage method for use in RNA expression microarrays. *BMC Genomics* 2004;5(1):88.

169. Yang WH, Yu JH, Nakajima A, Neuberg D, Lindor K, Bloch DB. Do antinuclear antibodies in primary biliary cirrhosis patients identify increased risk for liver failure? *Clin Gastroenterol Hepatol* 2004; 2(12):1116-22.
170. Ng AK, Hickey G, Li S, Neuberg D, Mauch PM. A randomized phase II trial of amifostine for head and neck irradiation in lymphoma. *Semin Oncol* 2004; 31(6 Suppl 18):20-24.
171. Wang LI, Giovannucci EL, Hunter D, Neuberg D, Su L, Christiani DC. Dietary intake of cruciferous vegetables, glutathione s-transferase (GST) polymorphisms and lung cancer risk in a caucasian population. *Cancer Causes and Control* 2004; 15(10):977-985.
172. Stone RM, DeAngelo DJ, Klimek V, Galinsky I, Estey E, Nimer SD, Grandin W, Lebwohl D, Wang Y, Cohen P, Fox EA, Neuberg D, Clark J, Gilliland DG, Griffin JD. Acute myeloid leukemia patients with an activating mutation in FLT3 respond to a small molecule FLT3 tyrosine kinase inhibitor, PKC412. *Blood* 2005; 105(1):54-60.
173. Smith PG, Wang F, Wilkinson KN, Savage KJ, Klein U, Neuberg DS, Bollag G, Shipp MA, Aguiar RC. The phosphodiesterase PDE4B limits cAMP associated, PI3K-AKT dependent, apoptosis in diffuse large B-cell lymphoma. *Blood* 2005;105(1):308-16.
174. Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, Wu B, Pasqualucci L, Neuberg D, Aguiar RC, Dal Cin P, Ladd C, Pinkus GS, Salles G, Harris NL, Dalla-Favera R, Habermann TM, Aster JC, Golub TR, Shipp MA. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. *Blood* 2005; 105(5):1851-1861.
175. Berghmans S, Murphey RD, Wienholds E, Neuberg D, Kutok JL, Fletcher CD, Morris JP, Liu TX, Schulte-Merker S, Kanki JP, Plasterk R, Zon L, Look AT. Tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. *Proc Natl Acad Sci USA* 2005; 102(2):407-412.
176. Larson GP, Ding Y, Cheng LS, Lundberg C, Gagalang V, Rivas G, Geller L, Weitzel J, Macdonald D, Archambeau J, Slater J, Neuberg D, Daly MB, Angel I, Benson AB 3rd, Smith K, Kirkwood JM, O'Dwyer PJ, Raskay B, Sutphen R, Drew R, Stewart JA, Werndli J, Johnson D, Ruckdeschel JC, Elston RC, Krontiris TG. Genetic linkage of prostate cancer risk to the chromosome 3 region bearing FHIT. *Cancer Res* 2005; 65(3):805-814.
177. Weisberg E, Manley PW, Breitenstein W, Bruggen J, Cowan-Jacob SW, Ray A, Huntly B, Fabbro D, Fendrich G, Hall-Meyers E, Kung AL, Mestan J, Daley GQ, Callahan L, Catley L, Cavazza C, Mohammed A, Neuberg D, Wright RD, Gilliland DG, Griffin JD. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. *Cancer Cell* 2005; 7(2):129-141.
178. Haining WN, Cardoso AA, Keczkemethy HL, Fleming M, Neuberg D, Deangelo DJ, Stone RM, Galinsky I, Silverman LB, Sallan SE, Nadler L, Guinan EC. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. *Exp Hematol* 2005; 33(3):286-294.
179. Suk R, Gurubhagavatula S, Park S, Zhou W, Su L, Lynch TJ, Wain JC, Neuberg D, Liu G, Christiani DC. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. *Clin Cancer Res* 2005; 11(4):1534-1538.
180. Brown JR, Yeckes H, Friedberg JW, Neuberg D, Kim H, Nadler LM, Freedman AS. Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-hodgkin's lymphoma. *J Clin Oncol* 2005; 23(10):2208-2214.
181. Calin GA, Trapasso F, Shimizu M, Dumitru CD, Yendamuri S, Godwin AK, Ferracin M, Bernardi G, Chatterjee D, Baldassarre G, Rattan S, Alder H, Mabuchi H, Shiraishi T, Hansen LL, Overgaard J, Herlea V, Mauro FR, Dighiero G, Movsas B, Rassenti L, Kipps T, Baffa R, Fusco A, Mori M,

- Russo G, Liu CG, Neuberg D, Bullrich F, Negrini M, Croce CM. Familial cancer associated with a polymorphism in ARLTS1. *N Engl J Med* 2005;352(16):1667-1676.
182. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP181 and response to next therapy. *Clin Cancer Res* 2005; 11(12):4430-4436.
183. Wang Z, Neuberg D, Li C, Su L, Kim JY, Chen JC, Christiani DC. Global gene expression profiling in whole-blood samples from individuals exposed to metal fumes. *Environ Health Perspect* 2005; 113(2):233-241.
184. Feuerhake F, Kutok JL, Monti S, Chen W, Lacasce AS, Cattoretti G, Kurtin P, Pinkus GS, de Leval L, Harris NL, Savage KJ, Neuberg D, Habermann TM, Dalla-Favera R, Golub TR, Aster JC, Shipp MA. NF6B activity, function and target-gene signatures in primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma subtypes. *Blood* 2005; 106(4):1392-1399.
185. Jaeschke A, Rincon M, Doran B, Reilly J, Neuberg D, Geiner DL, Shultz LD, Rossini AA, Flavel RA, Davis RJ. Disruption of the Jnk2 (Mapk9) gene reduces destructive insulinitis and diabetes in a mouse model of type I diabetes. *Proc Natl Acad Sci USA* 2005; 102(19):6931-6935.
186. Haining WN, Neuberg DS, Keczkemethy HL, Evans JW, Rivoli S, Gelman R, Rosenblatt HM, Shearer WT, Guenaga J, Douek DC, Silverman LB, Sallan SE, Guinan EC, Nadler LM. Antigen-specific T cell memory is preserved in children treated for acute lymphoblastic leukemia. *Blood* 2005; 106(5):1749-1754.
187. Gorgun G, Holderried TAW, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. *J Clin Invest* 2005; 115(7):1797-1805.
188. Heinrichs S, Berman JN, Ortiz TM, Kornblau SM, Neuberg DS, Estey EH, Look AT. CD34⁺ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome. *Brit J Hematol* 2005;130(1):83-86.
189. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM. Autologous and allogeneic stem cell transplantation for poor-risk chronic lymphocytic leukemia. *Blood* 2005; 106(13):4389-4396.
190. Shepard JL, Amatruda JF, Stern HM, Subramanian A, Finkelstein D, Ziai J, Finley KR, Pfaff KL, Hersey C, Zhou Y, Barut B, Freedman M, Lee C, Spitsbergen J, Neuberg D, Weber G, Golub TR, Glickman JN, Kutok JL, Aster JC, Zon LI. A zebrafish bmyb mutation causes genome instability and increased cancer susceptibility. *Proc Natl Acad Sci USA* 2005; 102(37):13194-13199.
191. Zhou W, Suk R, Liu G, Park S, Neuberg DS, Wain JC, Lynch TG, Giovannucci E, Christiani DC. Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev* 2005; 14(10):2303-2309.
192. Ng AK, Li S, Recklitis C, Neuberg D, Chakrabarti S, Silver B, Diller L. A comparison between long-term survivors of Hodgkin's disease and their siblings on fatigue level and factors predicting for increased fatigue. *Ann Oncol* 2005;16(12):1949-1955.
193. Kieran MW, Turner CD, Rubin JB, Chi SN, Zimmerman MA, Chordas C, Klement G, Laforme A, Gordon A, Thomas A, Neuberg D, Browder T, Folkman J. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. *J Pediatr Hematol Oncol* 2005;27(11):573-581.

194. Berman JN, Wang M, Berry W, Neuberg DS, Guinan EC. Herpes zoster infection in the post-hematopoietic stem cell transplant pediatric population may be preceded by transaminitis: an institutional experience. *Bone Marrow Transplant* 2006;37(1):73-80.
195. Hirano N, Butler MO, Xia Z, Ansen S, von Bergwelt-Baildon MS, Neuberg D, Freeman GJ, Nadler LM. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. *Blood* 2006; 107(4):1528-1536.
196. Guadagnolo BA, Li S, Neuberg D, Ng A, Hua L, Silver B, Stevenson MA, Mauch P. Long-term outcome and mortality trends in early-stage, Grade 1-2 follicular lymphoma treated with radiation therapy. *Int J Radiat Oncol Biol Phys* 2006;64(3):928-934.
197. Bradner JE, McPherson OM, Mazitschek R, Barnes-Seeman D, Shen JP, Dhaliwal J, Stevenson KE, Duffner JL, Park SB, Neuberg DS, Nghiem P, Schreiber SL, Koehler AN. A robust small-molecule microarray platform for screening cell lysates. *Chem Biol* 2006;13(5):493-504.
198. Loh ML, Goldwasser MA, Silverman LB, Poon WM, Vattikuti S, Cardoso A, Neuberg DS, Shannon KM, Sallan SE, Gilliland DG. Prospective analysis of TEL/AML1 positive patients treated on Dana-Farber Cancer Institute Consortium Protocol 95-01. *Blood* 2006;107(11):4508-4513.
199. Cripe LD, Rader K, Tallman MS, Gordon MS, Paietta E, Bennett J, Neuberg D, Litzow MR, O'Brien TE, Rowe JM. Phase II trial of subcutaneous recombinant human interleukin 11 with subcutaneous recombinant human granulocyte-macrophage colony stimulating factor in patients with acute myeloid leukemia (AML) receiving high-dose cytarabine during induction: ECOG 3997. *Leuk Res* 2006;30(7):823-827.
200. Palomero T, Odom DT, O'Neil J, Ferrando AA, Margolin A, Neuberg DS, Winter SS, Larson RS, Li W, Liu XS, Young RA, Look AT. Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia. *Blood* 2006; 108(3):986-992.
201. Walz C, Crowley BJ, Hudon HE, Gramlich JL, Neuberg DS, Podar K, Griffin JD, Sattler M. Activated JAK2 with the V617F point mutation promotes G1/S-phase transition. *J Biol Chem* 2006; 281(26):18177-18183.
202. Mueller BU, Pabst T, Hauser P, Neuberg D, Tenen DG. Mutations of the transcription factor PU.1 are not associated with acute lymphoblastic leukaemia (ALL). *Br J Cancer* 2006;95(4):554.
203. Pabst T, Stillner E, Neuberg D, Nimer S, Willman CL, List AF, Melo JV, Tenen DG, Mueller BU. Mutations of the myeloid transcription factor CEBPA are not associated with the blast crisis of chronic myeloid leukaemia. *Br J Haematol* 2006;133(4):400-402.
204. Takahashi H, Feuerhade F, Kutok JL, Monti S, Dal Cin P, Neuberg D, Aster JC, Shipp MA. FAS death domain deletions and cellular FADD-like interleukin 1beta converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrinsic apoptotic pathway in diffuse large B-cell lymphoma subtypes. *Clin Cancer Res* 2006, 12(11 Pt 1):3265-3271.
205. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, Shamberger RC, Pulsipher M, Grupp SA, Diller L. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. *J Clin Oncol* 2006;24(18):2891-2896.
206. Miller DP, Asomaning K, Liu G, Wain JC, Lynch TJ, Neuberg D, Su L, Christiani DC. An association between glutathione s-transferase P1 gene polymorphism and younger age at onset of lung carcinoma. *Cancer* 2006; 107(7):1570-1577.

207. Zhou W, Heist RS, Liu G, Park S, Neuberg DS, Asomaning K, Wain JC, Lynch TJ, Christiani DC. Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients. *Lung Cancer* 2006; 53(3):375-380.
208. Zirlik KM, Zahrieh D, Neuberg D, Gribben JG. Cytotoxic T-cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. *Blood* 2006; 108(12):3865-3870.
209. Ng AK, Li S, Neuberg D, Fisher DC, McMillan C, Silver B, Marcus KC, Stevenson MA, Mauch PM. Long-term results of a prospective trial of mantle irradiation alone for early-stage Hodgkin's disease. *Ann Oncol* 2006; 17(11):1693-1697.
210. Heist RS, Marshall AL, Liu G, Zhou W, Su L, Neuberg D, Lynch TJ, Wain J, Christiani DC. Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer. *Clin Cancer Res* 2006;12(18):5448-5453.
211. Zhou W, Heist RS, Liu G, Neuberg DS, Asomaning K, Su L, Wain JC, Lynch TJ, Giovannucci E, Christiani DC. Polymorphisms of vitamin d receptor and survival in early-stage non-small cell lung cancer patients. *Cancer Epidemiol Biomarkers Prev* 2006;15(11):2239-2245.
212. Palomero T, Lim WK, Odom DT, Sulis ML, Real PJ, Margolin A, Barnes KC, O'Neil J, Neuberg D, Weng AP, Aster JC, Sigaux F, Soulier J, Look AT, Young RA, Califano A, Ferrando AA. NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. *Proc Natl Acad Sci USA* 2006; 103(48):18261-18266.
213. Zhou W, Heist RS, Liu G, Asomaning K, Miller DP, Neuberg DS, Wain JC, Lynch TJ, Christiani DC. Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients. *Clin Cancer Res* 2006;12(23):7187-7193.
214. deCastro BR, Neuberg DS. The statistical performance of an MCF-7 cell culture assay evaluated using generalized linear mixed models and a score test. *Stat Med* 2007; 26(12):2501-2518.
215. Moghrabi A, Levy DE, Asselin B, Barr R, Clavell L, Hurwitz C, Samson Y, Schorin M, Dalton VK, Lipshultz SE, Neuberg DS, Gelber RD, Cohen HJ, Sallan SE, Silverman LB. Results of the Dana-Farber Cancer Institute ALL consortium protocol 95-01 for children with acute lymphoblastic leukemia. *Blood* 2007; 109(3):896-904.
216. Zhou W, Heist RS, Liu G, Asomaning K, Neuberg DS, Hollis BW, Wain JC, Lynch TJ, Giovannucci E, Su L, Christiani DC. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. *J Clin Oncol* 2007; 25(5):479-485.
217. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM, Hussein MA, Appelbaum FR, Larson RA, Moore DF, Tallman MS. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. *J Clin Oncol* 2007; 25(7):793-798.
218. Grever MR, Lucas DM, Dewald GW, Neuberg DS, Reed JC, Kitada S, Flinn JW, Tallman MS, Appelbaum FR, Larson RA, Paietta E, Jelinek DF, Gribben JG, Byrd JC. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: results from the US Intergroup Phase III Trial E2997. *J Clin Oncol* 2007; 25(7):799-804.
219. George RE, Attiyeh EF, Li S, Moreau LA, Neuberg D, Li C, Fox EA, Meyerson M, Diller L, Fortina P, Look AT, Maris JM. Genome-wide analysis of neuroblastomas using high-density single nucleotide polymorphism arrays. *PLoS ONE* 2007;2(2):e255.
220. Barry E, Deangelo DJ, Neuberg D, Stevenson K, Loh ML, Asselin BL, Barr RD, Clavell LA, Hurwitz CA, Moghrabi A, Samson Y, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Favorable

- outcome for adolescents with acute lymphoblastic leukemia treated on dana-farber cancer institute acute lymphoblastic leukemia consortium protocols. *J Clin Oncol* 2007;25(7):813-819.
221. Butler MO, Lee JS, Ansen S, Neuberg D, Hodi FS, Murray AP, Drury L, Berezovskaya A, Mulligan RC, Nadler LM, Hirano N. Long-lived anti-tumor CD8+ lymphocytes for adoptive therapy generated using an artificial antigen-presenting cell. *Clin Cancer Res* 2007; 13(6):1857-1867.
 222. Tsai SB, Tucci V, Uchiyama J, Fabian NJ, Lin MC, Bayliss PE, Neuberg DS, Zhdanova IV, Kishi S. Differential effects of genotoxic stress on both concurrent body growth and gradual senescence in the adult zebrafish. *Aging Cell* 2007; 6(2):209-224.
 223. Robertson MJ, Kahl BS, Vose JM, de Vos S, Laughlin M, Flynn PJ, Rowland K, Cruz JC, Goldberg SL, Musib L, Darstein C, Enas N, Kutok JL, Aster JC, Neuberg D, Savage KJ, Lacasce A, Thornton D, Slapak CA, Shipp MA. Phase II study of enzastaurin, a protein kinase c beta inhibitor, in patients with relapsed or refractory diffuse large b-cell lymphoma. *J Clin Oncol* 2007; 25(13):1741-1746.
 224. Enzler T, Gillesen S, Dougan M, Allison JP, Neuberg D, Oble DA, Mihm M, Dranoff G. Functional deficiencies of granulocyte-macrophage colony stimulating factor and interleukin-3 contribute to insulinitis and destruction of {beta}-cells. *Blood* 2007;110(3):954-961.
 225. Zhou J, Goldwasser MA, Li A, Dahlberg SE, Neuberg D, Wang H, Dalton V, McBride KD, Sallan SE, Silverman LB, Gribben JG. Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL consortium protocol 95-01. *Blood* 2007; 110(5):1607-1611.
 226. Langenau DM, Keefe MD, Storer NY, Guyon JR, Kutok JL, Le X, Goessling W, Neuberg DS, Kunkel LM, Zon LI. Effects of RAS on the genesis of embryonal rhabdomyosarcoma. *Genes Dev* 2007;12(11):1382-1395.
 227. Rohatiner AZ, Nadler L, Davies AJ, Apostolidis J, Neuberg D, Matthews J, Gribben JG, Mauch PM, Lister TA, Freedman AS. Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: long-term follow-up. *J Clin Oncol* 2007;25(18):2554-2559.
 228. Le X, Langenau DM, Keefe MD, Kutok JL, Neuberg DS, Zon LI. Heat shock-inducible Cre/Lox approaches to induce diverse types of tumors and hyperplasia in transgenic zebrafish. *Proc Natl Acad Sci USA* 2007;104(22):9410-9415.
 229. Heist RS, Zhou W, Chirieac LR, Cogan-Drew T, Liu G, Su L, Neuberg D, Lynch TJ, Wain JC, Christiani DC. MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer. *J Clin Oncol* 2007;25(16):2243-2247.
 230. Motiwala T, Majumder S, Kutay H, Smith DS, Neuberg DS, Lucas DM, Byrd JC, Grever M, Jacob ST. Methylation and silencing of protein tyrosine phosphatase receptor type O in chronic lymphocytic leukemia. *Clin Cancer Res* 2007;13(11):3174-3181.
 231. Feng H, Langenau DM, Madge JA, Quinkertz A, Gutierrez A, Neuberg DS, Kanki JP, Look AT. Heat-shock induction of T-cell lymphoma/leukaemia in conditional Cre/lox-regulated transgenic zebrafish. *Br J Haematol* 2007;138(2):169-175.
 232. Brown JR, Feng Y, Gribben JG, Neuberg D, Fisher DC, Mauch P, Nadler LM, Freedman AS. Long-term survival after autologous bone marrow transplantation for follicular lymphoma in first remission. *Biol Blood Marrow Transplant* 2007;13(9):1057-1065.
 233. Waber DP, Turek J, Catania L, Stevenson K, Robaey P, Romero I, Adams H, Alyman C, Jandet-Brunet C, Neuberg DS, Sallan SE, Silverman LB. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS

treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01. *J Clin Oncol* 2007;25(31):4914-4921.

234. O'Neil J, Tchinda J, Gutierrez A, Moreau L, Maser RS, Wong KK, Li W, McKenna K, Liu XS, Feng B, Neuberg D, Silverman L, Deangelo DJ, Kutok JL, Rothstein R, Depinho RA, Chin L, Lee C, Look AT. Alu elements mediate MYB gene tandem duplication in human T-ALL. *J Exp Med* 2007;204(13):3059-3066. PMID: PMC2150982
235. Ng AK, Li S, Recklitis C, Diller LR, Neuberg D, Silver B, Mauch PM. Health practice in long-term survivors of Hodgkin Lymphoma. *Int J Radiat Oncol Biol Phys*, 2008; 71(2):468-476.
236. Freedman RA, Bauer KA, Neuberg DS, Zwicker JI. Timing of postpartum enoxaparin administration and severe postpartum hemorrhage. *Blood Coagul Fibrinolysis* 2008; 19(1):55-59.
237. Jinushi M, Vanneman M, Munshi NC, Tai YT, Prabhala RH, Ritz J, Neuberg D, Anderson KC, Carrasco DR, Dranoff G. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. *Proc Natl Acad Sci USA* 2008; 105(4):1285-1290. PMID: PMC2234130.
238. Barry EV, Vrooman LM, Dahlberg SE, Neuberg DS, Asselin BL, Athale UH, Clavell LA, Larsen EC, Moghrabi A, Samson Y, Schorin MA, Cohen HJ, Lipshultz SE, Sallan SE, Silverman LB. Absence of secondary malignant neoplasms in children with high-risk acute lymphoblastic leukemia treated with dexrazoxane. *J Clin Oncol* 2008;26(7):1106-1111.
239. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Mamaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. *Proc Natl Acad Sci USA* 2008;105(8):3005-3010. PMID: PMC2268575.
240. Attar EC, Deangelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. *Clin Cancer Res* 2008;14(5):1446-1454.
241. Guha S, Li Y, Neuberg D. Bayesian hidden Markov modeling of array CGH data. *J Am Stat Assoc* 2008; 103(482):485-497. PMID: PMC3286622
242. Armistead PM, Mohseni M, Gerwin R, Walsh EC, Iravani M, Charhardouli B, Rostami S, Zhang W, Neuberg D, Rioux J, Chavanzadeh A, Ritz J, Antin JH, Wu CJ. Erythroid-lineage-specific engraftment in patients with severe hemoglobinopathy following allogeneic hematopoietic stem cell transplantation. *Exp Hematol*. 2008;36:1205-1215..
243. Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL. API-dependent galectin-1-expression delineates classical Hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. *Clin Cancer Res* 2008;14(11):3338-3344.
244. Ng AK, LI S, Neuberg D, Chi R, Fisher DC, Silver B, Mauch PM. A prospective study of pulmonary function in Hodgkin's lymphoma patients. *Ann Oncol* 2008; 19(10):1754-8.
245. Friedberg J, Jacobsen E, Neuberg D, Kutok J, Munoz O, Boussiotis V, Reynolds H, Fisher D, Szot A, Van Den Abbeele A, Freedman A. Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept. *Leuk Lymphoma* 2008;49(5):902-909.
246. Kishi S, Bayliss PE, Uchiyama J, Koshimizu E, Qi J, Nanjappa P, Imamura S, Islan A, Neuberg D, Amsterdam A, Roberts TM. The identification of zebrafish mutants showing alterations in senescence-associated biomarkers. *PLoS Genet* 2008;4(8):e1000152. PMID: PMC2515337

247. Rassenti LZ, Jain S, Keating MJ, Wierda WG, Grever MR, Byrd JC, Kay NE, Brown JR, Gribben JG, Neuberg DS, He F, Greaves AW, Rai KR, Kipps TJ. Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia. *Blood* 2008;112:1923-1930. PMID:PMC2518894
248. Haining WN, Davies J, Kanzler H, Drury L, Brenn T, Evans J, Angelosanto J, Rivoli S, Russell K, George S, Sims P, Neuberg D, Li X, Kutok J, Morgan J, Wen P, Demetri G, Coffman RL, Nadler LM. CpG Oligodeoxynucleotides alter lymphocyte and dendritic cell trafficking in humans. *Clin Cancer Res* 2008;14(7):5626-5634. PMID: 18765557.
249. Brown JR, Neuberg D, Phillips K, Reynolds H, Silverstein J, Clark JC, Ash M, Thompson C, Fisher DC, Jacobsen E, LaCasce A, Freedman AS. Prevalence of familial malignancy in a prospectively screened cohort of patients with lymphoproliferative disorders. *Br J Haematol* 2008; 143(3): 361-368. Epub 2008 Aug20. PMID: PMC2704548
250. Heist RS, Zhou W, Wang Z, Liu G, Neuberg D, Su L, Asomaning K, Hollis BW, Lynch TJ, Wain JC, Giovannucci E, Christiani DC. Circulating 25-Hydroxyvitamin D, VDR Polymorphisms, and survival in advanced non-small-cell lung cancer. *J Clin Oncol* 2008; 26(34):5596-5602. Epub 2008 Oct 20. PMID: PMC2651100
251. Wang Z, Neuberg D, Su L, Kim JY, Chen CK, Christiani DC. Prospective study of metal fume-induced responses of global gene expression profiling in whole blood. *Inhal Toxicol* 2008;20(14):1233-44. PMID: PMC2729438
252. Fonseca C, Soiffer R, Ho V, Vanneman M, Jinushi M, Ritz J, Neuberg D, Stone R, De Angelo D, Dranoff G. Protein disulfide isomerases are antibody targets during immune-mediated tumor destruction. *Blood* 2009; 113(8):1681-1688. PMID: PMC2647666
253. Abramson JS, Chen W, Juszczynski P, Takahashi H, Neuberg D, Kutok JL, Takeyama K, Shipp MA. The heat shock protein 90 inhibitor IPI-504 induces apoptosis of AKT-dependent diffuse large B-cell lymphomas. *Br J Haematol* 2009; 3:358-366. PMID: PMC4029164
254. Lin MC, Burkholder KA, Viswanathan AN, Neuberg D, Mutter GL. Involution of latent endometrial precancers by hormonal and nonhormonal mechanisms. *Cancer* 2009;115(10):2111-8. PMID: PMC2745907
255. Brown JR, Friedberg JW, Feng Y, Scofield S, Phillips K, Dal Cin P, Joyce R, Takvorian RW, Fisher DC, Fisher RI, Liesveld J, Marquis D, Neuberg D, Freedman AS. A phase 2 study of concurrent fludarabine and rituximab for the treatment of marginal zone lymphomas. *Br J Haematol* 2009;145(6):741-8. PMID: PMC2752822
256. Heinrichs S, Kulkarni RV, Bueso-Ramos CE, Levine RL, Loh ML, Li C, Neuberg D, Kornblau SM, Issa JP, Gilliland DG, Garcia-Manero G, Kantarjian HM, Estey EH, Look AT. Accurate detection of uniparental disomy and microdeletions by SNP array analysis in myelodysplastic syndromes with normal cytogenetics. *Leukemia* 2009;23(9):1605-13. PMID:PMC2950785
257. Gutierrez A, Sanda T, Grebliunaite R, Carracedo A, Salmena L, Ahn Y, Dahlberg S, Neuberg D, Moreau LA, Winter SS, Larson R, Zhang J, Protopopov A, Chin L, Pandolfi PP, Silverman LB, Hunger SP, Sallan SE, Look AT. High frequency of PTEN, P13K and AKT abnormalities in T cell Acute lymphoblastic leukemia. *Blood* 2009;114(3):647-650. PMID:PMC2713461
258. Friedberg JW, Kelly JL, Neuberg D, Peterson DR, Kutok JL, Salloum R, Brenn T, Fisher DC, Ronana E, Dalton V, Rich L, Marquis D, Sims P, Rothberg PG, Liesveld J, Fisher RI, Coffman R, Mosmann T, Freedman AS. Phase II study of TLR-9 agonist (1018 ISS) with rituximab in patients with relapses or refractory follicular lymphoma. *Br J Haematol.* 2009 Aug;146(3):282-291. PMID: PMC2747261

259. Rhodes J, Amsterdam A, Sanda T, Moreau LA, McKenna K, Heinrichs S, Ganem NJ, Ho KW, Neuberg D, Johnston A, Ahn Y, Kutok JL, Hromas R, Wray J, Lee C, Murphy C, Radke T, Downing JR, Fleming MD, Macconnaill LE, Amatruda JF, Guitierrez A, Galinsky I, Stone RM, Ross EA, Pellman DS, Kanki JP, Look AT. Emi1 Maintains Genomic Integrity during Zebrafish Embryogenesis and Cooperates with p53 in Tumor Suppression. *Mol Cell Biol* 2009;29(21):5911–22. PMID:PMC2772726.
260. Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. *Clin Cancer Res* 2009;15(22):6830–40. PMID:PMC2783253
261. Al-Shakfa F, Dulucq S, Brukner I, Milacic I, Ansari M, Beaulieu P, Moghrabi A, Laverdiere C, Sallan SE, Silverman LB, Neuberg D, Kutok JK, Sinnott D, Krajcinovic M. DNA variants in region for conoding interfering transcript of dihydrofolate reductase gene and outcome in childhood acute lymphoblastic leukemia. *Clin Cancer Res* 2009;15(22):6931–8. PMID: 19861437.
262. Guibal FC, Alberich-Jorda M, Hirai H, Ebralidze A, Levantini E, Dr Ruscio A, Zhang P, Santana-Lemos BA, Neuberg D, Wagers AJ, Rego EM, Tenen DG. Identification of a myeloid committed progenitor as the cancer initiating cell in acute promyelocytic leukemia. *Blood* 2009 Oct 1. 44(27):5415-5425. PMID:PMC2798860
263. Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin M, Schwartz CL, O'Brien JE, Cohen HJ, Sallan SE. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. *Blood* 2010 Feb 18; 115 (7): 1351-3. PMID:PMC 2832805
264. Sanda T, Li X, Gutierrez A, Ahn Y, Neuberg DS, O'Neil J, Strack PR, Winter CG, Winter SS, Larson RS, von Boehmer H, Look AT. Interconnecting molecular pathways in the pathogenesis and drug sensitivity of T-cell acute lymphoblastic leukemia. *Blood* 2010 Mar. 4; 115 (9):1735-45. PMID:PMC2832805
265. Silverman LB, Stevenson KE, O'Brien JE, Asselin BL, Barr RD, Clavell L, Cole PD, Kelly KM, Laverdiere C, Michon B, Schorin MA, Schwartz CL, O'Holleran EW, Neuberg DS, Cohen HJ, Sallan SE. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). *Leukemia* 2009 Dec 17. *Leukimia* 2010 Feb; 24(2):320-34. PMID: PMC2820141
266. Chen RC, Chin MS, Ng AK, Feng Y, Neuberg D, Silver B, Pinkus GS, Stevenson MA, Mauch PM. Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. *J Clin Oncol* 2010; 28(1):136-41. PMID: 19933914.
267. Vrooman LM, Supko JG, Neuberg DS, Asselin BL, Athale UH, Clavell L, Kelly KM, Laverdiere C, Michon B, Schorin M, Cohen HJ, Sallan SE, Silverman LB. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2010;54(2):199–205. PMID: PMC3706086
268. Biernacki MA, Marina O, Zhang W, Liu F, Bruns I, Cai A, Neuberg D, Canning CM, Alyea EP, Soiffer RJ, Brusci V, Ritz J, Wu CJ. Efficacious immune therapy in chronic myelogenous leukemia (CML) recognizes antigens that are expressed on CML progenitor cells. *Cancer Res* 2010; 70(3):906-15. PMID: PMC2832197
269. Rosenblatt J, Wu Z, Vasir B, Zarwan C, Stone R, Mills H, Friedman T, Konstantinopoulos PA, Spentzos D, Ghebremichael M, Stevenson K, Neuberg D, Levine JD, Joyce R, Tzachanis D, Boussiotis V, Kufe D, Avigan D. Generation of tumor-specific T lymphocytes using dendritic cell/tumor fusions and anti-CD3/CD28. *J Immunother* 2010; 33(2):155-66. PMID:PMC2938173

270. Gutierrez A, Santa T, Ma W, Zhang J, Grebliunaite R, Dahlberg S, Neuberg D, Protopopov A, Winter SS, Larson RS, Borowitz MJ, Silverman LB, Chin L, Hunger SP, Jamieson C, Sallan SE, Look AT. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. *Blood* 2010; Apr 8: 115 (14): 2845-51. PMID:PMC 2854430
271. Marina O, Hainz U, Biernacki MA, Zhang W, Cai A, Duke-Cohan JS, Liu F, Brusica V, Neuberg D, Kutok JL, Alyea EP, Canning CM, Soiffer RJ, Ritz J, Wu CJ. Serologic markers of effective tumor immunity against chronic lymphocytic leukemia include nonmutated b-cell antigens. *Cancer Res* 2010 Feb 15; 70(4): 1344-55. PMID:PMC2852266
272. Chen YB, Hochberg EP, Feng Y, Neuberg D, Rawal B, Motyckova G, Fisher DC, McAfee SL, Spitzer TR, Lacasce AS. Characteristics and outcomes after autologous stem cell transplant for patients with relapsed or refractory diffuse large B-cell lymphoma who failed initial rituximab, cyclophosphamide, adriamycin, vincristine, and prednisone therapy compared to patients who failed cyclophosphamide, adriamycin, vincristine, and prednisone. *Leuk Lymphoma* 2010; 51(5):789-96. PMID: 20367136
273. Monte NM, Webster KA, Neuberg D, Dressler GR, Mutter GL. Joint loss of PAX2 and PTEN expression in endometrial precancers and cancer. *Cancer Res* 2010; 70(15):6225-32. PMID: PMC2912978
274. Lee AL, Zuckerman DS, Van den Abbeele AD, Aquino SL, Crowley D, Toomey C, Lacasce AS, Feng Y, Neuberg DS, Hochberg EP. Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical economic analysis. *Cancer* 2010; 116(16):3835-42. PMID: 20564135.
275. George RE, Lahti JM, Adamson PC, Zhu K, Finkelstein D, Ingle AM, Reid JM, Krailo M, Neuberg D, Blaney SM, Diller L. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: A children's oncology group study. *Pediatr Blood Cancer* 2010; 55(4):629-38. PMID: PMC3025700
276. Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O'Donnell E, Chapuy B, Takeyama K, Neuberg D, Golub TR, Kutok JL, Shipp Ma. Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. *Blood* 2010; 116(17):3268-77. PMID: PMC2995356
277. Gutierrez A, Dahlberg SE, Neuberg DS, Zhang J, Grebliunaite R, Santa T, Protopopov A, Tosello V, Kutok J, Larson RS, Borowitz MJ, Loh ML, Ferrando AA, Winter SS, Mullighan CG, Silverman LB, Chin L, Hunger SP, Sallan SE, Look AT. Absence of Biallelic TCR{gamma} deletion predicts early treatment failure in pediatric t-cell acute lymphoblastic leukemia. *J Clin Oncol* 2010;28(24):3816-23. PMID:PMC2940399
278. Dougan M, Dougan S, Slisz J, Firestone B, Vanneman M, Draganov D, Goyal G, Li W, Neuberg D, Blumberg R, Hacohen N, Porter D, Zavel L, Dranoff G. IAP inhibitors enhance co-stimulation to promote tumor immunity. *J Exp Med* 2010; 207(10):2195-206. PMID:PMC2947073
279. Setlur SR, Ihm C, Tchinda J, Shams S, Werner L, Cho EK, Thompson C, Phillips K, Rassenti LZ, Kipps TJ, Neuberg D, Freedman AS, Lee C, Brown JR. Comparison of familial and sporadic chronic lymphocytic leukaemia using high resolution array comparative genomic hybridization. *Br J Haematol* 2010; 151(4):336-45. PMID: PMC3584328
280. Moslehi J, Minamishima YA, Shi J, Neuberg D, Charytan DM, Padera RF, Signoretti S, Liao R, Kaeling WG Jr. Loss of hypoxia-inducible factor prolyl hydroxylase activity in cardiomyocytes phenocopies ischemic cardiomyopathy. *Circulation* 2010; 122(10):1004-16. PMID:PMC2971656
281. Brown JR, Abramson J, Hochberg E, Mikler E, Dalton V, Werner L, Reynolds H, Thompson C, McDonough SM, Kuagn Y, Ritz J, Neuberg D, Freedman AS. A phase I study of lenalidomide in

- combination with fludarabine and rituximab in previously untreated CLL/SLL. *Leukemia* 2010; 24(11):1972-5. PMID: PMC3722583.
282. Lipschultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, Barry EV, Asselin BL, Athale U, Clavell LA, Larsen E, Moghrabi A, Samson Y, Michon B, Schorin MA, Cohen HJ, Neuberg DS, Orav EJ, Colan SC. Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomized, multicentre trial. *Lancet Oncol* 2010; 11(10):950-61. PMID: PMC3756093
283. Feng H, Stachura DL, White RM, Gutierrez A, Zhang L, Sanda T, Jette CA, Testa JR, Neuberg DS, Langenau DM, Kutok JL, Zon Li, Traver D, Fleming MD, Kanki JP, Look AT. T-lymphoblastic lymphoma cells express high levels of BCL2, S1P1, and ICAM1, leading to a blockade of tumor cell intravasation. *Cancer Cell* 2010; 18(4):353-66. PMID: PMC3003429
284. Singh H, Werner L, Deangelo D, Ballen K, Amrein P, Wadleigh M, Neuberg D, Fox E, Stone R, Attar E. Clinical outcome of patients with acute promyelocytic leukemia and FLT3 mutations. *Am J Hematol* 2010; 85:12:956-7. PMID: PMC3501727
285. Smoley SA, Van Dyke DL, Kay NE, Heerema NA, Dell' Aquila ML, Dal Cin P, Koduru P, Aviram A, Rassenti L, Byrd JC, Rai KR, Brown JR, Greaves AW, Eckel-Passow J, Neuberg D, Kipps TJ, Dewald GW. Standardization of fluorescence in situ hybridization studies on chronic lymphocytic leukemia (CLL) blood and marrow cells by the CLL Research Consortium. *Cancer Genet Cytogenet* 2010; 203(2):141-8. PMID: PMC3763815
286. Schoenfeld J, Jinushi M, Nakazaki Y, Wiener D, Park J, Soiffer R, Neuberg D, Mihm M, Hodi FS, Dranoff G. Active immunotherapy induces antibody responses that target tumor angiogenesis. *Cancer Res* 2010; 70(24):10150-10160. PMID: PMC3057563
287. Barnes JA, Lacasce AS, Zukotynski K, Israel D, Feng Y, Neuberg D, Toomey CE, Hochberg EP, Canellos GP, Abramson JS. End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma. *Ann Oncol* 2011; 22(4):910-5. epub Oct 15, 2010. PMID: 20952598
288. Wierda WG, Kipps TJ, Keating MJ, Brown JR, Gribben JG, Browning M, Rassenti LZ, Greaves AW, Neuberg D, O'Brien SM; and the CLL Research Consortium. Self-administered, subcutaneous alemtuzumab to treat residual disease in patients with chronic lymphocytic leukemia. *Cancer* 2011; 117(1):116-24. epub Aug 30, 2010. PMID: 20806349
289. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, Lapushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). *Blood* 2011; 117(5):1662-9. Epub 2010 Nov 29. PMID: PMC3318778
290. Da'as S, Teh EM, Dobson JT, Nasrallah GK, McBride ER, Wang H, Neuberg DS, Marshall JS, Lin TJ, Berman JN. Zebrafish mast cells possess an Fc ϵ RU-kuje receptor and participate in innate and adaptive immune responses. *Dev Comp Immunol* 2011 Jan; 35(1):125-34. [Epub 2010 Sept 19.] PMID: 20849876.
291. Green MR, Monti S, Dalla-Favera R, Pasqualucci L, Walsh NC, Schmidt-Supprian M, Kutok JL, Rodig SJ, Neuberg DS, Rajewsky K, Golub TR, Alt FW, Shipp MA, Manis JP. Signatures of murine B-cell development implicate Yy1 as a regulator of the germinal center-specific program. *Proc Natl Acad Sci USA* 2011; 108(7):2873-8. PMID: PMC3041080
292. Grace RF, Dahlberg SE, Neuberg D, Sallan SE, Connors JM, Neufeld EJ, Deangelo DJ, Silverman LB. The frequency and management of asparaginase-related thrombosis in paediatric

- and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. *Br J Haematol* 2011; 152(4):452-9. PMID: 21210774
293. Buhl AM, James DF, Neuberg D, Jain S, Rassenti LZ, Kipps TJ. Analysis of CLLU1 expression levels before and after therapy in patients with chronic lymphocytic leukemia. *Eur J Haematol* 2011; 86(5):405-11. PMID: 21323738.
294. Barnes JA, Lacasce AS, Feng Y, Toomey CE, Neuberg D, Michaelson JS, Hochberg EP, Abramson JS. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis. *Ann Oncol* 2011; 22(8):1859-64. PMID: 21339382.
295. Li S, Moffett HF, Lu J, Werner L, Zhang H, Ritz J, Neuberg D, Wucherpfennig KW, Brown JR, Novina CD. MicroRNA expression profiling identifies activated B cell status in chronic lymphocytic leukemia cells. *PLoS One* 2011; 6(3):e16956. PMCID: PMC3050979
296. Amrein PC, Attar EC, Takvorian RW, Hochberg EP, Ballen KK, Leahy KM, Fisher DE, Lacasce AS, Jacobsen ED, Armand P, Hasserjian RP, Werner L, Neuberg DS, Brown JR. Phase II study of dasatinib in relapsed or refractory chronic lymphocytic leukemia. *Clin Cancer Res* 2011; Mar 14 [epub]. PMCID: PMC3108904
297. Lin Y, Zhang L, Cai AX, Lee M, Zhang W, Neuberg D, Canning CM, Soiffer RJ, Alyea EP, Ritz J, Hacoheh N, Means TK, Wu CJ. Effective posttransplant antitumor immunity is associated with TLR-stimulating nucleic acid-immunoglobulin complexes in humans. *J Clin Invest* 2011; 121(4):1574-84. PMCID: PMC3069775
298. White RM, Cech J, Ratanasirintrao S, Lin CY, Rahl PB, Burke CJ, Langdon E, Tomlinson ML, Mosher J, Kaufman C, Chen F, Long HK, Kramer M, Datta S, Neuberg D, Granter S, Young RA, Morrison S, Wheeler GN, Zon LI. DHODH modulates transcriptional elongation in the neural crest and melanoma. *Nature* 2011; 471(7339):518-22. PMCID: PMC3759979
299. Winkfield KM, Tsai HK, Yao X, Larson E, Neuberg D, Pomeroy SL, Ullrich NJ, Cohen LE, Kieran MW, Scott RM, Goumnerova LC, Marcus KJ. Long-term clinical outcomes following treatment of childhood craniopharyngioma. *Pediatr Blood Cancer* 2011; 56(7):1120-6. Dec 1, 2010 [epub]. PMID: 21488157.
300. Vrooman LM, Neuberg DS, Stevenson KE, Asselin BL, Athale UH, Clavell L, Cole PD, Kelly KM, Larsen EC, Laverdière C, Michon B, Schorin M, Schwartz CL, Cohen JH, Lipshultz SE, Silverman LB, Sallan SE. The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. *Eur J Cancer* 2011; 47(9):1373-9. PMCID: PMC3736806.
301. Gordon CM, Gordon LB, Snyder BD, Nazarian A, Quinn N, Huh S, Giobbie-Hurder A, Neuberg D, Cleveland R, Kleinman M, Miller DT, Kieran MW. Hutchinson-Gilford progeria is a skeletal dysplasia. *J Bone Miner Res* 2011; 26(7):1670-9. PMID: 21445982.
302. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, Tanaka M, Berezovskaya A, Imatki O, Drury L, Brennan L, Flavin M, Neuberg D, Stevenson K, Lawrence D, Hodi FS, Velazquez EF, Jaklitsch MT, Russell SE, Mihm M, Nadler LM, Hirano N. Establishment of antitumor memory in humans using in vitro-educated CD8+ t cells. *Sci Transl Med* 2011; 3(80):80ra34. PMCID: PMC3861895
303. Narla A, Dutt S, McAuley JR, Al-Shahrour F, Hurst S, McConkey M, Neuberg D, Ebert BL. Dexamethasone and lenalidomide have distinct functional effects on erythropoiesis. *Blood* 2011; 118(8):2296-304. Epub Apr 28. PMCID:PMC3162357

304. Dougan M, Li D, Neuberg D, Mihm M, Googe P, Wong KK, Dranoff G. A dual role for the immune response in a mouse model of inflammation-associated lung cancer. *J Clin Invest* 2011; 121(6):2436-46. PMID: PMC3104747
305. Mrakotsky CM, Silverman LB, Dahlberg SE, Alyman MC, Sands SA, Queally JT, Miller TP, Cranston A, Neuberg DS, Sallan SE, Waber DP. Neurobehavioral side effects of corticosteroids during active treatment for acute lymphoblastic leukemia in children are age-dependent: Report from Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. *Pediatr Blood Cancer* 2011; 57(3):492-8. PMID: PMC3354622.
306. Bejar R, Stevenson K, Abdel-Wahab O, Galili N, Nilsson B, Garcia-Manero G, Kantarjian H, Raza A, Levine RL, Neuberg D, Ebert BL. Clinical effect of point mutations in myelodysplastic syndromes. *N Engl J Med* 2011; 364(26):2496-506. PMID: PMC3159042
307. Singh H, Asali S, Werner LL, Deangelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Neuberg DS, Fox EA, Stone RM, Attar EC. Outcome of older adults with cytogenetically normal AML (CN-AML) and FLT3 mutations. *Leuk Res* 2011 Dec;35(12):1611-5. Epub Jun 20. PMID: PMC3498766.
308. Singh H, Werner LL, Asali S, Deangelo DJ, Ballen KK, Amrein PC, Wadleigh M, Galinsky I, Wolpin B, Pidala J, Neuberg DS, Fox EA, Stone RM, Attar EC. Comparison of autologous stem cell transplantation versus consolidation chemotherapy for patients with cytogenetically normal acute myeloid leukemia (CN-AML) and FLT3ITD. *Am J Hematol* 2011; 86(7):625-7. PMID: PMC3495174.
309. Gutierrez A, Grebliunaite R, Feng H, Kozakewich E, Zhu S, Guo F, Payne E, Mansour M, Dahlberg SE, Neuberg DS, Hertog JD, Prochownik EV, Testa JR, Harris M, Kanki JP, Look AT. Pten mediates Myc oncogene dependence in a conditional zebrafish model of T cell acute lymphoblastic leukemia. *J Exp Med* 2011; 208(8):1595-603. PMID: PMC3149218
310. Smith MR, Neuberg D, Flinn IW, Grever MR, Lazarus HM, Rowe JM, Dewald G, Bennett JM, Paietta EM, Byrd JC, Hussein MA, Appelbaum FR, Larson RA, Litzow MR, Tallman MS. Incidence of therapy-related myeloid neoplasia after initial therapy for CLL with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. *Blood* 2011; 118(13):3525-7. PMID: PMC3186330
311. Gutierrez A, Kentsis A, Sanda T, Holmfeldt L, Schen SC, Zhang J, Protopopov A, Chin L, Dahlberg SE, Neuberg DS, Silverman LB, Winter SS, Hunger SP, Sallan SE, Zha S, Alt FW, Downing JR, Mullighan CG, Look AT. The BCL11B tumor suppressor is mutated across the major molecular subtypes of T-cell acute lymphoblastic leukemia. *Blood* 2011; 118(15):4169-73. Epub Aug 30. PMID: PMC3204734
312. Chiarle R, Zhang Y, Frock RL, Lewis SM, Molinie B, Ho YJ, Myers DR, Choi VW, Compagno M, Malkin DJ, Neuberg D, Monti S, Giallourakis CC, Golissa M, Alt FW. Genome-wide translocation sequencing reveals mechanisms of chromosome breaks and rearrangements in B cells. *Cell* 2011; 147(1):107-19. PMID: PMC3186939.
313. Rousseau J, Gagne V, Labuda M, Beauvois C, Sinnott D, Laverdiere C, Moghrabi A, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Krajcinovic M. ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. *Blood* 2011 Nov24;118(22):5883-90. PMID: PMC3342855.
314. Gerhard-Herman M, Smoot LB, Wake N, Kieran MW, Kleinman ME, Miller DT, Schwartzman A, Giobbie-Hurder A, Neuberg D, Gordon LB. Mechanisms of premature vascular aging in children with Hutchinson-Gilford progeria syndrome. *Hypertension* 2012 Jan; 59(1):92-8. Epub 2011 Nov 14. PMID: 3248242 PMID: PMC3248242

315. Lane AA, Armand P, Feng Y, Neuberg DS, Abramson JS, Brown JR, Fisher DC, Lacasce AS, Jacobsen ED, McAfee SL, Spitzer TR, Freedman AS, Chen YB. Risk factors for development of pneumonitis after high-dose chemotherapy with cyclophosphamide, BCNU and etoposide followed by autologous stem cell transplant. *Leuk Lymphoma* 2012 Jun; 53(6):1130-6. Jan 3 Epub ahead of print. PMID: 22132836 PMCID: PMC3376378.
316. Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. *N Engl J Med* 2011 Dec 29;365(26):2497-506. Epub 2011 Dec 12. PMCID: PMC3685413
317. George RE, Perez-Atayde AR, Yao X, London WB, Shamberger RC, Neuberg D, Diller L. tumor histology during induction therapy in patients with high-risk neuroblastoma. *Pediatr Blood Cancer* 2012 Sep; 59(3):506-10. PMID: 22162143
318. Lee AI, Campigotto F, Rawn JD, Neuberg D, Kaufman RM, Berliner N. Clinical significance of coagulation studies in predicting response to activated recombinant Factor VII in cardiac surgery patients. *Br J Haematol* 2012 May; 157(3):397-400. PMID: 22224596
319. Biernacki MA, Tai YT, Zhang GL, Alonso A, Zhang W, Prabhala R, Zhang L, Munshi N, Neuberg D, Soiffer RJ, Ritz J, Alyea EP, Brusic V, Anderson KC, Wu CJ. Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. *Blood* 2012 Mar 29; 119(13):3142-50. Jan 20 Epub ahead of print. PMID: 22267603 PMCID: PMC3321874
320. Green MR, Rodig SJ, Juszcaynski P, Ouyang J, Sinha P, O'Donnell E, Neuberg D, Shipp MA. Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and post-transplant lymphoproliferative disorders: implications for targeted therapy. *Clin Cancer Res* 2012 Mar 15; 18(6):1611-8. Jan 23 Epub ahead of print PMID: 22271878 PMCID: PMC3321508
321. Chen AB, Feng Y, Neuberg D, Recklitis C, Diller LR, mauch PN, Ng AK. Employment and insurance in survivors of Hodgkin lymphoma and their siblings: a questionnaire study. *Leuk Lymphoma* 2012 Aug;53(8):1474-80. PMID: 22280535
322. Weigert O, Kopp N, Lane AA, Yoda A, Dahlberg SE, Neuberg D, Bahar AY, Chapuy B, Kutok JL, Longtine JA, Kuo FC, Haley T, Salois M, Sullivan TJ, Fisher DC, Fox EA, Rodig SJ, Antin JH, Weinstock DM. Molecular ontogeny of donor-derived follicular lymphoma occurring after hematopoietic cell transplantation. *Cancer Discovery* 2012; 2:45-55. PMCID: PMC4530787
323. Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, Colan SD, Neuberg DS, Dahlberg SE, Henkel JM, Asselin BL, Athale UH, Clavell LA, Laverdiere C, Michon B, Schorin MA, Sallan SE. Changes in cardiac biomarkers during Doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. *J Clin Oncol* 2012 Apr 1;30(10):1042-9. Epub 2012 Feb 27 PMID: 22370326 PMCID: PMC3341148
324. Brown JR, Hanna M, Tesar B, Pochet N, Vartanov A, Fernandes SM, Werner L, Ash M, Roden CA, Macconnaill L, Hainz U, Longtine J, Wang YE, Correll M, Van de Peer Y, Regev A, Wu C, Neuberg D, Freedman AS. Germline copy number variation associated with Mendelian inheritance of CLL in two families. *Leukemia*. 2012 Jul;26(7):1710-3. PMID: 22382893
325. Leonard JP, Lacasce AS, Smith MR, Noy A, Chirieac LR, Rodig SJ, Yu JQ, Vallabhajosula S, Schoder H, English P, Neuberg DS, Martin P, Millenson MM, Ely SA, Courtney R, Shaik N, Wilner KD, Randolph S, Van den Abbeele AD, Chen-Kiang SY, Yap JT, Shapiro GI. Selective

- CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. *Blood*. 2012 May 17;119(20):4597-607. PMID: 22383795
326. Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, Rodig SJ, Neuberg DS, Helman D, Feng H, Stewart RA, Wang W, George RE, Kanki JP, Look AT. Activated ALK collaborates with MYCN in neuroblastoma pathogenesis. *Cancer Cell*. 2012 Mar 20;21(3):362-73. PMID: 22439933 PMCID: PMC3315700
327. Arnason JE, Campigotto F, Neuberg D, Bussel JB. Abnormalities in IgA and IgM are associated with treatment-resistant ITP. *Blood*. 2012 May 24;119(21):5016-20. PMID: 22490683
328. Kluk MJ, Chapuy B, Sinha P, Roy A, Dal Cin P, Neuberg DS, Monti S, Pinkus GS, Shipp MA, Rodig SJ. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. *PLoS One*. 2012;7(4):e33813. Epub 2012 Apr 12. PMID:22511926 PMCID: PMC3325231
329. Merryman R, Stevenson KE, Gostic WJ 2nd, Neuberg D, O'Brien J, Sallan SE, Silverman LB. Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2012 Nov;59(5):925-7. PMID: 22532399
330. Blackburn JS, Liu S, Raiser DM, Martinez SA, Feng H, Meeker ND, Gentry J, Neuberg D, Look AT, Ramaswamy S, Bernards A, Trede NS, Langenau DM. Notch signaling expands a pre-malignant pool of T-cell acute lymphoblastic leukemia clones without affecting leukemia propagating cell frequency. *Leukemia*. 2012 Sep; 26(9):2069-78. PMCID: PMC3435461.
331. Janas MM, Wang E, Love T, Harris AS, Stevenson K, Semmelmann K, Shaffer JM, Chen PH, Doench JG, Yerramilli SV, Neuberg DS, Iliopoulos D, Housman DE, Burge CB, Novina CD. Reduced expression of ribosomal proteins relieves microRNA-mediated repression. *Mol Cell*. 2012 Apr 27;46(2):171-86. PMID:22541556
332. Campigotto F, Neuberg D, Zwicker JJ. Biased estimation of thrombosis rates in cancer studies using the method of Kaplan and Meier. *J Thromb Haemost*. 2012 Jul; 10(7):1449-51. PMID: 22554355
333. Brown JR, Hanna M, Tesar B, Werner L, Pochet N, Asara JM, Wang YE, Dal Cin P, Fernandes S, Thompson C, Macconail LE, Wu CJ, Van de Peer Y, Correll M, Regev A, Neuberg D, Freedman AS. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8124 in chronic lymphocytic leukemia. *Clin Cancer Res*. 2012 Jul 15; 18(14):3791-802. PMCID: 3719990
334. Campigotto F, Neuberg D, Zwicker JJ. Accounting for death as a competing risk in cancer-associated thrombosis studies. *Thromb res* 2012 Apr;129 Suppl 1:S85-87. PMID: 22682141
335. Cleveland RH, Gordon LB, Kleinman ME, Miller DT, Gordon CM, Snyder BD, Nazarian A, Giobbie-Hurder A, Neuberg D, Kieran MW. A prospective study of radiographic manifestations in Hutchinson-Gilford progeria syndrome. *Pediatr Radiol* 2012 Sep;42(0):1089-98. PMID: 22752073
336. Bejar R, Stevenson KE, Caughey BA, Abdel-Wahab O, Steensma DP, Galili N, Raza A, Kantarjian H, Levine RL, Neuberg D, Garcia-Manero G, Ebert BL. Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes. *J Clin Oncol* 2012 Sep 20;30(27):3376-82. PMID: 22869879 PMCID: PMC3438234.
337. Cai A, Keskin DB, Deluca DS, Alonso A, Zhang W, Zhang GL, Hammond NN, Nardi V, Stone RM, Neuberg D, Sidney J, Brusci V, Wu CJ. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML Patients. *Clin Cancer Res* 2012 Oct 15;18(20):5761-72. PMCID: PMC375991
338. Matsuura S, Komeno Y, Stevenson KE, Biggs JR, Lam K, Tang T, Lo MC, Cong X, Yan M, Neuberg DS, Zhang DE. Expression of the runt homology domain of RUNX1 disrupts

- homeostasis of hematopoietic stem cells and induces progression to myelodysplastic syndrome. *Blood* 2012 Nov 8;120(19):4028-37. PMID: 22919028 PMCID: PMC3496957.
339. Naito M, Hainz U, Burkhardt UE, Fu B, Ahove D, Stevenson KE, Rajasagi M, Zhu B, Alonso A, Witten E, Matsuoka KI, Neuberg D, Duke-Cohan JS, Wu CJ, Freeman GJ. CD40L-Tri, a novel formulation of recombinant human CD40L that effectively activates B cells. *Cancer Immunol Immunother* 2013 Feb;62(2):347-57. PMCID: PMC3569584.
340. Monti S, Chapuy B, Takeyama K, Rodig SJ, Hao Y, Yeda KT, Inguilizian H, Mermel C, Currie T, Dogan A, Kutok JL, Beroukhim R, Neuberg D, Haberman TM, Getz G, Kung AL, Golub TR, Shipp MA. Integrative analysis reveals an outcome-associated and targetable pattern of p53 and cell cycle deregulation in diffuse large B cell lymphoma. *Cancer Cell* 2012 Sep 11;22(3):359-72. PMCID: PMC3778921
341. Gordon LB, Kleinman ME, Miller DT, Neuberg DS, Giobbie-Hurder A, Gerhand-Herman M, Smoot LB, Gordon CM, Cleveland R, Snyder BD, Fligor B, Bishop WR, Statkevich P, Regen A, Sonis A, Riles S, Ploski C, Correia An, Quinn N, Ullrich NJ, Nazarian A, Liang MG, Huh SY, Schwartzman A, Kieran MW. Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome. *Proc Natl Acad Sci USA* 2012 Oct9;109(41):16666-16671. PMID: 23012407 PMCID: PMC3478615
342. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG, Letai A. Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. *Cell* 2012 Oct 12;151:344-355. PMCID: PMC3534747
343. Fathi AT, Sadrzadeh H, Borger DR, Ballen KK, Amrein PC, Attar EC, Foster J, Burke M, Lopez HU, Matulis CR, Edmonds KM, Iafrate AJ, Straley KS, Yen KE, Agresta S, Schenkein DP, Hill C, Emadi A, Neuberg DS, Stone RM, Chen YB. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. *Blood*. 2012 Nov 29;120(23):4649-52. PMID: 23074281
344. Geng H, Brennan S, Milne TA, Chen WY, Li Y, Hurtz C, Kweon SM, Zickl L, Shojaee S, Neuberg D, Huang C, Biswas D, Xin Y, Racevskis J, Ketterling RP, Luger SM, Lazarus H, Tallman MS, Rowe JM, Litzow MR, Guzman ML, Allis CD, Roeder RG, Müschen M, Paietta E, Elemento O, Melnick AM. Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. *Cancer Discov*. 2012 Nov;2(11):1004-1023. PMID: 23107779 PMCID: PMC3516186
345. Barnes J, Jacobsen E, Feng Y, Freedman A, Hochberg E, Lacasce A, Armand P, Joyce R, Sohani A, Rodig S, Neuberg D, Fisher D, Abramson J. Everolimus in combination with rituximab induces complete responses in heavily pretreated diffuse large B-cell lymphoma. *Haematologica*. 2013 Apr;98(4):615-9. PMCID: PMC3659994.
346. Lipshultz SE, Miller TL, Lipsitz SR, Neuberg DS, Dahlberg SE, Colan SD, Silverman LB, Henkel JM, Franco VI, Cushman LL, Asselin BL, Clavell LA, Athale U, Michon B, Laverdière C, Schorin MA, Larsen E, Usmani N, Sallan SE; for the Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Continuous versus bolus infusion of doxorubicin in children with ALL: Long-term cardiac outcomes. *Pediatrics*. 2012 Dec; 130(6):1003-1011. PMCID: PMC3507254
347. Brusica A, Hainz U, Wadleigh M, Neuberg D, Su M, Canning CM, Deangelo DJ, Stone RM, Lee JS, Mulligan RC, Ritz J, Dranoff G, Sasada T, Wu CJ. Detecting T-cell reactivity to whole cell vaccines: Proof of concept analysis of t-cell response to K562 cell antigens in CML patients. *Oncoimmunology*. 2012 Oct 1;1(7):1095-1103. PMCID: PMC3494623.
348. Shalek AK, Gaublomme JT, Wang L, Yosef N, Chevrier N, Andersen MS, Robinson JT, Pochet N, Neuberg D, Gertner RS, Amit I, Brown JR, Hacohen N, Regev A, Wu CJ, Park H. Nanowire-

- mediated delivery enables functional interrogation of primary immune cells: application to the analysis of chronic lymphocytic leukemia. *Nano Lett.* 2012 Dec 12;12(12):6498-504. PMID: 23190424 PMCID: PMC3521500
349. Amabile G, Welner RS, Nombela-Arrieta C, D'Alise AM, Di Ruscio A, Ebralidze AK, Kraysberg Y, Ye M, Kocher O, Neuberger DS, Khrapko K, Silberstein LE, Tenen DG. In vivo generation of transplantable human hematopoietic cells from induced pluripotent stem cells. *Blood* 2013 Feb 21;121(8):1255-64. PMCID: PMC3701251
350. Zwicker JJ, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberger D, Furie B. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). *Br J Haematol.* 2013 Feb;160(4):530-7. PMCID: PMC3609903
351. Landau DA*, Carter SL*, Stojanov P*, McKenna A, Stevenson K, Lawrence MS, Sougnez C, Stewart C, Sivachenko A, Wang L, Wan YZ, Zhang W, Shukla SA, Vartanov A, Fernandes SM, Saksena G, Cibulskis K, Tesar B, Gabriel S, Hacohen N, Meyerson M, Lander ES, Neuberger D, Brown JR, Getz G*, Wu CJ.* Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. *Cell* 2013 Feb 14;152(4):714-26. PMCID: PMC3575604
352. Abramson JS, Takvorian RW, Fisher DC, Feng Y, Jacobsen ED, Brown JR, Barnes JA, Neuberger DS, Hockberg EP. Oral clofarabine for relapsed/refractory non-hodgkin lymphomas: results of a phase I study. *Leuk Lymphom.* 2013 Jan 30 [Epub ahead of print]. PMID: 23289359
353. Nathan DG, Field J, Lin G, Neuberger D, Majerus E, Onyekwere O, Keefer J, Okam M, Ross A, Linden J. Sick cell disease (SCD), iNKT cells, and regadenoson infusion. *Trans Am Clin Climatol Assoc* 2012;123:312-7, discussion 317-8. PMCID: PMC3540605
354. Vrooman LM, Stevenson KE, Supko JG, O'Brien J, Dahlberg SE, Asselin BL, Athale UH, Clavell LA, Kelly KM, Kutok JL, Laverdiere C, Lipshultz SE, Michon B, Schorin M, Relling MV, Cohen HJ, Neuberger DS, Sallan SE, Silverman LB. Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. *J Clin Oncol.* 2013 Mar 20;31(0):1202-10. PMCID: PMC3595424
355. Field JJ, Lin G, Okam MM, Majerus E, Keefer J, Onyekwere O, Ross A, Campigotto F, Neuberger D, Linden J, Nathan DG. Sick cell vaso-occlusion causes activation of iNKT cells that is decreased by the adenosine A2A receptor agonist regadenoson. *Blood.* 2013 Apr 25;121(17):3329-34. PMCID: PMC3637009
356. Ouyang J, Plutschow A, von Strandmann EP, Reiners KS, Ponader S, Rabinovich GA, Neuberger D, Engert A, Shipp MA. Galectin-1 serum levels reflect tumor burden and adverse clinical features in classical Hodgkin lymphoma. *Blood.* 2013 Apr 25; 121(17):3431-3. PMID: 23444403
357. Sanda T, Tyner JW, Gutierrez A, Ngo VN, Glover J, Chang BH, Yost A, Ma W, Fleischman AG, Zhou W, Yang Y, Kleppe M, Ahn Y, Tatarek J, Kelliher MA, Neuberger DS, Levine RL, Moriggi R, Muller M, Gray NS, Jamieson CH, Weng AP, Staudt LM, Druker BJ, Look AT. TYK2-STAT1-BCL2 pathway dependence in T-cell acute lymphoblastic leukemia. *Cancer Discov.* 2013 May;3(5):564-577. PMCID: PMC3651770
358. Wei Y, Chen R, Dimicoli S, Bueso-Ramos C, Neuberger D, Pierce S, Wang H, Yang H, Jia Y, Zheng H, Fang Z, Nguyen M, Ganon-Gomez I, Ebert B, Levine R, Kantarjian H, Garcia-Manero G. Global H3K4me3 genome mapping reveals alterations of innate immunity signaling and

- overexpression of JMJD3 in human myelodysplastic syndrome CD34+ cells. *Leukemia*. 2013 Mar 29. Doi: 10.1038/leu.2013.91. [Epub ahead of print] PMID: 23538751
359. Ng AK, Garber JE, Diller LR, Birdwell RL, Feng Y, Neuberg DS, Silver B, Fisher DC, Marcus KJ, Mauch PM. Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma. *J Clin Oncol*. 2013 Apr 22. [Epub ahead of print] PMID: 23610104
360. Brunner AM, Campigotto F, Sadrzadeh H, Drapkin BJ, Chen YB, Neuberg DS, Fathi AT. Trends in all-cause mortality among patients with chronic myeloid leukemia: A Surveillance, Epidemiology and End Results database analysis. *Cancer*. 2013 Apr 26. Doi: 10.1002/cncr.28106. PMID: 23625575
361. Leblebjian H, Deqangelo DJ, Skirvin JA, Stone RM, Wadleigh M, Werner L, Neuberg DS, Bartel S, McDonnell AM. Predictive factors for all-trans retinoic acid-related differentiation syndrome in patients with acute promyelocytic leukemia. *Leuk Res*. 2013 Jul;37(7):747-51. PMID: 23643326.
362. Brown JR, Messmer BT, Werner L, Davids MS, Mikler E, Supko JG, Fisher DC, Lacasce AS, Armand P, Jacobsen E, Dalton V, Tesar B, Fernandes SM, McDonough S, Ritz J, Rassenti L, Kipps TJ, Neuberg D, Freedman AS. A phase I study of escalated dose subcutaneous alemtuzumab given weekly with rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. *Haematologica*. 2013 Jun;98(6):967-70. PMCID: PMC3669454
363. Murphy DM, Bejar R, Stevenson K, **Neuberg D**, Shi Y, Cubrich C, Richardson K, Eastlake P, Garcia-Manero G, Kantarjian H, Ebert BL, Makrigiorgos MG. NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes. *Leukemia*. 2013 Oct;27(10):2077-81. PMCID: PMC3967719
364. Soumerai JD, Hellmann MD, Feng Y, Sohani AR, Toomey CE, Barnes JA, Takvorian RW, **Neuberg D**, Hochberg EP, Abramson JS. Treatment of primary mediastinal B-cell lymphoma with R-CHOP is associated with a high rate of primary refractory disease. *Leuk Lymphoma*. 2014 Mar;55(3):538-43.
365. Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, **Neuberg D**, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA. SYK inhibition modulates distinct PI3K/AKT-dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas. *Cancer Cell* 2013. Jun 10;23(6):826-38. PMCID: PMC3700321
366. Wei Y, Dimicoli S, Bueso-Ramos C, Chen R, Yang H, **Neuberg D**, Pierce S, Jia Y, Zheng H, Wang H, Wang X, Nguyen M, Wang SA, Ebert B, Bejar R, Levine R, Abdel-Wahab O, Kleppe M, Ganan-Gomez I, Kantarjian H, Garcia-Manero G. toll-like receptor alternations in myelodysplastic syndrome. *Leukemia*. 2013 Sep;27(9):1832-40. PMCID: PMC4011663
367. Attar EC, Amrein PC, Fraser JW, Fathi AT, McAfee S, Wadleigh M, Deangelo DJ, Steensma DP, Stone RM, Foster J, **Neuberg D**, Ballen KK. Phase I dose escalation study of bortezomib in combination with lenalidomide in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). *Leuk Res*. 2013 Sep;37(0):1016-20. PMCID: PMC3969839
368. Kiaii S, Clear AJ, Ramsay AG, Davies D, Sangaralingam A, Lee A, Calaminici M, Neuberg DS, Gribben JG. Follicular lymphoma cells induce changes in t-cell gene expression and function: Potential impact on survival and risk of transformation. *J Clin Oncol*. 2013 Jul 20;31(21):2654-61. PMCID: PMC3709054.
369. Armand P, Oki Y, Neuberg DS, Faham M, Cummings C, Klinger M, Weng L, Bhattar S, Lacasce AS, Jacobsen ED, Davids MS, Jacobson C, Fisher DC, Brown JR, Fowler NH, Alma Rodriguez M, Wallace MJ, Neelapu SS, Rodig S, Younes A, Freedman AS. Detection of circulating tumour

- DNA I patients with aggressive B-cell non-Hodgkin lymphoma. *Br J Haematol.* 2013 Oct;163(1):123-6. PMID: 23795711
370. Lipshultz SE, Lipsitz SR, Kutok JL, Miller TL, Colan SD, Neuberg DS, Stevenson KE, Fleming MD, Sallan SE, Franco VI, Henkel JM, Asselin BL, Athale UH, Clavell LA, Michon B, Laverdiere C, Larsen E, Kelly KM, Silverman LB. Impact of hemochromatosis gene mutations on cardiac status in doxorubicin-treated survivors of childhood high-risk leukemia. *Cancer.* 2013 Oct 1;119(19):3555-62. PMID: PMC3788065.
 371. Heinrichs S, Conover LF, Bueso-Ramos CE, Kilpivaara O, Stevenson K, Neuberg D, Loh ML, Wu WS, Rodig SJ, Garcia-Manero G, Kantarjian HM, Look AT. MYBL2 is a sub-haploinsufficient tumor suppressor gene in myeloid malignancy. *eLife.* 2013 Jul 16;2:e00825. Doi: 10.7554/eLife.00825. PMID: PMC3713455.
 372. Ullrich NJ, Kieran MW, Miller DT, Gordon LB, Cho YJ, Silvera VM, Giobbie-Hurder A, Neuberg D, Kleinman ME. Neurologic features of Hutchinson-Gilford progeria syndrome after lonafarnib treatment. *Neurology.* 2013 Jul 30;81(5):427-30. PMID: PMC3776537.
 373. Gagne V, Rosseau J, Labuda M, Sharif-Askari B, Brukner I, Laverdiere C, Ceppi F, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnett D, Krajcinovic M. Bim polymorphisms influence on function and response to treatment in children with acute lymphoblastic leukemia. *Clin Cancer Res.* 2013 Sep 15;19(18):5240-9. PMID: 23908358.
 374. Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, Wong J, Siervers QL, Brusica A, McDonough SM, Zeng W, Perrin A, Brown JR, Canning CM, Koreth J, Cutler C, Armand P, Neuberg D, Lee JS, Antin JH, Mulligan RC, Sasada T, Ritz J, Soiffer RJ, Dranoff G, Alyea EP, Wu CJ. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. *J Clin Invest.* 2013 Sep 3;123(9):3756-65. PMID: PMC3754265.
 375. Sanchez R, St-Cyr J, Lalonde ME, Healy J, Richer C, Gagne V, Laverdiere C, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Kritikou EA, Krajcinovic M, Sinnett D. Impact of promoter polymorphisms in key regulators of the intrinsic apoptosis pathway on the outcome of childhood acute lymphoblastic leukemia. *Haematologica.* 2014 Feb;99(2):314-21. PMID: PMC3912962.
 376. Li A, Yang Y, Gao C, Lu J, Jeong HW, Liu BH, Tang P, Yao X, Neuberg D, Huang G, Tenen DG, Chai L. A SALL4/MLL/HOXA9 pathway in murine and human myeloid leukemogenesis. *J Clin Invest.* 2013 Oct 1;123(10):4195-207. PMID: PMC3784519.
 377. Robison NJ, Campigotto F, Chi SN, Manley PE, Turner CD, Zimmerman MA, Chordas CA, Werger AM, Allen JC, Goldman S, Rubin JB, Isakoff MS, Pan WJ, Khatib ZA, Comito MA, Bendel AE, Pietrantonio JB, Kondrat L, Hubbs SM, Neuberg DS, Kieran MW. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer. *Pediatr Blood Cancer.* 2014 Apr;61(4):636-42. PMID: 24123865.
 378. Lin G, Field JJ, Yu JC, Ken R, Neuberg D, Nathan DG, Linden J. NF- κ B is activated in CD4+ iNKT cells by sickle cell disease and mediates rapid induction of adenosine A2A receptors. *PLoS One.* 2013 Oct 4;8(10):e74664. Doi: 10.1371/journal.pone.0074664. eCollection 2013. PMID: PMC3790763.
 379. Ojesina AI, Lichtenstein L, Freeman SS, Peadarallu CS, Imaz-Rosshandler I, Pugh TJ, Cherniack AD, Ambrogio L, Cibulskis K, Bertelsen B, Romero-Cordoba S, Trevino V, Vazquez-Santillan K, Guadarrama AS, Wright AA, Rosenberg MW, Duke F, Kaplan B, Wang R, Nicerson E, Walline HM, Lawrence MS, Sterwart C, Carter SL, McKenna A, Rodriguez-Sanchez IP, Espinosa-Castilla M, Woie K, Borge L, Wik E, Halle MK, Hoivik EA, Krakstad C, Gabino NB, Gomes-Macias GS, Valdez-Chapa LD, Garza-Rodriguez ML, Maytorena G, Vazquez J, Rodea C,

- Cravioto A, Cortes ML, Greulich H, Crum CP, Neuberg DS, Hidalgo-Miranda A, Escareno CR, Akslen LA, Carey TE, Vintermyr OK, Gabriel SB, Barrera-Saldana HA, Melendez-Zajgla J, Getz G, Salvesen HB, Meyerson M. Landscape of genomic alternations in cervical carcinoma. *Nature*. 2014 Feb 20;506(7488):371-5. PMID: PMC4161954.
380. Dutcher JP, Neuberg D, Atkins MB, Tester WJ, Wadler S, Stewart JA, Chacoua A, Schuchter LM. Report of a Phase I Evaluation of Dose and Schedule of Interleukin-1 Alpha and Cyclophosphamide in Patients with Advanced Tumors: And Eastern Cooperative Oncology Group Study (PX990) and Review of IL-1 Based Studies of Hematopoietic Reconstitution. *J Interferon Cytokine Res*. 2014 May;34(5):376-84. PMID: PMC4015471.
381. Deangelo DJ, Neuberg D, Amrein PC, Berchuck J, Wadleigh M, Sirulnik LA, Galinsky I, Golub T, Stegmaier K, Stone RM. A phase II study of the EGFR inhibitor gefitinib in patients with acute myeloid leukemia. *Leuk Res*. 2014 Apr;38(4):430-4. PMID: 24522247
382. Reynolds C, Roderick JE, Labelle JL, Bird G, Mathieu R, Bodaar K, Colon D, Pyati U, Stevenson KE, Qi J, Harris M, Silverman LB, Sallan SE, Bradner JE, Neuberg DS, Look AT, Walensky LD, Kelliher MA, Gutierrez A. Repression of BIM mediates survival signaling by MYC and AKT in high-risk T-cell acute lymphoblastic leukemia. *Leukemia*. 2014 Sep;28(0):1819-27. PMID: PMC4139485
383. Mar BG, Bullinger LB, McLean KM, Grauman PV, Harris MH, Stevenson K, Neuberg DS, Sinha AU, Sallan SE, Silverman LB, Kung AL, Lo Nigro L, Ebert BL, Armstrong SA. Mutations in epigenetic regulators including SETD2 are gained during relapse in paediatric acute lymphoblastic leukaemia. *Nat Commun*. 2014 Mar 24;5:3469. Doi: 10.1038/ncomms4469. PMID: PMC4016990
384. Mutter GL, Monte NM, Neuberg D, Ferenczy A, Eng C. Emergence, involution, and progression to carcinoma of mutant clones in normal endometrial tissues. *Cancer Res*. 2014 May 15;74(10):2796-802. PMID: PMC4058864
385. Szabatura AH, Cirrone F, Harris C, McDonnell AM, Feng Y, Voit D, Neuberg D, Butrynski J, Fisher DC. An assessment of risk factors associated with ifosfamide-induced encephalopathy in a large academic cancer center. *J Oncol Pharm Pract*. 2015 Jun;21(3):188-93. PMID: 24664476
386. Gutierrez A, Fend H, Stevenson K, Neuberg DS, Calzada O, Zhou Y, Langenau DM, Look AT. Loss of function TP53 mutations do not accelerate the onset of MYC-induced T-cell acute lymphoblastic leukaemia in the zebrafish. *Br J Haematol*. 2014 Jul;166(1):84-90. PMID: PMC4234197
387. Lane AA, Chapuy B, Lin CY, Tivey T, Li H, Townsend EC, van Bodegom D, Day TA, Wu SC, Liu H, Yoda A, Alexe G, Schinzel AC, Sullivan TJ, Malinger S, Taylor JE, Stegmaier K, Jaffe JD, Bustin M, Te Kronnie G, Izraeli S, Harris MH, Stevenson KE, Neuberg D, Silverman LB, Sallan SE, Bradner JE, Hahn WC, Crispino JC, Pellman D, Weinstock DM. Triplication of a 21q22 region contributes to B cell transformation through HMGN1 overexpression and loss of histone H3 Lys 27 trimethylation. *Nat Genet*. 2014 Jun;46(6):618-23. PMID: 4040006
388. Wang L, Shalek AK, Lawrence M, Ding R, Gaublot JM, Pochet N, Stojanov P, Sougnez C, Shukla SA, Stevenson KE, Zhang W, Wong J, Sievers QL, Macdonald BT, Vartanov AR, Goldstein NR, Neuberg D, He X, Lander E, Hacohen N, Regev A, Getz G, Brown JR, Park H, Wu CJ. Somatic mutation as a mechanism of Wnt/ β -catenin pathway activation in CLL. *Blood*. 2014 Aug 14;124(7):1089-98. PMID: PMC4133483
389. Brunner AM, Blonquist TM, Sadrazadeh H, Perry AM, Attar EC, Amrein PC, Ballen KK, Chen YB, Neuberg DS, Fathi AT. Population-based disparities in survival among patients with core-binding factor acute myeloid leukemia: A SEER database analysis. *Leuk Res*. 2014 Jul;38(7):773-80. PMID: PMC4214756

390. Zwicker JI, Rojan A, Campigotto F, Rehman N, Funches R, Connolly G, Webster J, Aggarwal A, Mobarek D, Faselis C, Neuberg D, Rickles FR, Wun T, Streiff MB, Khorana AA. Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: A prospective, cross-sectional, multicenter study. *J Clin Oncol*. 2014 Jun 10;32(17):1792-6. PMID: 4039867
391. Riches JC, O'Donovan CJ, Kingdon SJ, McClanahan F, Clear AJ, Neuberg DS, Werner L, Croce CM, Ramsay AG, Rassenti LZ, Kipps TJ, Gribben JG. Trisomy 12 chronic lymphocytic leukemia cells exhibit up-regulation of integrin signaling that is modulated by NOTCH1 mutations. *Blood*. 2014 Jun 26;123(26):4101-10. PMID: PMC4073326
392. James DF, Werner L, Brown JR, Wierda WG, Barrientos JC, Castro JE, Greaves A, Johnson AJ, Rassenti LZ, Rai KR, Neuberg D, Kipps TJ. Lenalidomide and rituximab for the initial treatment of patients with chronic lymphocytic leukemia: a multicenter clinical translational study from the Chronic Lymphocytic Leukemia Research Consortium. *J Clin Oncol*. 2014 Jul 1;32(19):2067-73. PMID: PMC4067945
393. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, Stevenson K, Ritz J, Neuberg D, Brusic V, Gabriel S, Lander ES, Getz G, Hacoheh N, Wu CJ. Systematic identification of personal tumor specific neoantigens in chronic lymphocytic leukemia. *Blood*. 2014 Jul 17;124(3):453-62. PMID: PMC4102716
394. Ben Tanfous M, Sharif-Askari B, Ceppi F, Laaribi H, Gagne V, Rousseau J, Labuda M, Silverman LB, Sallan SE, Neuberg D, Kutok JL, Sinnott D, Laverdiere C, Krajcinovic M. Polymorphisms of asparaginase pathway and asparaginase related complications in children with acute lymphoblastic leukemia. *Clin Cancer Res*. 2015 Jan 15;21(2):329-34. PMID: PMC4258187
395. Jacobsen E, Pozdnyakova O, Redd R, Fisher DC, Dorfman DM, Dal Cin P, LaCasce A, Armand P, Hochberg E, Cote G, Shahsafaei A, Neuberg D, Brown JR, Freedman AS. *Leuk Lymphoma*. 2015 Apr;56(4):993-8. PMID: 25012943
396. Hasserrjian RP, Campigotto F, Klepeis V, Fu B, Wang SA, Bueso-Ramos C, Cascio MJ, Rogers HJ, His ED, Soderquist C, Bagg A, Yan J, Ochs R, Orazi A, Moore F, Mahmoud A, George TI, Foucar K, Odem J, Booth C, Morice W, DeAngelo DJ, Steensma D, Stone RM, Neuberg D, Arber DA. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with $\geq 30\%$ blasts in older adults: a Bone Marrow Pathology Group study. *Am J Hematol*. 2014 Nov;89(11):E193-9. PMID: 25042343
397. DeAngelo DJ, Stevenson KE, Dahlberg SE, Silverman LB, Couban S, Supko JG, Amrein PC, Ballen KK, Seftel MD, Turner AR, Leber B, Howson-Jan K, Kelly K, Cohen S, Matthews JH, Savoie L, Wadleigh M, Sirulnik LA, Galinsky I, Neuberg DS, Sallan SE, Stone RM. Long-term outcome of a pediatric-inspired regimen used for adults ages 18 to 50 with newly diagnosed acute lymphoblastic leukemia. *Leukemia*. 2015 Mar;29(3):526-34. PMID: PMC4360211
398. Ceppi F, Langlois-Pelletier C, Gagne V, Rousseau J, Ciolino C, Lorenzo SD, Kevin KM, Cijov D, Sallan SE, Silverman LB, Neuberg D, Kutok JL, Sinnott D, Laverdiere C, Krajcinovic M. Polymorphisms of the vincristine pathway and response to treatment in children with childhood acute lymphoblastic leukemia. *Pharmacogenomics*. 2014 Jun;15(8):1105-16. Doi: 10.2217/pgs.1468. PMID: PMC4443746
399. Bejar R, Stevenson KE, Caughey B, Lindsley RC, Mar BG, Stojanov P, Getz G, Steensma DP, Ritz J, Soiffer R, Antin JH, Alyea F, Armand P, Ho V, Koreth J, Neuberg D, Cutler CS, Ebert BL. Somatic mutations predict poor outcome in patients with myelodysplastic syndrome after hematopoietic stem cell transplantation. *J Clin Oncol*. 2014 Sep 1;32(25):2691-8. PMID: PMC4207878

400. Movassaghian M, Brunner AM, Blonquist TM, Sadrzadeh H, Bhatia A, Perry AM, Attar EC, Amrein PC, Ballen KK, Neuberg DS, Fathi AT. Presentation and outcomes among patients with isolated myeloid sarcoma: A Surveillance, Epidemiology, and End Results database analysis. *Leuk Lymphoma*. 2014 September 11:1-26 [Epub ahead of print]
401. Bejar R, Lord A, Stevenson K, Bar-Natan M, Pérez-Ladaga A, Zaneveld J, Wang H, Caughey B, Stojanov P, Getz G, Garcia-Manero G, Kantarjian H, Chen R, Stone RM, **Neuberg D**, Steensma DP, Ebert BL. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. *Blood*. 2014 Oct 23;122(17):2705-12. PMID: PMC4208285
402. Coutinho R, Clear AJ, Mazzola E, Owen A, Greaves P, Wilson A, Matthews J, Lee A, Alvarez R, Gomes da Silva M, Cabeçadas J, **Neuberg D**, Calaminici M, Gribben JG. Revisiting the immune microenvironment of diffuse large B-cell lymphoma using a tissue microarray and immunohistochemistry: robust semi-automated analysis reveals CD3 and FoxP3 as potential predictors of response to R-CHOP. *Haematologica*. 2015 Mar;100(3):363-9. PMID: PMC4349275
403. Jaiswal S, Fontanillas P, Flannick J, Manning A, Grauman PV, Mar BG, Lindsley RC, Mermel CH, Burt N, Chavez A, Higgins JM, Moltchanov V, Kuo FC, Kluk MJ, Henderson B, Kinnunen L, Koistinen HA, Ladenvall C, Getz G, Correa A, Banahan BF, Gabriel S, Kathiresan S, Stringham HM, McCarthy MI, Boehnke M, Tuomilehto J, Haiman C, Groop L, Atzmon G, Wilson JG, **Neuberg D**, Altshuler D, Ebert BL. Age-related clonal hematopoiesis associated with adverse outcomes. *N Engl J Med*. 2014 Dec 25;371(26):2488-98. doi: 10.1056/NEJMoa1408617. Epub 2014 Nov 26. PMID: PMC4306669
404. Carey CD, Gusenleitner D, Chapuy B, Kovach AE, Kluk MJ, Sun HH, Crossland RE, Bacon CM, Rand V, Dal Cin P, Le LP, **Neuberg D**, Sohani AR, Shipp MA, Monti S, Rodig SJ. Molecular classification of MYC-driven B-cell lymphomas by targeted gene expression profiling of fixed biopsy specimens. *J Mol Diagn*. 2015 Jan;17(1):19-30. doi: 10.1016/j.jmoldx.2014.08.006. Epub 2014 Nov 7. PMID: PMC4279427
405. Meng FL, Du Z, Federation A, Hu J, Wang Q, Kieffer-Kwon KR, Meyers RM, Amor C, Wasserman CR, **Neuberg D**, Casellas R, Nussenzweig MC, Bradner JE, Liu XS, Alt FW. Convergent transcription at intragenic super-enhancers targets AID-initiated genomic instability. *Cell*. 2014 Dec 18;159(7):1538-48. doi: 10.1016/j.cell.2014.11.014. Epub 2014 Dec 4. PMID: PMC4322776
406. Landau DA, Clement K, Ziller MJ, Boyle P, Fan J, Gu H, Stevenson K, Sougnez C, Wang L, Li S, Kotliar D, Zhang W, Ghandi M, Garraway L, Fernandes SM, Livak KJ, Gabriel S, Gnirke A, Lander ES, Brown JR, **Neuberg D**, Kharchenko PV, Hacohen N, Getz G, Meissner A, Wu CJ. Locally disordered methylation forms the basis of intratumor methylome variation in chronic lymphocytic leukemia. *Cancer Cell*. 2014 Dec 8;26(6):813-25. doi: 10.1016/j.ccell.2014.10.012. PMID: PMC4302418
407. Lindsley RC, Mar BG, Mazzola E, Grauman PV, Shareef S, Allen SL, Pigneux A, Wetzler M, Stuart RK, Erba HP, Damon LE, Powell BL, Lindeman N, Steensma DP, Wadleigh M, DeAngelo DJ, **Neuberg D**, Stone RM, Ebert BL. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood*. 2014 Dec 30. pii: blood-2014-11-610543. [Epub ahead of print.] PMID: PMC4342352
408. Schram AM, Campigotto F, Mullally A, Fogerty A, Massarotti E, **Neuberg D**, Berliner N. Marked hyperferritinemia does not predict for HLH in the adult population. *Blood*. 2015 Mar 5;125(10):1548-52. PMID: 25573993.
409. Wang Z, Choi S, Lee J, Huang YT, Chen F, Zhao Y, Lin X, **Neuberg D**, Kim J, Christiani DC. Mitochondrial variations in non-small cell lung cancer (NSCLC) survival. *Cancer Inform*. 2015 Jan 27;14(Suppl 1):1-9. doi: 10.4137/CIN.S13976. eCollection 2015. PMID: PMC4310606.

410. Bhanot H, Reddy MM, Nonami A, Weisberg EL, Bonal D, Kirschmeier PT, Salgia S, Podar K, Galinsky I, Chowdary TK, **Neuberg D**, Tonon G, Stone RM, Asara J, Griffin JD, Sattler M. Pathological glycogenesis through glycogen synthase L and suppression of excessive AMP kinase activity in myeloid leukemia cells. *Leukemia*. 2015 Jul;29(7):1555063. PMC4497855.
411. Lucas DM, Stark A, Lozanski G, Dewald GW, Lozanski A, Claus R, Plass C, Flinn IW, Neuberg DS, Paietta EM, Bennett JM, Jelinek DF, Gribben JG, Hussein MA, Appelbaum FR, Larson RA, Moore DF Jr, Tallman MS, Byrd JC, Grever MR. Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated chronic leukemia patients treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroups phase III trial E2997. *Leuk Lymphoma*. 2015;56(11):3031-7. PMC4688910
412. Stone RM, Mazzola E, **Neuberg D**, Allen SL, Pigneux A, Stuart RK, Wetzler M, Rizzieri D, Erba HP, Damon L, Jang JH, Tallman MS, Warzocha K, Masszi T, Sekeres MA, Egyed M, Horst HA, Selleslag D, Solomon SR, Venugopal P, Lundberg AS, Powell B. Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia. *J Clin Oncol*. 2015 Apr 10;33(11):1252-7. PMID: 25732165.
413. Goldberg J, Fisher DE, Demetri GD, **Neuberg D**, Allsop S, Fonseca C, Nakazaki Y, Nemer D, Raut CP, George S, Morgan JA, Wagner AJ, Freeman GJ, Ritz J, Lezcano C, Mihm MC, Canning C, Hodi FS, Dranoff G. Biologic activity of autologous granulocyte-macrophage colony stimulating factor secreting alveolar soft parts sarcoma and clear cell sarcoma vaccines. *Clin Cancer Res*. 2015 Jul 15;21(14):3178-86. PMC4506240
414. Suarez A, Piña M, Nichols-Vinueza DX, Lopera J, Rengifo L, Mesa M, Cardenas M, Morrissey L, Veintemilla G, Vizcaino M, Del Toro L, Vicuna V, Fernandez J, **Neuberg D**, Stevenson K, Gutierrez A. A strategy to improve treatment-related mortality and abandonment of therapy for childhood ALL in a developing country reveals the impact of treatment delays. *Pediatr Blood Cancer*. 2015 Aug;62(8):1395-402. PMID: 25808195
415. Marshall AL, Campigotto F, **Neuberg D**, Rowe B, Connors JM. Recurrence of venous thromboembolism in patients with cancer treated with warfarin. *Clin Appl Thromb Hemost*. 2015 Oct;21(7):632-8. PMID: 25850917.
416. Brown JR, Tesar B, Yu L, Werner L, Takebe N, Mikler E, Reynolds HM, Thompson C, Fisher DC, Neuberg D, Freedman AS. Obatoclox in combination with fludarabine and rituximab (FR) is well-tolerated and shows promising clinical activity in relapsed chronic lymphocytic leukemia (CLL). *Leuk Lymphoma*. 2015;56(12):3336-42. PMID: 25971907
417. Weinberg OK, Pozdnyakova O, Campigotto F, DeAngelo DJ, Stone RM, Neuberg D, Hasserjian RP. Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. *Mod Pathol*. 2015 Jul;28(7):965-76. PMID 25975285.
418. McClanahan F, Riches JC, Miller S, Day WP, Kotsiou E, Neuberg D, Croce CM, Capasso M, Gribben JG. Mechanisms of PD-L1/PD-1 mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the E μ -TCL1 CLL mouse model. *Blood*. 2015 Jul 9;126(2):212-21. PMC4497962
419. Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, Zwicker JI. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. *Blood*. 2015 Jul 23;126(4):494-9. PMC4548746
420. Cole PD, Finkelstein Y, Stevenson KE, Blonquist TM, Vijayanathan V, Silverman LB, Neuberg DS, Sallan SE, Robaey P, Waber DP. Polymorphisms in genes related to oxidative stress are associated with inferior cognitive function after therapy for childhood acute lymphoblastic leukemia. *J Clin Oncol*. 2015 Jul 1;33(19):2205-11. PMC4477790.

421. Davids MS, Vartanov A, Werner L, Neuberg D, Dal Cin P, Brown JR. Controversial fluorescence in situ hybridization cytogenetic abnormalities in chronic lymphocytic leukaemia: new insights from a large cohort. *Br J Haematol*. 2015 Sep;170(5):694-703. PMID: 26032737
422. Okam MM, Esrick EB, Mandell E, Campigotto F, Neuberg DS, Ebert BL. Phase 1/2 trial of vorinostat in patients with sickle cell disease who have not benefitted from hydroxyurea. *Blood*. 2015 Jun 4;125(23):3668-9. PMC4458806.
423. Brunner AM, Hobbs G, Jalbut MM, Neuberg DS, Fathi AT. A population-based analysis of second malignancies among patients with myeloproliferative neoplasms in the SEER database. *Leuk Lymphoma* 2016 May;57(5):1197-200. PMC4943877
424. Pastore A, Jerinovic V, Kridel R, Hoster E, Staiger AM, Szczepanowski M, Pott C, Kopp N, Murakami M, Horn H, Leich E, Moccia AA, Mottok A, Sunkavalli A, Van Hummelen P, Ducar M, Ennishi D, Shulha HP, Hother C, Connors JM, Sehn LH, Dreyling M, Neuberg D, Moller P, Feller AC, Hansmann ML, Stein H, Rosenwald A, Ott G, Klapper W, Unterhall M, Hiddemann W, Gascoyne RD, Weinstock DM, Weigert O. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. *Lancet Oncol*. 2015 Aug 6. Pii: S1470-2045(15)00169-2. Doi: 10.1016/S1470-2045(15)00169-2. [Epub ahead of print] PMID: 26256760
425. Krajcinovic M, Elbared J, Drouin S, Bertout L, Rezgui A, Ansari M, Raboisson MJ, Lipshultz SE, Silverman LB, Sallan SE, Neuberg DS, Kutok JL, Laverdière C, Sinnett D, Andelfinger G. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. *Pharmacogenomics J*. 2016 Nov;16(6):530-535. PMID 26345518
426. Krajcinovic M, Elbared J, Drouin S, Bertout L, Rezgui A, Ansari M, Raboisson MJ, Lipshultz SE, Silverman LB, Sallan SE, Neuberg DS, Kutok JL, Laverdière C, Sinnett D, Andelfinger G. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. *Pharmacogenomics J*. Corrigendum. 2017 Jan;17(1):107.doi:10.1038/tpj.2016.86. PMID: 27958382
427. Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edlmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, **Neuberg D**, Getz G, Stilgenbauer S, Wu CJ. Mutations driving CLL and their evolution in progression and relapse. *Nature*. 2015 Oct 22;525(7574):525-30. PMC4815041
428. Walters MC, De Castro LM, Sullivan KM, Krishnamurti L, Kamani N, Bredeson C, Neuberg D, Hassell KL, Farnia S, Campbell A, Petersdorf E. Indications and results of human leukocyte antigen-identical sibling hematopoietic cell transplantation for sickle cell disease. *Biol Blood Marrow Transplant*. 2016 Feb;22(2):207-11. PMC5031360
429. Place AE, Stevenson KE, Vrooman LM, Harris MH, Hunt SK, O'Brien JE, Supko JG, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJ, Lipshultz SE, Kutok JL, Blonquist TM, Neuberg DS, Sallan SE, Silverman LB. Intravenous pegylated asparaginase versus intramuscular native *Escherichia coli*-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomized open-label phase 3 trial. *Lancet Oncol*. 2015 Dec;16(16):1677-90. PMID: 26549586
430. Yeap LS, Hwang JK, Du Z, Meyers RM, Meng FL, Jakubauskaitė A, Liu M, Mani V, **Neuberg D**, Kepler TB, Wang JH, Alt FW. Sequence-intrinsic mechanisms that target AID mutational outcomes on antibody genes. *Cell*. 2015 Nov 19;1124-37. PMC4751889

431. Beheshti A, **Neuberg D**, McDonald JT, Vanderburg CR, Evens AM. The impact of age and sex in DLBCL: Systems biology analyses identify distinct molecular changes and signaling networks. *Cancer Inform.* 2015 Dec 10;14:141-8. doi: 10.4137/CIN.S34144. eCollection 2015. PMC4676434
432. Seftel MD, **Neuberg D**, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ; Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium. Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. *Am J Hematol.* 2016 Mar;91(3):322-9. doi: 10.1002/ajh.24285. PMC4764423
433. Lipshultz SE, Anderson LM, Miller TL, Gerschenson M, Stevenson KE, Neuberg DS, Franco VI, LiButti DE, Silverman LB, Vrooman LM, Sallan SE; Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium. Impaired mitochondrial function is abrogated by dexrazoxane in dosorubicin-treated childhood acute lymphoblastic leukemia survivors. *Cancer.* 2016 Mar 15;122(6):946-53. PmMC4777628
434. Kluk MJ, Ho C, Yu H, Chen BJ, Neuberg DS, Dal Cin P, Woda BA, Pinkus GS, Rodig SJ. MYC immunohistochemistry to identify MYC-driven B-cell lymphomas in clinical practice. *Am J Clin Pathol.* 2016 Feb;145(2):166-79. PMID: 26834124
435. Van Dyke DL, Werner L, Rassenti LZ, **Neuberg D**, Ghia E, Heerema NA, Dal Cin P, Dell Aquila M, Sreekantaiah C, Greaves AW, Kipps TJ, Kay NE. The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): The CLL Research Consortium experience. *Br J Haematol.* 2016 Apr;173(1):105-13. PMC4963001
436. Anderson NM, Li D, Peng HL, Laroche FJ, Mansour MR, Gjini E, Aioub M, Helman DJ, Roderick JE, Cheng T, Harrold I, Samaha Y, Meng L, Amsterdam A, Neuberg DS, Denton TT, Sanda T, Kelliher MA, Singh A, Look AT, Feng H. the TCA cycle transferase DLST is important for MYC-mediated leukemogenesis. *Leukemia.* 2016 Jun;30(6):1365-74. PMC4889531
437. Howitt BE, Sun HH, Roemer MG, Kelley A, Chapuy B, Aviki E, Pak C, Connelly C, Gjini E, Shi Y, Lee L, Viswanathan A, Horowitz N, **Neuberg D**, Crum CP, Lindeman NL, Kuo F, Ligon AH, Freeman GJ, Hodi FS, Shipp MA, Rodig SJ. Genetic basis for PD-L1 expression in squamous cell carcinomas of the cervix and vulva. *JAMA Oncol.* 2016 Feb 25. doi: 10.1001/jamaoncol.2015.6326. [Epub ahead of print] PMID: 26913631
438. Bona K, Blonquist TM, Neuberg DS, Silverman LB, Wolfe J. Impact of socioeconomic status on timing of relapse and overall survival for children treated on Dana-Farber Cancer Institute ALL Consortium Protocols (2000-2010). *Pediatr Blood Cancer.* 2016 Feb 23. doi: 10.1002/pbc.25928. [Epub ahead of print] PMID: 26913850
439. Roemer MG, Advani RH, Ligon AH, Natkunam Y, Redd RA, Homer H, Connelly CF, Sun HH, Daadi SE, Freeman GH, Armand P, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Rodig SJ, Shipp MA. PD-L1 and PD-L2 genetic alternatins define classical Hodgkin lymphoma and predict outcome. *J Clin Oncol.* 2016 aug 10;34(23):2690-7. PMC5019753
440. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Koester J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu S-C, Plana O, Montero J, Stevenson KE, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf N, LaCasce AS, Lees E, Li L, Look AT, Murakami M, Muschen M, Neuberg D, Ng

- SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli M, Ritz J, Brown M, Long H, Aster JC, Shipp M, Griffin JD, Weinstock DM. The Public Repository of Xenografts (PRoXe) enables discovery and randomized phase II-like trials in mice. *Cancer Cell*. 2016 Apr 11;29(4):574-86. PMC5177991
441. Townsend EC, Murakami MA, Christodoulou A, Christie AL, Koester J, DeSouza TA, Morgan EA, Kallgren SP, Liu H, Wu S-C, Plana O, Montero J, Stevenson KE, Andreeff M, Armand P, Ballen KK, Barzaghi-Rinaudo P, Cahill S, Clark RA, Cooke VG, Davids MS, DeAngelo DJ, Dorman DM, Eaton H, Ebert BL, Etchin J, Firestone B, Fisher DC, Freedman AS, Galinsky IA, Gao H, Garcia JS, Garnache-Ottou F, Graubert TA, Gutierrez A, Halilovic E, Harris MH, Herbert ZT, Horwitz SM, Inghirami G, Intlekofer AM, Ito M, Izraeli S, Jacobsen ED, Jacobson CA, Jeay S, Jeremias I, Kelliher MA, Koch R, Konopleva M, Kopp N, Kornblau SM, Kung AL, Kupper TS, LeBoeuf N, LaCasce AS, Lees E, Li L, Look AT, Murakami M, Muschen M, Neuberg D, Ng SY, Odejide OO, Orkin SH, Paquette RR, Place AE, Roderick JE, Ryan JA, Sallan SE, Shoji B, Silverman LB, Soiffer RJ, Steensma DP, Stegmaier K, Stone RM, Tamburini J, Thorner AR, van Hummelen P, Wadleigh M, Wiesmann M, Weng AP, Wuerthner JU, Williams DA, Wollison BM, Lane AA, Letai A, Bertagnolli M, Ritz J, Brown M, Long H, Aster JC, Shipp M, Griffin JD, Weinstock DM. The Public Repository of Xenografts (PRoXe) enables discovery and randomized phase II-like trials in mice. *Cancer Cell*. 2016 Jul 11;30(1):183. Erratum
442. Wolach O, Stevenson KE, Wadleigh M, DeAngelo DJ, Steensma DP, Ballen KK, Soiffer RJ, Antin JH, Neuberg DS, Ho VT, Stone RM. Allogeneic transplantation is not superior to chemotherapy in most patients over 40 years of age with Philadelphia-negative acute lymphoblastic leukemia in first remission. *Am J Hematol*. 2016 Aug;91(8):793-9. PMID: 27171984
443. Fathi AT, DeAngelo DJ, Stevenson KE, Kolitz JE, Asch JD, Amrein PC, Attar EC, Steensma DP, Wadleigh M, Foster J, Connolly C, Galinsky I, Devoe CE, Stone RM, Neuberg DS, Ballen KK. Phase 2 study of intensified chemotherapy and allogeneic hematopoietic stem cell transplantation for older patients with acute lymphoblastic leukemia. *Cancer*. 2016 Aug 1;122(15):2379-88. PMID: 27171984
444. Burger JA, Landau DA, Taylor-Weiner A, Bozic I, Zhang, H, Sarosiek K, Wang L, Stewart C, Fan J, Hoellenriegel J, Sivina M, Dubuc AM, Fraser C, Han Y, Li S, Livak KJ, Zou L, Wan Y, Konoplev S, Sougnez C, Brown JR, Abruzzo LV, Carter SL, Keating MJ, Davids MS, Wierda WG, Cibulskis K, Zenz T, Werner L, Dal Cin P, Kharchenko P, Neuberg D, Kantarjian H, Lander E, Gabriel S, O'Brien S, Letai A, Weitz DA, Nowak MA, Getz G, Wu CJ. Clonal evolution in patients with chronic lymphocytic leukaemia developing resistance to BTK inhibition. *Nat Commun*. 2016 May 20;7:11589. PMCID: PMC4876453
445. Li S, Garrett-Bakelman FE, Chung SS, Sanders MA, Hricik T, Rapaport F, Patel J, Dillon R, Vijay P, Brown AL, Perl AE, Cannon J, Bullinger L, Luger S, Becker M, Lewis ID, To LB, Delwel R, Lowenberg B, Dohner H, Dohner K, Guzman M, Haasane D, Roboz G, Grimwade D, Valk PJM, D'Andrea RJ, Carroll M, Park CY, Neuberg D, Levine R, Melnick AM, Mason CE. Distinct patterning and dynamics of epigenetic and genetic heterogeneity in AML. *Nat Med*. 2016 Jul;22(7):792-9. PMCID: PMC4938719
446. Louissaint A Jr, Schafernak KT, Geyer JT, Kovach AE, Ghandi M, Gratzinger D, Roth CG, Paxton CN, Kim S, Namgyal C, Morin R, Morgan EA, Neuberg DS, South ST, Harris MH, Hasserjian RP, Hochberg EP, Garraway LA, Harris NL, Weinstock DM. Pediatric-type nodal follicular lymphoma: a biologically distinct lymphoma with frequent MAPK pathway mutations. *Blood*. 2016 Aug 25;128(8):1093-100. PMCID: PMC5000844

447. Yong KJ, Basseres DS, Welner RS, Zhang WC, Yang H, Yan B, Alberich-Jorda M, Zhang J, de Figueiredo-Pontes LL, Battelli C, Hetherington CJ, Ye M, Zhang H, Maroni G, O'Brien K, Magli MC, Borczuk AC, Varticovski L, Kocher O, Zhang P, Moon YC, Sydorenko N, Cao L, Davis TW, Thakkar BM, Soo RA, Iwama A, Lim B, Halmos B, **Neuberg D**, Tenen DG, Levantini E. Targeted BMI1 inhibition impairs tumor growth in lung adenocarcinoma with low CEBPa expression. *Sci Transl Med*. 2016 Aug 3;8(350):350ra104. PMID: 27488898
448. Xiang M, Kim H, Ho VT, Walker SR, Bar-Natan M, Anahtar M, Liu S, Toniolo PA, Kroll Y, Jones N, Giaccone ZT, Heppler LN, Ye DQ, Marineau JJ, Shaw D, Bradner JE, Blonquist T, **Neuberg D**, Hetz C, Stone RM, Soiffer RJ, Frank DA. Gene expression-based discovery of atovaquone as a STAT3 inhibitor and anti-cancer agent. *Blood*. 2016 Aug 16. pii: blood-2015-07-660506. [Epub ahead of print] PMC5054697
449. Bird GH, Mazzola E, Opoku-Nsiah K, Lammert MA, Godes M, Neuberg DS, Walensky LD. Biophysical determinants for cellular uptake of hydrocarbon-stapled peptide helices. *Nat Chem Biol*. 2016 Oct;12(10):845-52. doi: 10.1038/nchembio.2153. PMC5055751
450. Sivina M, Werner L, Rassenti L, Ferrajoli A, Wierda WG, Keating MJ, O'Brien S, **Neuberg D**, Kipps T, Burger JA. Dynamic changes in CCL3 and CCL4 plasma concentrations in patients with chronic lymphocytic leukemia managed with observation. *Br J Haematol*. 2016 Oct 21. doi: 10.1111/bjh.14398. [Epub ahead of print] No abstract available. PMID: 27766619
451. Roemer MG, Advani RH, Redd RA, Pinkus GS, Natkunam Y, Ligon AH, Connelly CF, Pak CJ, Carey CD, Daadi SE, Chapuy B, de Jong D, Hoppe RT, Neuberg DS, Shipp MA, Rodig SJ. Classical Hodgkin lymphoma with reduced β 2M/MHC class I expression is associated with inferior outcome independent of 9p24.1 status. *Cancer Immunol Res*. 2016 Nov;4(11):910-916. PMC5210180
452. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. High-level ROR1 associates with accelerated disease-progression in chronic lymphocytic leukemia. *Blood*. 2016 Nov 4. pii: blood-2016-04-712562. [Epub ahead of print] PMC5179332
453. Wang L, Brooks AN, Fan J, Wan Y, Gambe R, Li S, Hergert S, Yin S, Freeman SS, Levin JZ, Fan L, Seiler M, Buonamici S, Smith PG, Chau KF, Cibulskis CL, Zhang W, Rassenti LZ, Ghia EM, Kipps TJ, Fernandes S, Bloch DB, Kotliar D, Landau DA, Shukla SA, Aster JC, Reed R, DeLuca DS, Brown JR, **Neuberg D**, Getz G, Livak KJ, Meyerson MM, Kharchenko PV, Wu CJ. Transcriptomic characterization of SF3B1 mutation reveals its pleiotropic effects in chronic lymphocytic leukemia. *Cancer Cell*. 2016 Nov 14;30(5):750-763. PMC5127278
454. Morgan EA, Sweeney MP, Tomoka T, Kopp N, Gusenleitner D, Redd RA, Carey CD, Masamba L, Kamiza S, Pinkus GS, Neuberg DS, Rodig SJ, Milner DA Jr, Weinstock DM. Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. *Blood Adv*. 2016 Nov 22;1(1):84-92. PMC5744047
455. Hill SJ, Mordes DA, Cameron LA, Neuberg DS, Landini S, Eggan K, Livingston DM. Two familial ALS proteins function in prevention/repair of transcription-associated DNA damage. *Proc Natl Acad Sci U S A*. 2016 Nov 29;113(48):E7701-E7709. PMC5137757
456. Scharenberg C, Giai V, Pellagatti A, Saft L, Dimitriou M, Jansson M, Jädersten M, Grandien A, Douagi I, Neuberg DS, LeBlanc K, Boulwood J, Karimi M, Jacobsen SE, Woll PS, Hellström-Lindberg E. Progression in patients with low- and intermediate-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations. *Haematologica*. 2016 Nov 24. pii: haematol.2016.152025. [Epub ahead of print] PMID: 27884971
457. Edelmann J, Tausch E, Landau DA, Robrecht S, Bahlo J, Fischer K, Fink AM, Bloehdorn J, Holzmann K, Böttcher S, Werner L, Kneba M, Gribben JG, Neuberg DS, Wu CJ, Hallek M,

- Döhner H, Stilgenbauer S. Frequent evolution of copy number alternations in CLL following first-line treatment with FC® is enriched with TP53 alterations: results from the CLL8 trial. *Leukemia*. 2017 Mar;31(3):734-738. PMC5332302
458. Rosenblatt J, Stone RM, Uhl L, **Neuberg D**, Joyce R, Levine JD, Arnason J, McMasters M, Luptakova K, Jain S, Zwicker JI, Hamdan A, Boussiotis V, Steensma DP, DeAngelo DJ, Galinsky I, Dutt PS, Logan E, Bryant MP, Stroopinsky D, Werner L, Palmer K, Coll M, Washington A, Cole L, Kufe D, Avigan D. Individualized vaccination of AML patients in remission is associated with induction of antileukemia immunity and prolonged remissions. *Sci Transl Med*. 2016 Dec 7;8(368):368ra171. PMID: 27928025
459. Finkelstein Y, Blonquist TM, Vijayanathan V, Stevenson KE, Neuberg DS, Silverman LB, Vrooman LM, Sallan SE, Cole PD. A thymidylate synthase polymorphism is associated with increased risk for bone toxicity among children treated for acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2016 Dec 13. doi: 10.1002/pbc.26393. [Epub ahead of print] PMID: 27957785
460. Cui B, Ghia EM, Chen L, Rassenti LZ, DeBoever C, Widhopf GF 2nd, Yu J, Neuberg DS, Wierda WG, Rai KR, Kay NE, Brown JR, Jones JA, Gribben JG, Frazer KA, Kipps TJ. High-level ROR1 associates with accelerated disease-progression in chronic lymphocytic leukemia. *Blood*. 2016 Dec 22;128(25):2931-2940. PMC5179332
461. Fathi AT, Wander SA, Blonquist TM, Brunner AM, Amrein PC, Supko J, Hermance NM, Manning AL, Sadrzadeh H, Ballen KK, Attar EC, Graubert TA, Hobbs G, Joseph C, Perry AM, Burke M, Silver R, Foster J, Bergeron M, Romos AY, Som TT, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Chen YB. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia. *Haematologica*. 2017 Apr;102(4):719-727. PMC5395112
462. Gibson CJ, Lindsley RC, Tchekmedyan V, Mar BG, Shi J, Jaiswal S, Bosworth A, Francisco L, He J, Bansal A, Morgan EA, Lacasce AS, Freedman AS, Fisher DC, Jacobsen E, Armand P, Alyea EP, Koreth J, Ho V, Soiffer RJ, Antin JH, Ritz J, Nikiforow S, Forman SJ, Michor F, Neuberg D, Bhatia R, Bhatia S, Ebert BL. Clonal hematopoiesis associated with adverse outcomes after autologous stem-cell transplantation for lymphoma. *J Clin Oncol*. 2017 May 10;35(14):1598-1605. PMC5455707
463. Stopa JD, **Neuberg D**, Puligandla M, Furie B, Flaumenhaft R, Zwicker JI. Protein disulfide isomerase inhibition blocks thrombin generation in humans by interfering with platelet factor V activation. *JCI Insight*. 2017 Jan 12;2(1):e89373. doi: 10.1172/jci.insight.89373. PMC5214567
464. Murphy EJ, Neuberg DS, Rassenti LZ, Hayes G, Redd R, Emson C, Li K, Brown JR, Wierda WG, Turner S, Greaves AW, Zent CS, Byrd JC, McConnel C, Barrientos J, Kay N, Hellerstein MK, Chiorazzi N, Kipps TJ, Rai KR. Leukemia-cell proliferation and disease progression in patients with early stage chronic lymphocytic leukemia. *Leukemia*. 2017 Jun;31(6):1348-1354. PMC5462857
465. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, **Neuberg D**, Ebert BL. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. *N Engl J Med*. 2017 Feb 9;376(6):536-547. PMC5438571
466. Kalaitzidis D, Lee D, Efeyan A, Kfoury Y, Nayyar N, Sykes DB, Mercier FE, Papazian A, Baryawno N, Victora GD, **Neuberg D**, Sabatini DM, Scadden DT. Amino acid-insensitive mTORC2 regulation enables nutritional stress resilience in hematopoietic stem cells. *J Clin Invest*. 2017 Apr 3;127(4):1405-1413. doi: 10.1172/JCI89452. Epub 2017 Mar 20. PMC5373863
467. Weinberg OK, Gibson CJ, Blonquist TM, **Neuberg D**, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP. NPM1 mutation but not RUNX1 mutation or multilineage dysplasia defines a

- prognostic subgroup within de novo acute myeloid leukemia lacking recurrent cytogenetic abnormalities in the revised 2016 WHO classification. *Am J Hematol.* 2017 Jul;92(7):E123-E124.. doi: 10.1002/ajh.24739. [Epub 2017 May 26] PMC5470583
468. Friedman AA, Xia Y, Trippa L, Le LP, Igras V, Frederick DT, Wargo JA, Tanabe KK, Lawrence DP, Neuberg DS, Flaherty KT, Fisher D. Feasibility of ultr-high-throughput functional screening of melanoma biopsies for discovery of novel cancer drug combinations. *Clin Cancer Res.* 2017 Aug 15;23(16):4680-4692.. pii: clincanres.3029.2016. doi: 10.1158/1078-0432.CCR-16-3029. [Epub Apr 26] PMC5559310
469. Perry AM, Brunner AM, Zou T, McGregor KL, Amrein PC, Hobbs GS, Ballen KK, Neuberg DS, Fathi AT. Association between insurance status at diagnosis and overall survival in chronic myeloid leukemia: A population-based study. *Cancer.* 2017 Jul 1;123(13):2561-2569. doi: 10.1002/cncr.30639. [Epub 2017 May 2] PMC5464167
470. Mantia C, Uhlmann EJ, Puligandla M, Weber GM, **Neuberg D**, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. *Blood.* 2017 Jun 22;129(25):3379-3385. pii: blood-2017-02-767285. doi: 10.1182/blood-2017-02-767285. [Epub May 3] PMID: 28468796
471. Abaji R, Gagne V, Xu CJ, Spinella JF, Ceppi F, Laverdiere C, Leclerc JM, Sallan SE, Neuberg D, Kutok JL, Silverman LB, Sinnett D, Krajcinovic M. whole-exome sequencing identified genetic risk factors for asparaginase-related complications in childhood ALL patients. *Oncotarget.* 2017 Jul 4; 8(27):43752-43767. Doi: 10.18632/oncotarget.17959. [Epub ahead of print] PMC5546438
472. Jaiswal S, Natarajan P, Silver AJ, Givson CJ, Bok AG, Shvartz E, McConkey M, Gupta N, Gabriel S, Ardissino D, Baber U, Merhran R, Fuster V, Daneesh J, Frossard P, Saleheen D, Melander O, Sukhova GK, Neuberg D, Libby P, Kathiresan S, Ebert BL. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med.* 2017 July 13;377(2):111-121. PMID:28636844
473. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaippan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, **Neuberg D**, Ritz J, Lander ES, Fritsch EF, Hacoheh N, Wu CJ. An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature.* 2017 Jul 13;547(7662):217-221. doi: 10.1038/nature22991. [Epub 2017 Jul 5] PMC5577644
474. Wang L, Fan J, Francis JM, Georghiou G, Hergert S, Li S, Gambe R, Zhou CW, Yang C, Xiao S, Cin PD, Bowden M, Kotliar D, Shukla SA, Brown JR, **Neuberg D**, Alessi DR, Zhang CZ, Kharchenko PV, Livak KJ, Wu CJ. Integrated single-cell genetic and transcriptional analysis suggests novel drivers of chronic lymphocytic leukemia. *Genome Res.* 2017 Aug;27(8):1300-1311. doi: 10.1101/gr.217331.116. [Epub 2017 Jul 5] PMC5538547
475. Bhanot H, Weisberg EL, Reddy MM, Nonami A, **Neuberg D**, Stone RM, Podar K, Salgia R, Griffin JD, Sattler M. Acute myeloid leukemia cells require 6-phosphogluconate dehydrogenase for cell growth and NADPH-dependent metabolic reprogramming. *Oncotarget.* 2017 Jun 28;8(40):67639-67650. doi: 10.18632/oncotarget.18797. eCollection 2017 Sep 15. PMC5620199
476. Hwang JK, Wang C, Du Z, Meyers RM, Kepler TB, Neuberg D, Kwong PD, Mascola JR, Joyce MG, Bonsignori M, Haynes BF, Yeap LS, Alt FW. Sequence intrinsic somatic mutation mechanisms contribute to affinity maturation of VRC01-class HIV-1 broadly neutralizing antibodies. *Proc Natl Acad Sci U.S.A.* 2017 Aug 8;114(32):8614-8619. pii: 201709203. doi:10.1073/pnas.1709203114. [Epub 2017 Jul 26] PMC5559054

477. Zhu S, Zhang X, Weichert-Leahey N, Dong Z, Zhang C, Lopez G, Tao T, He S, Wood AC, Oldridge D, Ung CY, van Ree JH, Khan A, Salazar BM, Lummertz da Rocha E, Zimmerman MW, Guo F, Cao H, Hou X, Weroha SJ, Perez-Atayde AR, Neuberg DS, Meves A, McNiven MA, van Deursen JM, Li H, Maris JM, Look AT. LMO1 syndergizes with MYCN to promote neuroblastoma initiation and metastasis. *Cancer Cell*. 2017 Sep 11;32(3):310-323. pii: S1535-6108(17)30345-8. Doi: 10.1016/j.ccell.2017.08.002. [Epub 2017 Aug 11] PMC5605802
478. Field JJ, Majerus E, Gordeuk VR, Gowhari M, Hoppe C, Heeney MM, Achebe M, George A, Chu H, Sheehan B, Puligandla M, **Neuberg D**, Lin G, Linden J, Nathan DG. Randomized phase 2 study of regadenoson for treatment of acute vaso-occlusive crises in sickle cell disease. *Blood Adv*. 2017 Aug 28;1(20):1645-48. PMC5728341
479. Carey CD, Gusenleitner D, Lipschitz M, Roemer MGM, Stack EC, Gjini E, Hu X, Redd R, Freeman GJ, Neuberg D, Hodi FS, Liu XS, Shipp MA, Rodig SJ. Topological analysis reveals a PD-L1 associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. *Blood*. 2017 Nov 30;130(22):2420-2430. pii: blood-2017-03-770719. doi: 10.1182/blood-2017-03-770719. [Epub 2017 Sep 11] PMC5766840
480. Fathi AT, Blonquist TM, Hernandez D, Amrein PC, Ballen KK, McMasters M, Avigan DE, Joyce R, Logan EK, Hobbs G, Brunner AM, Joseph C, Perry AM, Burke M, Behnan T, Foster J, Bergeron MK, Moran JA, Ramos AY, Som TT, Rae J, Fishman KM, McGregor KL, Connolly C, Neuberg DS, Levis MJ. Cabozatinib is well tolerated in acute myeloid leukemia and effectively inhibits the resistance-conferring FLT3/tyrosine kinase domain/F691 mutation. *Cancer*. 2018 Jan 15;124(2):306-314 doi: 10.1002/cncr.31038. [Epub 2017 Sep 28] PMID: 28960265
481. Brunner AM, Blonquist TM, Hobbs GS, Amrein PC, Neuberg DS, Steensma DP, Abel GA, Fathi AT. Risk and timing of cardiovascular death among patients with myelodysplastic syndromes. *Blood Adv*. 2017 Oct 18;1(23):2032-2040. PMC5728287
482. Kahn JM, Cole PD, Blonquist TM, Stevenson K, Jin Z, Barrera S, Davila R, Roberts E, Neuberg DS, Athale UH, Clavell LA, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Sallan SE, Silverman LB, Kelly KM. An investigation of toxicities and survival in Hispanic children and adolescents with ALL: Results from the Dana-Farber Cancer Institute ALL Consortium protocol 05-001. *Pediatr Blood Cancer*. 2018 Mar;65(3). doi: 10.1002/pbc.26871. [Epub 2017 Nov 1] PMC5766393
483. Bullman S, Pedomallu CS, Sicinska E, Clancy TE, Zhang X, Cai D, **Neuberg D**, Huang K, Guevara F, Nelson T, Chipashvili O, Hagan T, Walker M, Ramachandran A, Diosdado B, Serna G, Mulet N, Landolfi S, Ramon Y Cajal S, Fasani R, Aguirre AJ, Ng K, Élez E, Ogino S, Taberner J, Fuchs CS, Hahn WC, Nuciforo P, Meyerson M. Analysis of *Fusobacterium* persistence and antibiotic response in colorectal cancer. *Science*. 2017 Dec 15;358(6369):1443-1448. pii: eaal5240. doi: 10.1126/science.aal5240. [Epub 2017 Nov 23] PMC5823247
484. Landau DA, Sun C, Rosebrock D, Herman SEM, Fein J, Sivina M, Underbayev C, Liu D, Hoellenriegel J, Ravichandran S, Farooqui MZH, Zhang W, Cibulskis C, Zviran A, Neuberg DS, Livitz D, Bozic I, Leshchiner I, Getz G, Burger JA, Wiestner A, Wu CJ. The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy. *Nat Commun*. 2017 Dec 19;8(1):2185. doi: 10.1038/s41467-017-02329-y. PMC5736707
485. Grace RF, DeAngelo DJ, Stevenson KE, **Neuberg D**, Sallan SE, Mourad YRA, Bergeron J, Seftel MD, Kokulis C, Connors JM. The use of prophylactic anticoagulation during induction and consolidation in adults with acute lymphoblastic leukemia. *J Thromb Thrombolysis*. 2018 Feb;45(2):306-314. doi: 10.1007/s11239-017-1597-7. PMID: 29260426
486. Plesa M, Gagné V, Glisovic S, Younan M, Sharif-Askari B, Laverdière C, Alos N, Leclerc JM, Sallan SE, **Neuberg D**, Kutok JL, Silverman LB, Sinnott D, Krajcinovic M. Influence of BCL2L1 polymorphism on osteonecrosis during treatment of childhood acute lymphoblastic

- leukemia. *Pharmacogenomics J.* 2019 Feb;19(1):33-41. doi: 10.1038/s41397-017-0002-4. PMID 29282361
487. Sulis ML, Blonquist TM, Stevenson KE, Hunt SK, Kay-Green S, EpAthale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JG, Neuberg DS, Sallan SE, Silverman LB. Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2018 May;65(5):e26952. Jan 10. doi: 10.1002/pbc.26952. [Epub 2018 Jan 10] PMID: 29319209
488. Weinberg OK, Gibson CJ, Blonquist TM, **Neuberg D**, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP. Association of mutations with morphologic dysplasia in de novo acute myeloid leukemia without 2016 WHO classification-defined cytogenetic abnormalities. *Haematologica.* 2018 Apr;103(4):626-633. pii: haematol.2017.181842. doi: 10.3324/haematol.2017.181842. [Epub 2018 Jan 11] PMC5865424
489. Roemer MGM, Redd RA, Cader FZ, Pak CJ, Abdelrahman S, Ouyang J, Sasse S, Younes A, Fanale M, Santoro A, Zinzani PL, Timmerman J, Collins GP, Ramchandren R, Cohen JB, De Boer JP, Kuruvilla J, Savage KJ, Trneny M, Ansell S, Kato K, Farsaci B, Sumbul A, Armand P, Neuberg DS, Pinkus GS, Ligon AH, Rodig SJ, Shipp MA. Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. *J Clin Oncol.* 2018 Apr 1;36(10):942-950. doi: 10.1200/JCO.2017.77.3994. PMC5877802
490. Tran TH, Harris MH, Nguyen JV, Blonquist TM, Stevenson KE, Stonerock E, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JJG, Reshmi SC, Neuberg DS, Sallan SE, Loh ML, Silverman LB. Prognostic impact of kinase-activating fusions and IKZF1 deletions in pediatric high-risk B-lineage acute lymphoblastic leukemia. *Blood Adv.* 2018 Mar 13;2(5):529-533. doi: 10.1182/bloodadvances.2017014704. PMC5851421
491. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, Zhang W, Luoma A, Giobbie-Hurder A, Peter L, Chen C, Olive O, Carter TA, Li S, Lieb DJ, Eisenhaure T, Gjini E, Stevens J, Lane WJ, Javeri I, Nellaiappan K, Salazar AM, Daley H, Seaman M, Buchbinder EI, Yoon CH, Harden M, Lennon N, Gabriel S, Rodig SJ, Barouch DH, Aster JC, Getz G, Wucherpfennig K, **Neuberg D**, Ritz J, Lander ES, Fritsch EF, Hacohen N, Wu CJ. Corrigendum: An immunogenic personal neoantigen vaccine for patients with melanoma. *Nature.* 2018 Mar 14;555(7696):402. doi: 10.1038/nature22991. PMC6064631
492. Chen Y, Chaudhary N, Yang N, Granato A, Turner JA, Howard SL, Devereaux C, Zuo T, Shrestha A, Goel RR, **Neuberg D**, Wesemann DR. Microbial symbionts regulate the primary Ig repertoire. *J Exp Med.* 2018 May 7;215(5):1397-1415. doi: 10.1084/jem.20171761. PMC5940265
493. Place AE, Pikman Y, Stevenson KE, Harris MH, Pauly M, Sulis ML, Hijiya N, Gore L, Cooper TM, Loh ML, Roti G, Neuberg DS, Hunt SK, Orloff-Parry S, Stegmaier K, Sallan SE, Silverman LB. Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia. *Pediatr Blood Cancer.* 2018 Jul;65(7):e27062. doi: 10.1002/pbc.27062. PMID: 29603593
494. McBrayer SK, Olenchock BA, DiNatale GJ, Shi DD, Khanal J, Jennings RB, Novak JS, Oser MG, Robbins AK, Modiste R, Bonal D, Moslehi J, Bronson RT, **Neuberg D**, Nguyen QD, Signoretti S, Losman JA, Kaelin WG Jr.. Autochthonous tumors drive by *Rb1* loss have an ongoing requirement for the RBP2 histone demethylase. *Proc Natl Acad Sci U S A.* 2018 Apr 17;115(16):E3741-E3748. doi: 10.1073/pnas.1716029115. PMC5910822
495. Wolach O, Sellar RS, Martinod K, Cherpokova D, McConkey M, Chappell RJ, Silver AJ, Adams D, Castellano CA, Schneider RK, Padera RF, DeAngelo DJ, Wadleigh M, Steensma DP,

- Galinsky I, Stone RM, Genovese G, McCarroll SA, Iliadou B, Hultman C, **Neuberg D**, Mullally A, Wagner DD, Ebert BL. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. *Sci Transl Med*. 2018 Apr 11;10(436). pii: eaan8292. doi: 10.1126/scitranslmed.aan8292. PMC6442466
496. Burns MA, Liao ZW, Yamagata N, Pouliot GP, Stevenson KE, Neuberg DS, Thorner AR, Ducar M, Silverman EA, Hunger SP, Loh ML, Winter SS, Dunsmore KP, Wood B, Devidas M, Harris MH, Silverman LB, Sallan SE, Gutierrez A. Hedgehog pathway mutations drive oncogenic transformation in high-risk T-cell acute lymphoblastic leukemia. *Leukemia*. 2018 Oct;32(10):2126-2137. doi: 10.1038/s41375-018-0097-x. PMC6148437
497. Shukla SA, Bachireddy P, Schilling B, Galonska C, Zhan Q, Bango C, Langer R, Lee PC, Gusenleitner D, Keskin DB, Babadi M, Mohammad A, Gnirke A, Clement K, Cartun ZJ, Van Allen EM, Miao D, Huang Y, Snyder A, Merghoub T, Wolchok JD, Garraway LA, Meissner A, Weber JS, Hacohen N, **Neuberg D**, Potts PR, Murphy GF, Lian CG, Schadendorf D, Hodi FS, Wu CJ. Cancer-germline antigen expression discriminates clinical outcome to CTLA-4 blockade. *Cell*. 2018 Apr 19;173(3):624-633.e8. . Doi: 10.1016/j.cell.2018.03.026. PMC6044280
498. Goyal G, Wong K, Nirschi CJ, Souders N, Neuberg D, Anandasabapathy N, Dranoff G. PPAR- γ contributes to immunity by cancer vaccines that secrete GM-CSF. *Cancer Immunol Res*. 2018 Jun;6(6):723-732. doi: 10.1158/2326-6066.CIR-17-0612. PMID: 29669721.
499. Hasan MK, Yu J, Widhopf GF 2nd, Rassenti LZ, Chen L, Shen Z, Briggs SP, Neuberg DS, Kipps TJ. Wnt5a induces ROR1 to recruit DOCK2 to activate Rac1/2 in chronic lymphocytic leukemia. *Blood*. 2018 Jul 12;132(2):170-178. Doi: 10.1182/blood-2017-12-819383. PMC6043980
500. Sulis ML, Blonquist TM, Stevenson KE, Hunt SK, Kay-Green S, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Welch JG, Neuberg DS, Sallan SE, Silverman LB. Reply to comment on: Effectiveness of antibacterial prophylaxis during induction chemotherapy in children with acute lymphoblastic leukemia. *Pediatr Blood Cancer*. 2018 Aug;65(8):e27082. Doi: 10.1002/pbc.27082. PMID: 29693795
501. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Reinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Peadarallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukheim R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trumper L, Getz G, Shipp MA. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med*. 2018 May;24(5):679-690. PMC6613387
502. Gupta N, Goumnerova LC, Manley P, Chi SN, **Neuberg D**, Puligandla M, Fangusaro J, Goldman S, Tomita T, Alden T, DiPatri A, Rubin JB, Gauvain K, Limbrick D, Leonard J, Geyer JR, Leary S, Browd S, Wang Z, Sood S, Bendel A, Nagib M, Gardner S, Karajannis MA, Harter D, Ayyanar K, Gump W, Bowers DC, Weprin B, MacDonald TJ, Aguilera D, Brahma B, Robison NJ, Kiehna E, Krieger M, Sandler E, Aldana P, Khatib Z, Ragheb J, Bhatia S, Mueller S, Banerjee A, Bredlau AL, Gururangan S, Fuchs H, Cohen KJ, Jallo G, Dorris K, Handler M, Comito M, Dias M, Nazemi K, Baird L, Murray J, Lindeman N, Hornick JL, Malkin H, Sinai C, Greenspan L, Wright KD, Prados M, Bandopadhyay P, Ligon KL, Kieran MW. Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. *Neuro Oncol*. 2018 Oct 9;20(11):1547-1555. Doi: 10.1093/neuroonc/noy070. PMC6176802
503. Athale UH, Puligandla M, Stevenson KE, Asselin B, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JG, Harris MH, Neuberg DS, Sallan SE, Silverman LB. Outcome of children and adolescents with Down syndrome treated on Dana-

- Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium protocols 00-001 and 05-001. *Pediatr Blood Cancer*. 2018 Oct;65(10):e21256. PMID29878490
504. Cader FZ, Schackmann RCJ, Hu X, Wienand K, Redd R, Chapuy B, Ouyang J, Paul N, Gjini E, Lipschitz M, Armand P, Wu D, Fromm JR, Neuberg D, Liu XS, Rodig SJ, Shipp MA. Mass cytometry of Hodgkin lymphoma reveals a CD4+ exhausted T-effector and T-regulatory cell rich microenvironment. *Blood*. 2018 Aug 23;132(8):826-836. PMC6107878
505. Bellutti F, Tigan AS, Nebenfuehr S, Dolezal M, Zojer M, Grausenburger R, Hartenberger S, Kollmann S, Doma E, Prchal-Murphy M, Uras IZ, Höllein A, **Neuberg DS**, Ebert BL, Ringler A, Mueller AC, Loizou JI, Hinds PW, Vogl C, Heller G, Kubicek S, Zuber J, Malumbres M, Farlik M, Villunger A, Kollmann K, Sexl V. CDK6 antagonizes p53-induced responses during tumorigenesis. *Cancer Discov*. 2018 Jul;8(7):884-907. PMC6031305
506. Vrooman LM, Blonquist TM, Harris MH, Stevenson KE, Place AE, Hunt SK, O'Brien JE, Asselin BL, Athale UH, Clavell LA, Cole PD, Kelly KM, Laverdiere C, Leclerc JM, Michon B, Schorin MA, Sulis ML, Welch JJG, Neuberg DS, Sallan SE, Silverman LB. Refining risk classification in childhood B acute lymphoblastic leukemia: results of DFCI ALL Consortium Protocol 05-001. *Blood Adv*. 2018 Jun 26;2(12):1449-58. doi:10.1182/bloodadvances.2018016584. PMC6020806
507. Mansour MR, He S, Li Z, Lobbardi R, Abraham BJ, Hug C, Rahman S, Leon TE, Kuang YY, Zimmerman MW, Blonquist T, Gjini E, Gutierrez A, Tang Q, Garcia-Perez L, Pike-Overzet K, Anders L, Berezovskaya A, Zhou Y, Zou LI, **Neuberg D**, Fielding AK, Staal FJT, Langenau DM, Sanda T, Young RA, Look AT. JDP2: An oncogenic bZIP transcription factor in T cell acute lymphoblastic leukemia. *J Exp Med*. 2018 Jul 2;215(7):1929-1945. PMC6028512
508. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Peadarallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhi R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Publisher Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med*. 2018 Aug;24(8):1292. doi: 10.1038/s41591-018-0098-3. PMID: 29955181
509. Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, Lawrence MS, Roemer MGM, Li AJ, Ziepert M, Staiger AM, Wala JA, Ducar MD, Leshchiner I, Rheinbay E, Taylor-Weiner A, Coughlin CA, Hess JM, Peadarallu CS, Livitz D, Rosebrock D, Rosenberg M, Tracy AA, Horn H, van Hummelen P, Feldman AL, Link BK, Novak AJ, Cerhan JR, Habermann TM, Siebert R, Rosenwald A, Thorner AR, Meyerson ML, Golub TR, Beroukhi R, Wulf GG, Ott G, Rodig SJ, Monti S, Neuberg DS, Loeffler M, Pfreundschuh M, Trümper L, Getz G, Shipp MA. Author Correction: Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. *Nat Med*. 2018 Aug;24(8):1290-1291. doi: 10.1038/s41591-018-0097-4. PMID: 29955182
510. Barnes JA, Redd R, Fisher DC, Hochberg EP, Takvorian T, **Neuberg D**, Jacobsen E, Abramson JS. Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: results of a phase II study. *Hematol Oncol*. 2018 Oct;36(4):633-637. PMID:29956350
511. Hu Z, Anandappa AJ, Sun J, Kim J, Leet DE, Bozym DJ, Chen C, Williams L, Shukla SA, Zhang W, Tabbaa D, Steelman S, Olive O, Livak KJ, Kishi H, Muraguchi A, Guleria I, Stevens J, Lane WJ, Burkhardt UE, Fritsch EF, **Neuberg D**, Ott PA, Keskin DB, Hacohen N, Wu CJ. A cloning

- and expression system to probe T cell receptor specificity and assess functional avidity to neoantigens. *Blood*. 2018 Nov 1;132(18):1911-1921. PMC6213317
512. Nemer DM, Stewart GC, Puligandla M, Neuberg DS, Givertz MM, Mehra MR, Couper GS, Connors JM. Postoperative bridging anticoagulation and left ventricular assist system thrombosis. *J Thromb Thrombolysis*. 2019 Jan;47(1):57-66.PMID: 30255419
513. Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, Deng J, Gruber M, Wong J, Zheng M, Gill AL, Seiler M, Smith P, Thomas M, Buonamici S, Ghia EM, Kim E, Rassenti LZ, Burger JA, Kipps TJ, Meyerson ML, Bachireddy P, Wang L, Reed R, Neuberg D, Carrasco RD, Brooks AN, Letai A, Davids MS, Wu CJ. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. *JCI Insight*. 2018 Oct 4;3(19). pii: 121438. Doi: 10.1172/jci.insight.121438. PMC6237462
514. Poluben L, Puligandla M, **Neuberg D**, Bryke CR, Hsu Y, Shumeiko O, Yuan X, Voznesensky O, Pihan G, Adam M, Fraenkel E, Rasnic R, Linial M, Klymenko S, Balk SP, Fraenkel PG. Genomic characteristics of myeloproliferative neoplasms in patients exposed to ionizing radiation following the Chernobyl nuclear accident. *Am J Hematol*. 2019 Jan;94(1):62-73. PMC6371805
515. Baumeister SH, Murad J, Werner L, Daley H, Trebeden-Negre H, Gicobi JK, Schmucker A, Reder J, Sentman CL, Gilham DE, Lehmann FF, Galinsky I, DiPietro H, Cummings K, Munshi NC, Stone RM, Neuberg DS, Soiffer R, Dranoff G, Ritz J, Nikiforow S. Phase 1 Trial of Autologous CAR T cells Targeting NKG2D Ligands in Patients with AML/MDS and Multiple Myeloma. *Cancer Immunol Res*. 2019 Jan; 94(1):62-73. PMID: 30396908.
516. Ariès IM, Bodaar K, Karim SA, Chonghaile TN, Hinze L, Burns MA, Pffirmann M, Degar J, Landrigan JT, Balbach S, Peirs S, Menten B, Isenhardt R, Stevenson KE, Neuberg DS, Devidas M, Loh ML, Hunger SP, Teachey DT, Rabin KR, Winter SS, Dunsmore KP, Wood BL, Silverman LB, Sallan SE, Van Vlierberghe P, Orkin SH, Knoechel B, Letai AG, Gutierrez A. PrC2 loss induces chemoresistance by repressing apoptosis in T cell acute lymphoblastic leukemia. *J Exp Med*. 2018 Dec 3;215(12):3094-3114. PMC6279404
517. Brunner AM, Neuberg DS, Wander SA, Sadrzadeh H, Ballen KK, Amrein PC, Attar E, Hobbs GS, Chen YB, Perry A, Connolly C, Joseph C, Burke M, Ramos A, Galinsky I, Yen K, Yang H, Straley K, Agresta S, Adamia S, Borger DR, Iafrate A, Graubert TA, Stone RM, Fathi AT. Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia. *Cancer*. 2019 Feb 15;125(4):541-549. PMID: 30422308
518. Gansner JM, Rahmani M, Jonsson AH, Fortin BM, Brimah I, Ellis M, Smeland-Wagman R, Li ZJ, Schenkel JM, Brenner MB, Yefidoff-Freedman R, Sloan SR, Berliner N, Issa NC, Baden LR, Longo DL, Wesemann DR, Neuberg D, Rao DA, Kaufman RM. Plateletpheresis-associated lymphopenia in frequent platelet donors. *Blood*. 2019 Feb 7;133 (6):605-614. PMC6367645
519. Carney BJ, Uhlmann EJ, Puligandla M, Mantia C, Weber GM, Neuberg DS, Zwicker JJ. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. *J Thromb Haemost*. 2019 Jan;17(1):72-76. doi: 10.1111/jth.14336. PMID: 03450803
520. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, Oliveira G, Giobbie-Hurder A, Felt K, Gjini E, Shukla SA, Hu Z, Li L, Le PM, Allesøe RL, Richman AR, Kowalczyk MS, Abdelrahman S, Geduldig JE, Charbonneau S, Pelton K, Iorgulescu JB, Elagina L, Zhang W, Olive O, McCluskey C, Olsen LR, Stevens J, Lane WJ, Salazar AM, Daley H, Wen PY, Chiozza EA, Harden M, Lennon NJ, Gabriel S, Getz G, Lander ES, Regev A, Ritz J, Neuberg D, Rodig SJ, Ligon KL, Suvà ML, Wucherpfennig KW, Hacohen N, Fritsch EF, Livak KJ, Ott PA, Wu CJ, Reardon DA. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. *Nature*. 2019 Jan;(565)7738:234-239. PMC6546179

521. Haase D, Stevenson KE, Neuberg D, Maciejewski JP, Nazha A, Sekeres MA, Ebert BL, Garcia-Manero G, Haferlach C, Haferlach T, Kern W, Ogawa S, Nagata Y, Yoshida K, Graubert TA, Walter MJ, List AF, Komrokji RS, Padron E, Sallman D, Papaemmanuil E, Campbell PJ, Savona MR, Seegmiller A, Ades L, Fenaux P, Shih LY, Bowen D, Groves MJ, Tauro S, Fontenay M, Kosmider O, Bar-Natan M, Steensma D, Stone R, Heuser M, Thol F, Cazzola M, Malcovati L, Karsan A, Ganster C, Hellstrom-Lindberg E, Boultonwood J, Pellagatti A, Santini V, Quek L, Vyas P, Tuchler H, Greenberg PL, Bejar R; International Working Group for MDS Molecular Prognostic Committee. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. *Leukemia*. 2019 Jul;33(7):1747-1758. Doi: 10.1036/s41375-018-0351-2. PMC6609480
522. Krishnamurti L, Neuberg DS, Sullivan KM, Kamani NR, Abraham A, Campigotto F, Zhang W, Dahdoul T, De Castro L, Parikh S, Bakshi N, Haight A, Hassell KL, Loving R, Rosenthal J, Smith SL, Smith W, Spearman M, Stevenson K, Wu CJ, Wiedl, C, Waller EK, Walters MC. Bone marrow transplantation for adolescents and young adults with sickle cell disease: Results of a prospective multicenter pilot study. *Am J Hematol*. 2019 Apr;94(4):446-454. Doi: 10.1002/ajh.25401. PMC6542639
523. Zwicker JI, Schlechter BL, Stopa JD, Liebman H, Aggarwal A, Puligandla M, Caughey T, Bauer KA, Kuemmerle N, Wong E, Wun T, McLaughlin M, Hidalgo M, Neuberg D, Furie B, Flaumenhaft R. Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. *JCI Insight*. 2019 Feb 21;4(4).. Pii: 125851. Doi: 10.1172/jci.insight.125851. PMC6478409
524. Yin S, Gambe RG, Sun J, Martines AZ, Cartun ZJ, Regis FFD, Wan Y, Fan J, Brooks AN, Herman SEM, Hacken ET, Taylor-Weiner A, Rassenti LZ, Ghia EM, Kipps TJ, Obeng EA, Cibulskis CL, Neuberg D, Campagna DR, Fleming MD, Ebert BL, Wiestern A, Leshschiner I, DeCaprio JA, Getz G, Reed R, Carrasco RD, Wu CJ, Wang L. A murine model of chronic lymphocytic leukemia based on B cell-restricted expression of Sf3b1 mutation and Atm deletion. *Cancer Cell*. 2019 Feb 11;35(2):283-296. PMC6372356
525. Rahmani M, Fortin BM, Berliner N, Issa N, Neuberg D, Kaufman RM, Gansner JM. CD4₊ T-cell lymphopenia in frequent platelet donors who have ceased platelet donation for at least 1 year. *Transfusion*. 2019 May;59(5):1644-1647. Doi:10.1111/trf.15192. PMC6504640
526. Ghia EM, Rassenti LZ, Neuberg DS, Blanco A, Yousif F, Smith EN, McPherson JD, Hudson TJ, Harismendy O, Frazer KA, Kipps TJ. Activation of Hedgehog signaling associates with early disease progression in chronic lymphocytic leukemia. *Blood*. 2019 Jun 20;133(25):2651-2663. doi: 10.1182/blood-2018-09-873695. PMC6587306
527. Hinze L, Pfirrmann M, Karim S, Degar J, McGuckin C, Vinjamur D, Sacher J, Stevenson KE, Neuberg DS, Orellana E, Stanulla M, Gregory RI, Bauer DE, Wagner FF, Stegmaier K, Gutierrez A. Synthetic lethality of Wnt pathway activation and asparaginase in drug-resistant acute leukemias. *Cancer Cell*. 2019 Apr 15;35(4):664-676.e7. doi: 10.1016/j.ccell.2019.03.004. PMC6541931
528. Soumerai JD, Davids MS, Werner L, Fisher DC, Armand P, Amrein PC, **Neuberg D**, Hochberg EP, Brown JR, Abramson JS. Phase 1 study of lenalidomide, bendamustine, and rituximab in previously untreated patients with chronic lymphocytic leukemia. *Leuk Lymphoma*. 2019 Dec;60(12):2931-2938. doi: 10.1080/10428194.2019.1608533. PMID: 31074316
529. Gruber M, Bozic I, Leshchiner I, Livitz D, Stevenson K, Rassenti L, Rosebrock D, Taylor-Weiner A, Olive O, Goyette R, Fernandes SM, Sun J, Stewart C, Wong A, Cibulskis C, Zhang W, Reiter JG, Gerold JM, Gribben JG, Rai KR, Keating MJ, Brown JR, **Neuberg D**, Kipps TJ,

- Nowak MA, Getz G, Wu CJ. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. *Nature*. 2019 Jun;570(7762):474-479. Doi: 10.1038/s41586-019-1252-x. [Epub ahead of print]. PMC6630176
530. Abramson JS, Arnason JE, LaCasce AS, Redd R, Barnes JA, Sokol L, Joyce R, Avigan D, **Neuberg D**, Takvorian RW, Hochberg EP, Bello CM. Brentuximab Vedotin, Doxorubicin, Vinblastine and Dacarbazine for Non-bulky Limited Stage Classical Hodgkin Lymphoma. *Blood*. 2019 Aug 15;134(7):606-613. doi: 10.1182/blood.2019001272. PMID: 31186274.
531. Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, Louissaint A Jr, Lovitch SB, Dogan A, Fathi AT, Stone RM, Tallman MS, Rampal RK, Neuberg DS, Stevenson KE, Horwitz SM, Lane AA. Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark. *Blood*. 2019 Aug 22;134(8):678-687. doi: 10.1182/blood.2019001144. Epub 2019 Jun 26. PMC6706810
532. Gansner JM, Papari M, Goldstein J, Gaufberg RA, **Neuberg D**, Makar RS, Kaufman RM. Severe CD4+ T-cell lymphopenia is not observed in frequent plateletpheresis donors collected on the Fenwal Amicus. *Transfusion*. 2019 Jul 4. doi: 10.1111/trf.15441. PMC6611596
533. Lindner JR, Belcik T, Widlansky M, Harman LM, Karafin MS, Wandersee NJ, Puligandla M, **Neuberg D**, Linden J, Field JJ. Contrast-enhanced ultrasound detects changes in microvascular blood flow in adults with sickle cell disease. *PLoS One*. 2019 Jul5;14(7):e0218783.doi:10.1371/journal.pone.0218783. eCollection 2019. PMID: 31276520
534. Boettcher S, Miller PG, Sharma R, McConkey M, Leventhal M, Krivtsov AV, Giacomelli AO, Wong W, Kim J, Chao S, Kurppa KJ, Yang X, Milenkovic K, Piccioni F, Root DE, Rücker FG, Flamand Y, **Neuberg D**, Lindsley RC, Jänne PA, Hahn WC, Jacks T, Döhner H, Armstrong SA, Ebert BL. A dominant-negative effect drives selection of *TP53* missense mutations in myeloid malignancies. *Science*. 2019 Aug 9;365(6453):599-604. doi: 10.1126/science.aax3649. PMID: 31395785
535. Chen L, Ouyang J, Wienand K, Bojarczuk K, Hao Y, Chapuy B, **Neuberg D**, Juszczynski P, Lawton LN, Rodig SJ, Monti S, Shipp MA. CXCR4 upregulation is an indicator of sensitivity to B-cell receptor/PI3K blockade and a potential resistance mechanism in B-cell receptor-dependent diffuse large B-cell lymphomas. *Haematologica*. 2019 Aug 30. pii: haematol.2019.216218. doi: 10.3324/haematol.2019.216218. [Epub ahead of print]. PMID: 31471373
536. Guièze R, Liu VM, Rosebrock D, Jourdain AA, Hernández-Sánchez M, Martínez Zurita A, Sun J, Ten Hacken E, Baranowski K, Thompson PA, Heo JM, Cartun Z, Aygün O, Iorgulescu JB, Zhang W, Notarangelo G, Livitz D, Li S, Davids MS, Biran A, Fernandes SM, Brown JR, Lako A, Ciantra ZB, Lawlor MA, Keskin DB, Udeshi ND, Wierda WG, Livak KJ, Letai AG, **Neuberg D**, Harper JW, Carr SA, Piccioni F, Ott CJ, Leshchiner I, Johannessen CM, Doench J, Mootha VK, Getz G, Wu CJ. Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in B cell malignancies. *Cancer Cell*. 2019 Oct 14;36(4):369-384. PMC6801112
537. Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, **Neuberg D**, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL. Pembrolizumab in relapsed or refractory mediastinal large B-cell lymphoma. *J Clin Oncol*. 2019 Dec 1;37(34):3291-3299. PMC6881098

538. Gagne V, Aubry-Morin A, Plesa M, Abaji R, Petrykev K, St-Onge P, Beaulieu P, Lavadiere C, Alos N, Leclerc JM, Sallan SE, Neuberg D, Kutok JL, Silverman LB, Sinnett D, Krajcinovic M. Genes identified through genome-wide association studies of osteonecrosis in childhood acute lymphoblastic leukemia patients. *Pharmacogenomics*. 2019 Nov;20(17):1189-1197. PMC7026765
539. Nze C, Fortin B, Freedman R, Mandell E, Puligandla M, Neuberg D, Achebe M. Sudden death in sickle cell disease: current experience. *Br J Haematol*. 2020 Feb;188(4):e43-e45. Doi: 10.1111/gjh.16314. Epub 2019 Dec 5. PMID: 31804704.
540. Garcia JS, Bhatt S, Fell G, Sperling AS, Burgess M, Keshishian H, Yilma B, Brunner A, **Neuberg D**, Carr SA, Ebert BL, Ballen K, Stone RM, DeAngelo DJ, Medeiros BC, Letai A. Increased mitochondrial apoptotic priming with targeted therapy predicts clinical response to re-induction chemotherapy. *Am J Hematol*. 2020 Mar;95(3):245-250. Doi: 10.1002/ajh.25692. Epub 2019 Dec 22. PMID: 31804723.
541. Narayan R, Blonquist TM, Emadi A, Hasserjian RP, Burke M, Lescinskas C, Neuberg DS, Brunner AM, Hobbs G, Hock H, McAfee SL, Chen YB, Attar E, Graubert TA, Bertoli C, Moran JA, Bergeron MK, Foster JE, Ramos AY, Som TT, Vartanian MK, Story JL, McGregor K, Macrae M, Behnan T, Wey MC, Rae J, Preffer FI, Lesho P, Duong VH, Mann ML, Ballen KK, Connolly C, Amrein PC, Fathi AT. A phase I study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expression relapsed/refractory acute myeloid leukemia. *Cancer*. Mar 15;126(6):1264-1273. PMID: 31860140
542. Brunner AM, Blonquist TM, DeAngelo DJ, McMasters M, Fell G, Hermance NM, Winer ES, Lindsley RC, Hobbs GS, Amrein PC, Hock HR, Steensma DP, Garcia JS, Luskin MR, Stone RM, Ballen KK, Rosenblatt J, Avigan D, Nahas MR, Mendez LM, McAfee SL, Moran JA, Bergeron M, Foster J, Bertoli C, Manning AL, McGregor KL, Fishman KM, Kuo FC, Baltay MT, Macrae M, Burke M, Behnan T, Wey MC, Som TT, Ramos AY, Rae J, Lombardi Story J, Nelson N, Logan E, Connolly C, Neuberg DS, Chen YB, Graubert TA, Fathi AT. Alisertib plus induction chemotherapy in previously untreated patients with high-risk acute myeloid leukaemia: a single-arm phase 2 trial. *Lancet Haematol*. 2020 Feb;7(2):e122-e133. doi: 10.1016/S2352-3026(19)30203-0. Epub 2019 Dec 11. PMID: 31837959
543. Truex NL, Holden RL, Wang BY, Chen PG, Hanna S, Hu Z, Shetty K, Olive O, Neuberg D, Hacoheh N, Keskin DB, Ott PA, Wu CJK, Pentelute BL. Automated flow synthesis of tumor neoantigen peptides for personalized immunotherapy. *Sci Rep*. 2020 Jan 20;10(1):723. Doi: 10.1038/s41598-019-56943-5. PMC6971261
544. Rowell TR, Redd RA, Neuberg DS, Walensky LD. Mid the gap: Expediting gender parity in MD-PhD admissions. *JCI Insight*. 2020 Feb 27;5(4). Pii: 136037. Doi: 10.1172/jci.insight.136037. PMC7101133
545. Parsons HA, Rhoades J, Reed SC, Gydush G, Ram P, Exman P, Xiong K, Lo CC, Li T, Fleharty M, Kirkner GJ, Rotem D, Cohen O, Yu F, Fitarelli-Kiehl M, Leong KW, Hughes ME, Rosenberg SM, Collins LC, Miller KD, Blumenstiel B, Trippa L, Cibulskis C, Neuberg DS, DeFelice M, Freeman SS, Lennon NJ, Wagle N, Ha G, Stover DG, Choudhury AD, Getz G, Winer EP, Meyerson M, Lin NU, Krop I, Love JC, Makrigiorgos GM, Partridge AH, Mayer EL, Golub TR, Adalsteinsson V. Sensitive detection of minimal residual disease in patients treated for early-stage breast cancer. *Clin Cancer Res*. 2020 Mar 13. Pii: clincanres.3005.2019. doi: 10.1158/1078-0432.CCR-19-3005. [Epub ahead of print] PMID: 32170028

546. Malcovati L, Stevenson K, Papaemmanuil E, **Neuberg D**, Bejar R, Boulton J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, Haferlach T, Heuser M, Jansen JH, Komrokji RS, Maciejewski JP, Walter MJ, Fontenay M, Garcia-Manero G, Graubert TA, Karsan A, Meggendorfer M, Pellagatti A, Sallman DA, Savona MR, Sekeres M, Steensma DP, Tauro S, Thol F, Vyas P, Van de Loosdrecht AA, Haase DT, Tuechler H, Greenberg PL, Ogawa S, Hellstrom-Lindberg ES, Cazzola M. SF3B1-mutant myelodysplastic syndrome as a distinct disease subtype—A proposal of the International Working Group for the Prognosis of Myelodysplastic Syndromes (IWG-PM). *Blood*. 2020 Apr 29. pii: blood.2020004850. doi: 10.1182/blood.2020004850. [Epub ahead of print] PMID: 32347921

Other peer-reviewed

1. Olson JE, Neuberg D. Postmastectomy radiation. A modest benefit prevails for high risk patients---reply. *Cancer*. 1997; 79(6):1067-1068.
2. Cerletti M, Stevenson K, Neuberg D, Jurga S, Witzak CA, Hirshman MF, Shadrach JL, Goodyear LJ, Wagers AJ. Response: skeletal muscle precursor grafts in dystrophic mice. *Cell* 2008;12:135(6):998-9.
3. Calin GA, Croce CM, Neuberg D. Authors' reply to De Brakeleer et. al. in reference to Table 1 of our article, Familial Cancer and ARLTS1 (*NEJM* Apr 21, 2005). *N Engl J Med* 2005; 353(3):314.
4. Neuberg DS. Reprise: Gemtuzumab ozogamicin for older patients with acute myeloid leukemia. *J Clin Oncol* 2012 Nov 10;30(32):3905-6. PMID: 22987082
5. Neuberg D, Arceci RJ. When "rare" is no excuse for progress. *Blood*. 2013 Jun 20; 121(25):4970-2. PMID: 23788022.
6. Farrar JE, Neuberg D, Triche T Jr, Bodine DM. Making "perfect" the enemy of good. *Blood*. 2017 Jul 28. Pii: blood-2017-07-789107. Doi: 10.1182/blood-2017-07-789107 [Epub ahead of print] PMID: 28754684
7. Neuberg D. How many mice? Design considerations for murine studies. *Blood Adv*. 2017 Aug 8;1(18):1466. PMC5747848
8. Neuberg D. Wrangling with P-values. *Pediatr Blood Cancer*. 2017 Sep 27. Doi: 10.1002/pbc.26834. PMID: 28960684J
9. Neuberg DS. Statistics Everywhere. *Hemasphere*. 2018 Feb 2;2(1):e30. Doi: 10.1097/HS9.000000000000030. eCollection 2018 Jan-Feb. PMID: 31723758
10. Neuberg DS, Rodig SJ, Shipp MA. Reply to Z. Wu et al. *J Clin Oncol*. 2018 May 30: JCO201878789826. Doi: 20.1200/JCO.2018.78.9826. PMID29847290
11. Bianchi G, Duarte D, Neuberg DS. The benefits of TRTHing along. *Hemasphere*. 2018 Jul 27;2(4):e138. Doi: 10.1097/HS9.000000000000138. eCollection 2018Aug.
12. Neuberg D. Dissecting the web of ischemic stroke sickle cell trait, and chronic kidney disease. *Am J Hematol*. 2019 Dec;94(12):1302. PMID: 31591745

NON-PEER REVIEWED PUBLICATIONS:

Books and Other Monographs

1. Neuberg D and Neuberg L. Study questions for Statistics: Guide to Political and Social Issues and Statistics: Guide to the Unknown, 2nd edition, edited by J. Tanur, E. Lehmann, et al., Holden-Day, San Francisco, 1977 and 1978.
2. Neuberg DS, et al. A compendium of statistical terms and procedures used in cancer clinical trials. In: Anderson JR, Propert KJ, eds. *Advances in Oncology* 1989;5:7-26
3. Gelman RS, Neuberg DS. Interpreting clinical data. In: Harris JR, Hellman S, Henderson IC, Kinne DW, eds. *Breast Diseases*, 2nd Edition. Philadelphia: JB Lippincott Company, 1991:883-905.
4. Harrington DP, Neuberg DS. Statistical Principles of Clinical Trials. In: Brain MC, Carbone PC, eds. *Current Therapy in Hematology-Oncology*, 5th Edition. St. Louis: Mosby, 1995: 39-49.
5. Neuberg DS. Group Sequential Stopping Rules for Clinical Trials: A Statistical Guide to Acting on Early Results. American Society of Clinical Oncology Education Book, 2008.